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     CHAPTER 1 
 
The first descriptions of hereditary spinocerebellar ataxias date from the late 18th century. 
Friedreich published several papers between 1863 and 1877 about, for that time, a new 
clinical entity: a hereditary (autosomal recessive) cerebellar ataxia. In 1893, Pierre Marie 
described families with a dominant form of cerebellar ataxia; the clinical features were 
heterogeneous but evidently different from Friedreich’s ataxia.1 Hereafter, the field of 
degenerative cerebellar ataxias was mainly characterized by various attempts to classify the 
hereditary spinocerebellar ataxias based on pathological findings. The earliest pathological 
classification consisted of three forms. First, olivo-ponto-cerebellar atrophy, originally 
described by Menzel in 1891.2 The term ‘OPCA’ (for olivo-ponto-cerebellar atrophy) was 
however coined by Dejerine-Thomas in a report of a patient with a sporadic ataxia in 1904. 
Second, cerebello-olivary degeneration, based on the description of Holmes in 1907 of a 
recessive ataxia with additional hypogonadism (although ‘Holmes type of ataxia’ was also 
used for dominant ataxias without gonadal abnormalities but with similar autopsy findings).3 
And third, the parenchymatous cortical cerebellar atrophy. In 1907, Holmes himself proposed 
to classify the hereditary ataxias as: primary parenchymatous degeneration, olivo-ponto-
cerebellar atrophy, or spinocerebellar tract degeneration.4 Greenfield, in 1954, suggested to 
divide the autosomal dominant ataxias in type A (Menzel’s type) for spinocerebellar forms 
and type B (Holmes type) for predominantly cerebellar forms.5. Because all these 
classifications were mainly based on neuropathological findings, Koningsmark and Weiner 
(1970) attempted to integrate pathological findings with clinical details and mode of 
inheritance.6 However, their classification of OPCA type I to V was characterized by a 
marked clinical and pathological overlap and the presence of different OPCA types even in 
one family illustrated the fact that, again, this was not a robust classification. It may thus be 
clear that these eponyms and classifications were not very helpful in clinical practice and did 
not contribute much to the understanding of degenerative cerebellar diseases. 
A first important milestone in ataxia research originates from the early 80’s of the last 
century, when the late Anita Harding classified the hereditary cerebellar ataxias based on 
corresponding phenotypes and the presumed underlying genetic or biologic causes.7 
Regarding the autosomal dominant cerebellar ataxias (ADCA), three subtypes were 
recognized by Harding: type I included ADCAs with the additional involvement of various 
other central or peripheral nervous system structures (dementia, ophthalmoplegia, 
extrapyramidal features, optic nerve atrophy, amyotrophy); type II referred to ADCA with 
pigmentary macular degeneration (with or without dementia, ophthalmoplegia, 
extrapyramidal features); and type III corresponded to a late-onset (>60 years), pure 
cerebellar ataxia. The originally proposed ADCA type IV (with myoclonus and deafness) was 
later recognized to be a mitochondrial cytopathy. Eventually, Harding’s classification of the 
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dominant ataxias could indeed (partly) be corroborated by the identification of different genes 
for some of these distinct ADCA subtypes. 
A second milestone in ataxia research was the discovery in 1993 of the first gene that was 
found to be associated with ADCA.8 This gene was designated SCA1 (for spinocerebellar 
ataxia 1) and the mutation consisted of an expanded trinucleotide repeat (CAG) in the coding 
region of the gene. Ataxias were now added to the (growing) list of trinucleotide repeat 
expansion disorders, which at that time already included fragile-X, Kennedy’s disease, 
Huntington’s disease, and myotonic dystrophy. 
Since then, the molecular genetic and cell biological knowledge of the ADCAs has taken an 
enormous leap, which is for example illustrated by the genetic symbol reserved for the most 
recent locus identified in an ADCA family: SCA27. Certain subtypes on the rapidly expanding 
list of SCA genes and loci (and corresponding phenotypes) are however, in a sense, 
confusing. There is, for example, debate about the actual pathogeneity of the non-coding 
CTG expansion in the SCA8 gene, as these expansions have also been found in healthy 
subjects or patients with non-cerebellar neurological diseases.9 The SCA22 locus seems to 
overlap with the SCA19 locus, which is also the case for SCA5 and SCA20.10,11 Finally, the 
phenotype of the single SCA18 family reported resembles more a hereditary sensory 
neuropathy than cerebellar ataxia.12 Therefore, careful genetic classification and detailed 
clinical information seem mandatory in order to obtain and maintain a classification that can 
be used for both clinical practice and research purposes. 
The first five SCA gene mutations that were found still account for the majority of ADCA 
cases: SCA1, SCA2, SCA3, SCA6, and SCA7. Based on clinical data, these SCA genes 
could more or less be grouped into Harding’s ADCA subtypes. SCA1, SCA2, and SCA3 
patients mostly display significant extracerebellar symptoms (ADCA type I). At present, only 
one genotype has been found in patients with an ADCA type II (with coexisting macular 
degeneration): SCA7. A pure, relatively late-onset (>50 years) cerebellar ataxia  (ADCA type 
III) is encountered in patients with a SCA6 mutation. While in SCA6 the onset of disease is 
mostly after 45 years of age, the age at onset in the other subtypes is commonly between 30 
and 40 years.13 Although clinical presentation does not predict the underlying genotype, 
there may be some distinctive features.14 In SCA1, patients often also develop, in the course 
of the disease, ophthalmoplegia, dysphagia, marked pyramidal tract involvement, and frontal 
executive dysfunction. Severe slowing of saccades, low or absent tendon reflexes, and 
dementia are characteristic non-cerebellar signs in SCA2.15 SCA2 patients might even 
present with levodopa-responsive parkinsonism. The SCA3 phenotype, previously referred to 
as Machado-Joseph disease, can be highly variable; in addition to the cerebellar syndrome, 
lower motor neuron involvement (with generalized or split hand atrophy), bulging eyes, and 
cognitive disturbances may be encountered.16,17 Parkinsonism, spastic paraparesis, or 
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polyneuropathy with or without restless leg syndrome (instead of ataxia) can be core 
features.18,19 SCA6 patients mostly show a pure cerebellar ataxia that starts after the age of 
45-50 years.20 Sometimes a downbeat nystagmus or vertigo syndrome are present. Due to 
the late onset and absence of anticipation (see later), SCA6 must also be considered in 
presumed sporadic disease.21 SCA7 patients develop or can even present with pigmentary 
macular degeneration, which eventually leads to a total loss of vision. Multi-organ disease 
and early death have been reported in SCA7 infants.22 
The genes involved in these five SCA subtypes share as the mutational mechanism an 
expanded CAG repeat in the coding region of the gene. A similar expansion has also been 
revealed in SCA17 and dentato-rubro-pallido-luysian atrophy (DRPLA). The CAG expansion 
is translated into an elongated polyglutamine tract in the encoded proteins, which, except for 
SCA6, are termed ataxins. The length of the expanded CAG repeat is inversely correlated 
with the age at onset and the repeat length explains 50 to 80% of variance in age at onset in 
these SCAs.23-25 In addition, these diseases show anticipation, an earlier age at onset 
evolving in the next generation, which is largely due to a further expansion of the unstable 
repeat during transmission. The repeat often shows more instability on paternal than on 
maternal transmission.26-28 
The classical (and now obsolete) term olivo-ponto-cerebellar atrophy (OPCA) still adequately 
summarizes the pathological findings in these SCA types, although there is hardly any 
pontine involvement in SCA6 and the grade and extent of atrophy and neuronal loss in the 
affected brain and spinal regions differ per SCA type.29 The most interesting microscopical 
autopsy finding in SCA brains is the presence of polyglutamine aggregates in neuronal nuclei 
(SCA1, SCA2, SCA3, SCA7) or in the cytoplasm of affected neurons (SCA2, SCA6).30-34 
Twelve years after SCA1, the mechanisms that constitute the final common pathway in these 
polyglutamine diseases are still not clear, although there are numerous hypotheses. 
Basically, the main issues are: is the polyglutamine fragment itself neurotoxic; are the 
nuclear or cytoplasmic inclusions, in which polyglutamine-containing peptides are 
aggregated, toxic or do the aggregates represent an efficient way of the cell to store toxic 
proteins; does the polyglutamine-containing proteins set off processes that are detrimental 
for vital mechanisms of the affected neuron; and does a loss of function of the protein in 
which the elongated amino acid is contained contribute to the neuronal dysfunction. 
The elucidation of the exact disease mechanisms is evidently needed to generate drugs that 
potentially intervene with these mechanisms. It is most likely that drugs acting on processes 
shared by all the polyglutamine diseases will be available first. However, the recent 
identification of new genes (and other mutational mechanisms) associated with dominant 
ataxia, PRKCG (SCA14) en FGF14, will probably give new directions to research that 
endeavours to unravel pathogenesis. 
13
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     CHAPTER 2 
At the time the studies described in this thesis were initiated (1999-2000), the prevalence of 
autosomal dominant cerebellar ataxias (ADCA) in the Netherlands was unknown. Some 
prevalence estimates in other countries had been published, but these studies were 
conducted prior to the discovery of genes involved in ADCA, included also the recessive 
ataxias, or only described regional prevalences (often in an inbred population). The first aim 
of study was to assess the prevalence of ADCA in the total Dutch population, based on the 
data of the three DNA diagnostic laboratories that perform mutation analysis for the entire 
country (chapter 3.1).  
 
The first five genes that were found to be associated with ADCA (SCA1, SCA2, SCA3, 
SCA6, and SCA7) share an expanded CAG repeat as the mutational mechanism. It had 
already been established that an inverse relation exists between the length of the CAG 
repeat expansion and the age at disease onset. This suggested a dominant role of the CAG 
expansion, or more particularly the translated polyglutamine stretch at the protein level, in the 
pathophysiology of these diseases. However, there remained much debate about the 
characteristics of this relation (i.e. the proportion of variance in age at onset explained by the 
CAG repeat length). Such data would give fundamental insight into the true contribution of 
the polyglutamine tract as well as the contribution of other (non-CAG) factors to the disease 
mechanisms. The second aim of study was to study genotype – phenotype correlations and 
more specifically the relation between CAG repeat expansion and age at onset for the 
established genotypes (chapters 3.1 and 3.2). One example of the consequences of such 
genotype – phenotype correlations in these diseases, an infantile onset of the SCA7 subtype 
due to extreme anticipation, is described in chapter 3.3. 
The routine analysis of the SCA1, SCA2, SCA3, SCA6, and SCA7 genes in the Dutch ADCA 
patients and families does not always reveal a mutation. The percentage of ADCA patients/ 
families with an unknown genotype was previously estimated to be about 30 to 40%. This 
implies that other yet unidentified SCA loci and genes had to be present in the Dutch ADCA 
population. The third aim of study was to identify novel SCA loci and genes in well-
characterized large Dutch ADCA families. The results of these studies are described in 
chapters 3.4 to 3.6. 
 
The exciting advances in the molecular genetic and cell biological aspects of ADCA have 
also resulted in a paradoxal decrease in the (interest for) clinical and physiologic studies in 
this group of diseases. However, clinical disease characteristics can be relevant for more 
fundamental studies. Moreover, for future clinical trials of drugs that potentially retard disease 
progression, it is essential to have detailed documentation of natural disease history as well 
as of all functional consequences. The outpatient ataxia clinic of the Department of 
 19
Neurology of the Radboud University Nijmegen Medical Centre is a setting that provides 
access to a large number of ADCA patients in order to address relevant clinical and 
physiologic issues. One of these issues was the question whether ADCA is a true central 
nervous system disease or also affects the peripheral nervous tissues. The fourth aim of 
study was to investigate the presence and type of peripheral nerve involvement in ADCA 
(chapter 4.1).  
From studies in other movement disorders, such as Parkinson’s disease, it is known that gait 
and balance disturbances often lead to falls. The incidence and characteristics of this 
devastating consequence of balance problems in patients who suffer from a cerebellar ataxia 
were studied and the results are described in chapter 4.2.  
Data on the primary disturbances of balance from a physiologic perspective in ADCA are 
scarce. We had the opportunity to the study balance as reflected by trunk sway in ADCA 
patients with a novel device, yielding insights into the cerebellar physiology and balance 
problems in this disease (chapter 4.3).  
 
Finally, a review of the recent advances in the field of hereditary ataxias, more or less 
covering the years needed for completion of this thesis, is provided in chapter 5. The 
recessive ataxias are also included in this review, because the disease mechanisms that are 
currently being explored in the recessive ataxias are very likely to be (at least partially) linked 
to those involved in the dominant ataxias. 
 
A summary and general discussion of the results presented in this thesis are given in 
chapter 6. The thesis concludes with a Dutch chapter summary (chapter 7). 
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CHAPTER 3.1 
 
Prevalence of spinocerebellar ataxias in the Netherlands 
and age at onset variance analysis (part I) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published as: 
Van de Warrenburg BPC, Sinke RJ, Verschuuren-Bemelmans CC, Scheffer H, Brunt 
ER, Ippel PF, Maat-Kievit JA, Dooijes D, Notermans, NC, Lindhout D, Knoers NVAM, 
Kremer HPH. Spinocerebellar ataxias in the Netherlands: prevalence and age-at-
onset variance analysis. Neurology 2002; 58:702-708. 
      
Abstract 
Background - International prevalence estimates of autosomal dominant cerebellar ataxias 
(ADCA) vary from 0.3 to 2.0 per 100,000. The prevalence of ADCA in the Netherlands is 
unknown. At present, fifteen genetic loci have been identified (SCA1-8, SCA10-14, SCA16, 
and SCA17) and nine of the corresponding genes have been cloned. In SCA1, SCA2, SCA3, 
SCA6, SCA7, SCA12, and SCA17 the mutation has been shown to be an expanded CAG 
repeat. Previously, the length of the CAG repeat was found to account for 50 to 80% of 
variance in age-at-onset. Because of heterogeneity in encoded proteins, different 
pathophysiologic mechanisms leading to neurodegeneration could be involved. The 
relationship between CAG repeat length and age-at-onset would then differ accordingly.  
 
Methods - Based on the results of SCA mutation analysis in the three DNA-diagnostic 
laboratories that serve the entire Dutch population, we surveyed the number of families and 
affected individuals per SCA gene, as well as individual repeat length and age-at-onset. 
Regression analysis was applied to study the relationship between CAG repeat length and 
age-at-onset per SCA gene. The slopes of the different regression curves were compared. 
 
Results - On November 1, 2000, mutations were found in 145 ADCA families and 391 
affected individuals were identified. We extrapolated a minimal prevalence of 3.0 per 100,000 
(range 2.8 to 3.8/100,000). SCA3 was the most frequent mutation. CAG repeat length 
contributed to 52 to 76% of age-at-onset variance. Regression curve slopes for SCA1, SCA2, 
SCA3, and SCA7 did not differ significantly.  
 
Conclusions - The estimated minimal prevalence of ADCA in the Netherlands is 3.0 per 
100,000 inhabitants. Except for SCA6, the relationship between age-at-onset and CAG 
repeat expansion does not differ significantly between SCA1, SCA2, SCA3, and SCA7 
patient groups in our population, indicating that these SCAs share similar mechanisms of 
polyglutamine-induced neurotoxicity, despite the heterogeneity in gene products. 
 24 
      CHAPTER 3.1
Introduction 
Autosomal dominant cerebellar ataxias (ADCAs) are characterized by gait and limb ataxia, 
dysarthria, oculomotor disturbances, and an additional variable spectrum of clinical 
characteristics, usually with an onset after childhood.1 
Recently, genetic mapping studies in ADCA families resulted in the detection of 15 genetic 
loci (SCA1-8, SCA10-14, SCA16, and SCA17), whereas nine of the corresponding genes 
have already been cloned.2-17 In spinocerebellar ataxia type 1 (SCA1), SCA2, SCA3, SCA6, 
SCA7, and SCA17, the common mutation is an expanded CAG repeat in the coding region of 
the corresponding gene, resulting in an elongated polyglutamine (polyQ) tract in the encoded 
protein. How this polyQ stretch induces selective neuronal loss remains unclear. Despite the 
similarity of the mutational mechanisms, the difference in structure and function of the 
encoded proteins may result in different pathophysiologic pathways for these SCA subtypes. 
The specific contributions of the CTG repeat expansion in the untranslated region of the 
SCA8 gene on chromosome 13q, the ATTCT pentanucleotide repeat in intron 9 of the 
E46/SCA10 gene on chromosome 22q, and the CAG repeat expansion in the 5’-untranslated 
region of a brain-specific protein phosphatase gene (PP2A-PR55β/SCA12) on chromosome 
5q remain to be determined.9,12,18  
In trinucleotide repeat expansion disorders, the length of the expanded repeat is inversely 
correlated with age-at-onset. CAG repeat length explains 50 to 80% of age-at-onset variance 
in SCA, as well as in Huntington’s disease (HD).19-21 This suggests a direct role of the polyQ-
tail in neurodegeneration. In addition, trinucleotide repeat expansion diseases show 
anticipation, i.e. an earlier age-at-onset evolves in successive generations. This is largely 
due to a further expansion of the unstable repeat during transmission. In SCA1, SCA2, and 
SCA7, the repeat shows more instability during paternal compared to maternal disease 
transmission.22-24 
Prevalence studies of ADCA are rare. They have mostly been conducted before the 
identification of SCA loci and genes, include the entire group of hereditary ataxias (including 
recessive forms) with little agreement in nosologic definitions, or describe regional 
prevalence only. International descriptive investigations of inherited ataxias provide overall 
prevalence estimates of less than 6/100,000, mostly ranging from 0.3 to 2.0 per 100,000 
inhabitants.25-31 In a historical survey of autosomal dominant SCA in western Norway, a 
prevalence rate of 3.2/100,000 was found.32 The prevalence of ADCA in the Netherlands is 
unknown.  
In the Netherlands, DNA diagnostic testing of patients with ADCA and their families is 
concentrated in three laboratories that serve the entire Dutch population. We provide a 
comprehensive survey of the number of Dutch ADCA families and patients diagnosed at 
these three centers and extrapolate the minimal prevalence of ADCA in the Netherlands, 
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based on the assumption that SCA1, SCA2, SCA3, SCA6, and SCA7 mutations are found in 
about 64% of ADCA families.33 The relative frequency of SCA mutations was assessed. 
Furthermore, the relationship between age-at-onset and CAG repeat length was studied for 
the various genotypes. Because, as explained earlier, the SCA gene encoded proteins are 
structurally and functionally heterogeneous and the pathophysiologic mechanisms may differ 
accordingly, the relationship between age-at-onset and repeat expansion may be different for 
each gene and the protein it encodes.20 Mathematical descriptions of the relationship 
between age-at-onset and CAG repeat length would then be different for each SCA gene.  
 
 
Patients and methods 
Genetic analysis and data acquisition 
Since the identification of the SCA1 gene in 1993,2 SCA mutation analysis in the Netherlands 
has been conducted in the DNA-diagnostic laboratories of the University Hospitals in Utrecht, 
Groningen, and Rotterdam. Current mutation analysis includes the SCA1, SCA2, SCA3, 
SCA6, and SCA7 genes. Routine analysis does not yet include the other SCA loci and genes 
because their clinical relevance remains unclear. Genotyping is based on the detection of 
expanded CAG repeats in these genes, using PCR primers as described elsewhere.2,4,7,34 In 
order to be able to compare the results of the three laboratories, identical samples were 
tested to assess the difference in CAG repeat length estimation. 
On November 1, 2000, we analyzed the results of SCA mutation analysis conducted in the 
three laboratories with respect to the number of families and gene carriers per SCA gene, as 
well as individual repeat length of the normal and the disease allele. Attention was focused 
on the possibility that mutation analysis in different members of one family had been 
performed in distinct laboratories. Family pedigrees, drawn by the consulting clinical 
geneticist, were studied to determine the number of clinically affected individuals that were 
still alive. Age-at-onset was assessed by the referring neurologist (mainly H.K. or E.B.) or 
consulting clinical geneticist (N.K., P.I., J.M., C.V.).  
 
Prevalence assessment 
The minimal prevalence of ADCA was extrapolated, based on the observation by others that 
in approximately 36% of Caucasian ADCA families a mutation cannot be found through 
simultaneous mutation analysis of the SCA1, SCA2, SCA3, SCA6, and SCA7 genes.33 We 
assumed that every extrapolated family consisted of at least one affected individual. We 
were unable to determine the exact number and percentage of ADCA families in which 
routine mutation analysis was without results in our study population because requests for 
SCA mutation analysis originated from all over the country, with clinical diagnoses varying 
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from sporadic ataxia to mild parkinsonism, while in the majority of instances of SCA-negative 
cases no detailed pedigree was provided. The census of the number of inhabitants in the 
Netherlands in November 2000 was obtained through the Dutch Central Bureau of Statistics 
(available at: http://www.cbs.nl). 
 
Statistical analysis of age-at-onset vs. CAG repeat length 
Age-at-onset means were compared with Student’s t-test. Previously, the best-fitting 
relationship between age-at-onset and CAG repeat length was shown to be nonlinear.35-38 To 
construct a linear regression curve accurately, logarithmic transformation of age-at-onset 
data was performed. Multiple linear regression analysis was then applied to assess the 
correlation coefficient of log10(age-at-onset) vs. larger CAG repeat length, as well as the 
contribution of the nonpathogenic allele’s CAG repeat size, because a significant negative 
correlation between age-at-onset and CAG repeat length on the normal allele in SCA3 
patients was previously observed.39 
The slopes of linear regression curves where compared using a Welch t-test (because 
between-group variance > within-group variance; F-test). The level of significance was set on 
p ≤ 0.005 (Bonferroni-correction). All analyses were carried out by using the SPSS computer 
package, version 10.0.7 (SPPS Inc., Chicago, IL.).     
 
 
Results 
Prevalence estimate 
On November 1, 2000, mutation analysis had resulted in the identification of 14 SCA1 
families, 16 SCA2 families, 64 SCA3 families, 34 SCA6 families, 17 SCA7 families, with a 
total number of 145 ADCA families (table 1). From these families, 391 clinically affected 
individuals were known to be alive. Five families were of non-Dutch origin (two Moroccan 
SCA2 families, one Spanish SCA3 family, one Scottish and one French SCA7 family).  
 
 SCA1 SCA2 SCA3 SCA6 SCA7 Unknown Total 
 
No. of families 
 
 
14 
 
16 
 
64 
 
34 
 
17 
 
- 
 
 
145 
Relative frequency (group 
‘genotyped’), % 
 
 
9.7 
 
11.0 
 
44.1 
 
23.5 
 
11.7 
 
- 
 
100% 
Relative frequency 
(group ‘extrapolated’), % 
 
 
6.2 
 
7.1 
 
28.2 
 
15.0 
 
7.5 
 
36.0 
 
100% 
 
Table 1: Overview of the number of families per SCA genotype and the relative frequencies of SCA 
mutations. 
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In the literature, analysis of the SCA1, SCA2, SCA3, SCA6, and SCA7 genes was shown to 
result in identification of a mutation in about 64% of ADCA families.33 Therefore, we expect 
(145 + 36% =) 227 ADCA families in the Netherlands. As stated earlier, all extrapolated 
families have at least one affected individual and hence we estimate a minimal number of 
473 affected individuals. In November 2000 the census of inhabitants in the Netherlands was 
stated at 15,863,950 inhabitants. This results in an estimated minimal ADCA prevalence of 
3.0 per 100,000 inhabitants.  
In ethnically less well-defined patient groups, the percentage of ADCA families in which no 
mutation was detectable was found to vary from 29 to 43%,40,41 which would then result in a 
calculated prevalence range between 2.8 and 3.3 per 100,000 inhabitants. Applying a 
number of two instead of one affected individual per extrapolated ADCA family, this 
prevalence range estimate changes to 3.2-3.8 per 100,000 inhabitants. 
 
 
 SCA1 
(n=18) 
SCA2 
(n=15) 
SCA3 
(n=134) 
SCA6 
(n=34) 
SCA7 
(n=10) 
 
Age-at-onset, y, mean ± SD 
 
 
36.6 ± 12.5 
 
34.7 ± 15.3 
 
39.7 ± 11.7 
 
49.5 ± 10.3¶
 
31.1 ± 14.4 
No. of CAG repeat units, range  
     Normal allele 
     Mutant allele 
 
 
29-37 
41-69 
 
21-26 
32-58 
 
14-35 
53-82 
 
7-14 
22-25 
 
10-12 
38-55 
Correlation coefficient : age-at-
onset vs expanded CAG repeat 
length, r, (p value) 
 
 
-0.87 (<0.001)
 
-0.77 (0.001) 
 
-0.75 (<0.001)
 
-0.72 (<0.001) 
 
-0.87 (0.001) 
Partial correlation coefficient: 
age-at-onset vs normal CAG 
repeat length, r, (p value) 
 
 
0.28 (0.33) 
 
-0.39 (0.17) 
 
0.11 (0.22) 
 
-0.08 (0.67) 
 
-0.37 (0.33) 
 
 
Variance in age-at-onset 
explained by larger CAG repeat 
length (r2 x 100), % 
 
 
76% 
 
59% 
 
56% 
 
52% 
 
76% 
Slope of regression curve ± SE 
 
-0.02 ± 0.003 -0.03 ± 0.007 -0.02 ± 0.002 -0.10 ± 0.018¶ -0.04 ± 0.008 
 
Table 2: Age-at-onset means and results of linear regression analysis of age-of-onset vs normal and 
pathologic CAG repeat length (SD: standard deviation, SE: standard error, ¶: statistically significant). 
 
 
CAG repeat expansions 
No homozygous gene carriers were found. The range of CAG repeat expansions on mutated 
and normal alleles that we detected are shown in table 2 and confirm results reported earlier. 
Notably, in Dutch SCA6 patients only three repeat lengths (22, 23, 25) were detected, with 
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41 of 52 patients carrying 22 CAG repeats on the pathologic allele. Interlaboratory variance 
in repeat length assessment was one repeat unit for SCA1, SCA2, SCA3, and SCA6, and 
two repeat units for SCA7.  
 
Age-at-onset 
As shown in table 2, mean age-at-onset in SCA1 was 36.6 years (range 11 to 66), in SCA2 
34.7 years (10 to 61), in SCA3 39.7 years (14 to 70), in SCA6 49.5 years (16 to 72), and in 
SCA7 31.1 years (8 to 53). Patients with SCA6 experienced a significantly later age-at-onset 
compared with other SCA patients. Although age-at-onset ranged from 16 to 72 years in 
SCA6, only one patient experienced a disease-onset of 16 years, while all other patients 
were 35 years or older when first symptoms emerged. 
 
 
 
 
Figure: Linear regression analysis of age-of-onset vs CAG repeat length after logarithmic 
transformation of age-of-onset (vertical axis; inverse-log of data [years]); note different ranges on 
horizontal axis. 
 
Age-at-onset vs. CAG repeat length  
Data on age-at-onset and number of CAG repeat units from 211 patients were available 
(table 2; figure). After logarithmic transformation of age-at-onset data, linear regression 
analysis showed a significant inverse relationship between length of CAG repeat on the 
mutant allele and age-at-onset in all SCA subtypes. The highest correlation coefficients were 
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found in SCA1 and SCA7 patients (r = -0.87). Pathologic CAG repeat length contributed to 
52 to 76% of variance in age-at-onset. In multiple regression analysis, the length of the CAG 
repeat on the normal allele did not contribute significantly to age-at-onset variance for any of 
the SCA subtypes (r = -0.39 to 0.28).  
Slopes of the different regression curves are depicted in table 2. Applying a Welch t-test 
comparison of regression curve slopes, we found that the slope of the SCA6 curve differed 
significantly from the slopes of the other SCA mutations. Thus, in SCA1, SCA2, SCA3, and 
SCA7, a change in CAG repeat size resulted in a similar change in age-at-onset. 
 
 
Discussion 
Our cross-sectional nation-wide survey indicated that, on November 1, 2000, 145 ADCA 
families with a known mutation, including 391 clinically affected individuals, had been 
identified in the Netherlands. Extrapolating the percentage of ADCA families in which a 
mutation has not yet been found (36%), we estimated a total number of 227 ADCA families, 
473 clinically affected individuals, and a minimal prevalence of 3.0/100,000. Applying the 
extremes of percentages of ADCA families in which a mutation is not found (29 to 43%),40,41 
the prevalence rate would range from 2.8 to 3.3/100,000. This prevalence number exceeds 
most international prevalence estimates of inherited ataxias, but equals the prevalence rate 
of autosomal dominant SCA in western Norway, an area that was considered to display high 
rates of autosomal dominant disorders because of its isolation and the immobility of its 
inhabitants.32 Because some ADCA families and patients still remain unrecognized and 
because the extrapolated families usually consist of more than the assumed number of one 
affected individual, we consider this prevalence number to be an underestimate. When 
assuming that an extrapolated ADCA family consists of two (in stead of the primarily 
assumed one) affected individuals, the calculated prevalence range increases to 3.2 to 
3.8/100,000. 
The relative frequency of the different SCA mutations displays marked geographical and 
ethnical variability. Globally, SCA3 is the most frequent mutation. SCA3 usually accounts for 
20 to 25% of ADCA cases,42 while in Portuguese/Azorean ADCA families, SCA3 is 
responsible for 84% of cases.43 In Cuba, SCA2 is relatively frequent, as is the case in Korea, 
Italy, and India.44-47 SCA6 is frequently found in German and Japanese ADCA families, but is 
rare in Chinese and Indian families.38,48,49 However, these relative frequency assessments do 
not include the (estimated) proportion of ADCA patients who are not under medical attention. 
In Dutch ADCA patients, SCA3 is also the most frequent mutation, followed by SCA6 (see 
table 1). A comparable distribution of genotypes was found among German kindreds.19 
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Because of historical migratory influences, it is possible that in Dutch and German ADCA 
families common founder effects are involved. 
Regression analysis showed that 52 to 76% of variance in age-at-onset is explained by the 
number of repeat units on the mutant allele, a range also reported by others.19,35,37-39,48,50  
Why expanded polyQ-tails result in selective neuronal loss is unclear. Possible mechanisms 
include nuclear accumulation of misfolded protein, interaction with nuclear matrix or nuclear 
proteins, dysfunction of ubiquitin-mediated proteolytic pathways, and alterations in gene 
expression through interaction with transcription factors or alteration of RNA processing.20,51-
55 If the toxic effect of the mutated proteins is primarily protein specific or if different polyQ-
strings have different effects on cell death, significant differences in regression slopes would 
be expected. Alternatively, if the toxic effect is primarily polyQ-dependent, regression slopes 
would yield similar slopes.  
Others have suggested that, because the slope of the regression curve differs for each gene, 
the nature of the encoded protein could modulate the relationship between age-at-onset and 
repeat expansion.20 However, this suggestion is largely based on results obtained via 
different types of regression analyses (linear regression analysis, regression analysis after 
square root transformation, exponential data fit model) and are therefore incomparable. Only 
one group applied linear regression analysis to all (untransformed) data of 119 SCA1, SCA2, 
SCA3, and SCA6 patients and indeed observed different regression curve slopes for each 
mutation: age-at-onset decreased with 0.85 to 4.53 years per expanded CAG repeat.19  
Using a universal statistical approach for all SCA genes in an ethnic homogenous population 
(only five non-Dutch families), we found that only the regression curve slope in SCA6 differed 
significantly from slopes of the regression curves in the other SCA genes. Thus, our 
comparison of regression slopes showed that for the SCA1, SCA2, SCA3, and SCA7 genes, 
the relationship between age-at-onset and CAG repeat expansion is not different. These 
results contradict a modulation of this relationship by the structure and function of the 
encoded proteins. We therefore suggest that SCA1, SCA2, SCA3, and SCA7 share similar 
basic mechanisms of polyQ-mediated toxicity, despite differences in protein function. This 
hypothesis is strengthened by the finding that in HD, another CAG repeat expansion 
disorder, an earlier regression analysis of CAG repeat size versus log(age-at-onset) 
produced a comparable slope of –0.03.21 In addition, there is accumulating evidence 
resulting from chemical and cell biological experiments that the polyQ-tract is indeed the 
most important link in the pathophysiologic chain.56-59 
Despite this finding of similar alterations in age-at-onset per alteration of the CAG repeat unit 
for the SCA1, SCA2, SCA3, and SCA7 subtypes, our findings do not explain why the 
different genes have different threshold repeat lengths above which pathogenicity starts. For 
example, why are repeats over 32 units already deleterious in SCA2, while SCA3-induced 
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neuronal damage starts only over 53 repeat units? Different environments or cerebral 
regions in which the SCA genes are expressed cannot account for these differences: the 
SCA2 and SCA3 genes are both ubiquitously expressed throughout the brain. Clearly, the 
protein context, i.e. the chemical and functional characteristics of the encoded proteins and 
the protein’s interactions with other proteins, must play a role in these threshold effects. It 
might be expected that a sufficiently large data set will ultimately yield significant differences 
between regression curve slopes, and will then shed light on the true contribution of the 
protein context. 
There are arguments to suspect the essentially different behaviour of the SCA6 mutation. 
First, the CAG repeat expansion is small and relatively stable compared with other SCA 
mutations. Second, a distinct pathophysiologic mechanism may be involved in SCA6: the 
SCA6 gene encodes a voltage-gated calcium channel and the CAG repeat expansion results 
in channel dysfunction.60  
In this study, 24 to 48% of variance in age-at-onset remains unexplained. In SCA3 kindreds, 
a significant negative correlation between age-at-onset and CAG repeat length on the normal 
allele (r=-0.25) was observed once.39 This was not confirmed in SCA1 and SCA7 
patients.35,37,40 We must also conclude that, in our study population, the length of the CAG 
repeat on the normal allele does not contribute significantly to age-at-onset variance. Several 
small age-at-onset modifiers have been detected, such as the sex of the transmitting parent 
in SCA1 (2.1%),37 overall interfamilial genetic differences in SCA1 (5%),37 and length of a 
CAG repeat in the RAI1 gene in SCA2 (4.1%).61 In addition, genotype variation in the GluR6 
gene and the Δ2642 polymorphism in the HD gene provided additional yet minor contribution 
to age-at-onset variance in HD.62,63 Recently, several proteins that interact with the SCA 
gene encoded proteins or with expanded polyQ stretches have been identified (e.g. A1Up, 
CBP, A2BP1). These proteins function as transcription coactivators, contain RNA-binding or 
ubiquitinlike motifs, regulate heat shock responses, or are involved in oxidative/chemical 
stress reactions.51,52,64,65 In SCA1 transgenic mice for example, these interacting proteins 
result in the down-regulation of several genes involved in Purkinje cell calcium homeostasis, 
signal transduction, and neurotransmission.64 The characteristics of these interactions modify 
polyQ-induced cytotoxicity and as such may account for the remaining variance in age-at-
onset.    
Several issues must be addressed. First, different physicians performed the assessment of 
disease onset. The age-at-onset estimation is known to be susceptible to biases and to be 
characterized by a low interobserver reliability. Retrospective estimations of onset age in a 
disease with a slow progressive course remain difficult, both for the physician and the 
patient. Older patients have the tendency to estimate a later age-at-onset. Nevertheless, 
average age-at-onset data and our results of variance analysis were similar to results 
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observed by others. From a statistical point of view, it can be argued that even a 5-years 
difference in age-at-onset determination does not alter results significantly, as long as no 
systematic bias is introduced. Second, the SCA1, SCA2, and SCA7 groups were relatively 
small compared with the SCA3 and SCA6 groups (owing to differences in relative 
frequencies of these SCA mutations). Third, the independent variable (CAG repeat size) was 
not distributed normally. However, repeat linear regression analysis after additional 
logarithmic transformation of pathologic CAG repeat length showed identical regression 
coefficients (data not shown). Fourth, mutation analysis did not include the SCA4, SCA5, 
SCA11, SCA13, and SCA14 loci, or the SCA8, SCA10, SCA12, and SCA17 genes. Besides 
SCA8, these mutations have been detected in only a small number of families. SCA12 and 
SCA17 mutation analysis in a large sample of our ADCA population (150 to 300 patients) 
was negative (unpublished data, 2001). It appears that these two recently detected SCA 
genes do not play an important role in Dutch ADCA families and patients. The transcript of 
the SCA8 gene was shown to be an antisense RNA transcript encoding an actin-binding 
protein, termed KLHL1.66 However, the pathogeneity of the CTG-expansion in the 
untranslated region of the SCA8 gene remains uncertain.67,68 Remarkable features include a 
contraction of the repeat on paternal disease transmission, a reduced penetrance, and the 
detection of expanded repeats in healthy controls and patients with psychiatric disorders.67,69 
We detected expanded CTG repeats in the SCA8 gene in 13 of a sample of 100 patients with 
cerebellar ataxia, incuding a sporadic case of multiple system atrophy, as well as in SCA6 
and SCA7 patients (unpublished data, 2001). It is therefore possible that the CTG repeat 
expansions are polymorphisms juxtaposed to the true causative mutation on chromosome 
13q21.69  
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 Abstract 
Introduction – In dominant spinocerebellar ataxias (SCA), the issue of whether non-CAG 
dependent factors contribute to age at onset remains unsettled. We sought to address this 
issue from a mathematical perspective. 
 
Methods – Data on SCA subtype, age at onset, normal and expanded CAG repeat length, 
sex of the patient and transmitting parent, and family details were available from 802 Dutch 
and French SCA patients. Analyses were based on the model [log10 (age at onset) = k – b 
CAGexp + ε] and we examined changes in adjusted R2 and residual standard error following 
incorporation of the other factors in this model. 
 
Results –The size of the expanded repeat explained 44.3 to 74.9% of the variance in age at 
onset, although this was less than 50% in SCA3 and SCA6, implicating a large effect of non-
CAG factors. The relation between age at onset and CAG repeat length was similar for 
SCA1, 3, 6, and 7, but different for SCA2, which points to different polyglutamine effects in 
SCA2. For SCA2 and SCA3, 17.1% and 45.5% of the age at onset variance, respectively, 
was explained by yet unidentified familial factors. We found a significant contribution of the 
non-expanded allele to the age at disease onset in SCA1 and SCA6. Sex of the patient and 
transmitting parent had no effect on onset age. Comparisons with Huntington’s disease data 
did not rule out a possible effect of neuronal tissue context factors. 
 
Conclusion - Besides the polyglutamine motif (determined by the length of the expanded 
CAG repeat) this statistical analysis identified the following age at onset modifiers: protein 
context in SCA2; familial factors in SCA2 and SCA3; and the CAG repeat length on the non-
mutated allele in SCA1 and SCA6.  
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Introduction 
Trinucleotide (CAG) repeat expansions are the causal mutations in at least six autosomal 
dominant cerebellar ataxias (SCA1, 2, 3, 6, 7, and 17), as well as in Huntington’s disease 
(HD).1-7 There is a strong and consistent relationship between the age at onset and the 
length of the expansion in these disorders. Typically, 50% to 80% of onset variance has been 
attributed to CAG length.1,8-13 It was felt that this relationship was indicative of the underlying 
molecular pathology, which was supported by the finding that the length of the CAG 
translated polyglutamine (polyQ) sequence predicted the propensity towards aggregation of 
polyQ-containing peptides.14 It is now believed that the identification of non-CAG-size 
dependent factors that explain remaining onset age variance would possibly allow treatments 
that retard disease onset. 
The hunt for such contributing factors, however, has been much less successful, as these 
were either very small in magnitude, such as TAA repeat polymorphisms in the GluR6 gene 
in HD,15,16 or were never consistently established, such as the CAG size on the non-disease 
allele.17  
Moreover, a number of methodological issues have complicated interpretation of such 
genotype-phenotype correlation studies: statistical overfitting of the function of onset age 
versus CAG length due to focussing on one disease; statistical outliers and non-normal 
independent variable distribution due to the fact that the majority of pathogenic CAG sizes 
are in the lower pathogenic range; no true variable-independency due to including data from 
multiple family members; too much emphasis on the proportion of explained variance and not 
on the slope and the intercept of the regression curves or on the distribution to the residual 
variance.  
Onset age of a CAG expansion disorder can be thought of as being potentially determined 
by: (1) the size of the polyQ expansion in the cognate protein that is completely determined 
by the size of the genomic CAG repeat; (2) the nature of the protein itself – the protein 
context;  (3) cis-acting genetic factors in linkage disequilibrium with the gene on the affected 
chromosome – typically familial or ethnic factors; (4) transacting genetic factors – again, 
(partially) recognizable as familial or ethnic factors (e.g. CAG size on the normal allele); (5) 
the tissue context in which the cognate protein is expressed; and (6) environmental factors. 
Comparing genotype-phenotype correlations for the various trinucleotide expansion 
disorders has rarely been performed.18 Yet, such a comparison might offer additional insight 
into the intrinsic toxicity of polyQ peptides and the contribution of tissue context factors. 
In this study, we performed a comprehensive analysis of onset age in relation to CAG 
expansion size, and from the statistical analysis we attempted to derive the relative 
contributions of the various biological determinants, in order to test within a quantitative 
framework the importance of the various mechanistic qualitative hypotheses that have been 
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 raised regarding the mechanism of polyQ-induced neurodegeneration.  
 
 
Subjects and methods 
Data collection 
Data on clinically affected SCA patients with a mutation in the SCA1, 2, 3, 6, or 7 gene were 
collected from the Dutch SCA database and from the Department of Genetics, Hôpital de la 
Salpétrière, Paris, France. Patient data were included if age at onset and length of expanded 
(and normal) CAG repeat were known.  
The data set included the following variables: SCA subtype, age at onset, expanded and 
non-expanded CAG repeat length, gender, and family. Size of the CAG repeat had been 
assessed by direct mutation analysis according to previously published protocols.1-4,19 Age at 
onset, determined as the age at which the first symptoms of ataxia appeared and assessed 
by neurologists or clinical geneticists experienced in the care for ataxia patients, was 
extracted from clinical records. 
Data on 211 Dutch SCA patients, which are included in this study, have been used in a 
previous analysis.10 
In addition, we collected similar data on 63 Dutch patients with Huntington disease (HD) from 
the database of the Department of Neurology, University Medical Center Nijmegen. Only one 
member per HD family was included. The size of the CAG repeat in HD cases was assessed 
at the laboratory for DNA diagnostics, Leiden University Medical Center. 
 
Statistical analysis 
For statistical analysis, packages Splus version 6.0.1 (release 1, Silicon Graphics Irix, IRIX 
6.5, 2001) and “R” version 1.6.2 for Windows were used.20 
Visual inspection of the age at onset means and standard deviations plotted against the 
expanded CAG repeat length for each given SCA subtype showed a remarkable proportional 
relationship. Therefore, in order to obtain homoscedasticity, logarithmic transformation of age 
at onset was performed.  
Linear regression analysis was then applied to assess the linear relationship of (the logarithm 
of the) age at onset as depending on the expanded CAG repeat length. One model to fit all 
SCA subtypes as well as the HD data was tested to allow comparisons of the absolute 
magnitudes of the residual standard errors and slopes of the regression curves. 
 
The presumed model per SCA subtype is described as follows: 
 log10 (age at onset) = k – b CAGexp + ε ,  
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where ‘k’ represents the SCA subtype specific intercept, ‘b’ the slope of the regression curve, 
‘CAGexp’ the length of the expanded CAG repeat, and ‘ε’ the random residual of age at onset 
from the regression curve for a given repeat size (which holds a standard error).  
 
The model that incorporates all five SCA subtypes is described as: 
 log10 (age at onset) = kSCA – bSCA CAGexp + ε 
With these models, dependency of age at onset on the expanded repeat length and on SCA 
subtype (intercept, slope) was investigated.  
 
Subsequently, dependency of the onset age on the length of the non-expanded repeat 
(CAGnorm) was studied: 
 log10 (age at onset) = k – b CAGexp + c CAGnorm + ε 
 
The dependency of age at onset on familial factors (FAM) was studied as: 
log10 (age at onset) = kFAM – bFAM CAGexp + ε,  
which means that for each SCA type separately an ANCOVA analysis was performed with 
log10(age at onset) as numerical response variable, CAGexp  as numerical regressor variable, 
and FAM as factor. 
 
The influence of gender factors (G) and the sex of the transmitting parent (S) were studied 
as: 
 log10 (age at onset) = kSCA, G – bSCA, G CAGexp + ε,  
log10 (age at onset) = kSCA, S – bSCA, S CAGexp + ε, respectively 
 
Traditionally, the linear model with the highest coefficient of determination (R2) is adopted. 
However, during preliminary analysis, the R2 appeared not to be informative when family 
dependence was considered, due to the fact that the dataset contains a large number of 
families that comprise only ‘one’ or two patients. The perfect fit for these patients, when 
family dependence is considered, is very likely responsible for very high, yet overestimated, 
values of R2.  We therefore chose to assess regression by means of the adjusted R2, which 
includes an adjustment for the degrees of freedom involved in the regression. We employed 
the residual standard error as another measure of fit. The residual standard error is an 
estimate of the standard deviation of the age at onset given a particular value of the 
explanatory variables (SCA subtype, expanded repeat length, and family factors). There is a 
fixed relation between residual standard error and adjusted R2. We consider the proportion of 
unexplained age at onset variance (1-adjusted R2) or the residual standard error to represent 
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 the total magnitude and complexity of non-CAG dependent mechanisms. 
 
 
Results 
Dataset 
Data from 806 patients were collected (217 patients from the Dutch and 589 from the French 
database). Inspection of age at onset vs. expanded CAG size plots pointed to four patients 
as relative outliers: two SCA7 patients with CAG repeat lengths > 300 and onset ages < 1 
year, one SCA2 patient with an age at onset of 10 years and 82 CAG repeats, and a SCA6 
patient with 25 repeats and an onset at age 16 years. Using the influence criterion based on 
Cook’s distance, as built in the statistical package “R”, these four patients were indeed 
identified as influential, having too great an impact on the model by overruling the bulk of 
other data.20 These data were therefore excluded from further analysis, which thus included 
802 patients. The corresponding descriptive statistics are depicted in table 1. 
 
 SCA1 SCA2 SCA3 SCA6 SCA7 
 
No. of patients 
 
138 
 
166 
 
342 
 
53 
 
103 
 
Sex 
male 
female 
N.D. 
 
 
74 
55 
9 
 
 
94 
70 
2 
 
 
157 
160 
25 
 
 
27 
14 
12 
 
 
60 
41 
2 
 
Age at onset 
mean, yrs ± SD 
range, yrs 
 
 
35.5 ± 10.6 
11-66 
 
 
34.6 ± 13.3 
8-67 
 
 
39.5 ± 11.6 
5-73 
 
 
49.2 ± 9.8 
24-72 
 
 
29.2 ± 15.2 
1-70 
 
CAG repeat length 
normal  
  mean ± SD 
  range 
expanded  
  mean ± SD 
  range 
 
 
 
30.3 ± 1.94 
26-37 
 
49.7 ± 5.8 
40-69 
 
 
 
22.2 ± 1.05 
15-29 
 
40.5 ± 3.6 
35-58 
 
 
 
22.0 ± 4.82 
3-35 
 
71.5 ± 4.3 
58-82 
 
 
 
12.4 ± 1.86 
6-14 
 
23.1 ± 2.0 
21-28 
 
 
 
10.9 ± 3.82 
0-35 
 
50.3 ± 13.2 
38-130 
 
Number of families 
with 2 members 
with 3 members 
with 4 members 
with ≥5 members 
 
 
 
9 
6 
2 
8 
 
 
9 
5 
5 
11 
 
 
17 
21 
4 
12 
 
 
5 
3 
1 
1 
 
 
8 
5 
2 
6 
 
Table 1: Descriptive statistics of collected data (N.D. = no data, S.D. = standard deviation). 
 
CAG repeat / polyQ contribution 
The parameters of the model for each SCA subtype are shown in table 2. 
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Depending on the SCA subtype, the size of the expanded repeat explained 44.3 to 74.9% of 
the variance in age at onset. The size of the expanded triplet in SCA3 and SCA6 was 
responsible for less than 50% of variance in age at onset, which suggests a major influence 
of other factors.  
 
Protein context 
Although one might argue that the differences in the intercept of the various regression 
curves point to protein context factors, this may also be interpreted as representing a 
threshold effect that does depend on the native protein but is not related to the polyQ tract 
itself. 
 
 SCA1 SCA2 SCA3 SCA6 SCA7 
Intercept (k) 2.48 3.29 3.18 2.38 2.41 
Slope (b ) ± s.e. -0.019 ± 
0.0012 
-0.044 ± 
0.0021 
-0.022 ± 
0.0013 
-0.030 ± 
0.0047 
-0.020 ± 
0.0012 
r.s.e. of ε 0.080 0.097 0.106 0.069 0.157 
R2 0.66 0.73 0.45 0.44 0.75 
Adjusted R2 0.66 0.73 0.45 0.43 0.75 
Familial dependency 
   r.s.e. 
   R2
   adjusted R2
 
0.082 
0.84 
0.63 
 
0.082 
0.91 
0.80 
 
0.080 
0.87 
0.70 
 
0.062 
0.83 
0.56 
 
0.16 
0.90 
0.75 
Table 2: Parameters based on the model: log10 (age at onset) = k – b CAGexp + ε; s.e. = standard 
error, r.s.e. = residual standard error. 
 
Answering the question whether the relation between age at onset and CAG repeat length is 
similar for the different SCA types will clarify whether the context of the protein in which the 
polyQ tract is contained attributes to the disease mechanism. When the data from all 
subtypes are handled together (i.e. allowing corrections in the intercept that depends on the 
SCA subtype), it is observed that allowing corrections for the slope of the various SCA 
subtypes induces a significant improvement of the model (F=26.400, df=(4,792), p < 3e-16), 
with a change of adjusted R2 from 0.6280 to 0.6701, a gain of 6.3%. However, when the 
SCA2 patients are removed from the data set, the significant contribution to the model 
disappears. The different slope is illustrated in the figure. Thus, the relation between age at 
onset and CAG repeat length is similar for SCA1, 3, 6, and 7, pointing to identical polyQ 
effects in these subtypes and suggesting that in SCA2 the polyQ tail exerts its effect in a 
slightly different way.  
 
Contribution of non-CAG dependent factors  
The residual standard error may reflect the magnitude or complexity of the non-CAG-related 
disease pathways. Larger residual standard errors would implicate either a larger 
 45
 contribution of individual non-CAG factors or a larger number of non-CAG factors that 
contribute to the age at onset for a given repeat size. Pair-wise comparison of the residual 
variances of the different SCA subtypes identified three distinct groups that withhold similar 
residual standard errors: SCA1 and SCA6 (common residual standard error 0.077, df=187); 
SCA2 and SCA3 (common residual standard error 0.103, df=504); and SCA7 (residual 
standard error 0.157, df=101). In terms of ascending order of residual standard error 
magnitude, the different SCA subtypes could be listed as: SCA6, SCA1, SCA2, SCA3, and 
SCA7. 
 
 
Figure: Curves of age at onset (after logarithmic transformation; AGE.ONS) versus length of expanded 
CAG repeat (CAG.EXP) for the five SCA subtypes studied. Note the different steepness of the SCA2 
curve.  
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Familial dependency 
If trans-acting genetic or environmental factors (both shared by family members) indeed 
modulate age at onset, a subset of these factors will manifest by causing a significant 
reduction of residual variance in age at onset within SCA families as compared to between 
families.  
In SCA2 and SCA3, a significant improvement was obtained by incorporating familial 
dependency into the model (table 2). For SCA2, the residual standard error decreased from 
0.096 to 0.082 and the adjusted R2 increased from 0.732 to 0.804 (p-value=0.011). In SCA3, 
this resulted in a decrease of the residual standard error from 0.107 to 0.079, while the 
adjusted R2 increased from 0.454 to 0.697 (p-value<0.001). Thus, 17.1% and 45.5% of the 
age at onset variance in the SCA2 and SCA3 cohort, respectively, can be explained by 
interfamilial differences, indicating that yet unknown trans-acting genetic or environmental 
factors are involved in the polyQ pathway.  
No significant familial dependency of the model was found for SCA1, 6, and 7. 
 
Contribution of non-expanded CAG-repeat 
We observed a significant contribution of the length of the CAG repeat on the normal allele to 
the variance in age at onset (F= 4.04, df=(5,782), p-value=0.0013), although the 
corresponding reduction in residual standard error is low: 0.95%. Further analysis revealed 
that this effect is accounted for by a small but significant contribution of the normal allele in 
the SCA1 (F=12.6, df=(1,132), p-value=0.00054) and SCA6 (F=6.23, df=(1,50), p-
value=0.016) subtypes, accompanied by a decrease in the residual standard error of 4.09 
and 4.76%, respectively. While the coefficient of the CAGnorm-term in SCA6 was found to be 
–0.0139, meaning that larger repeat sizes on the normal allele are associated with an earlier 
age at onset in SCA6, this coefficient in SCA1 was +0.0120, indicating that larger non-
expanded repeats slightly counteract the effect of the expanded repeat on onset age in 
SCA1. This observation supports the hypothesis that trans-acting genetic factors influence 
age at onset. 
 
Tissue context 
In order to address the question whether the effect of the elongated polyQ tracts depends on 
the neuronal populations that suffer from such a mutation, we studied a small sample of 63 
HD patients (mean age at onset 42.7 ± 12.2 years; mean length of expanded CAG repeat 
45.9 ± 4.2) and compared the results with the SCA data. The residual standard error was 
0.075, and for this parameter, HD should be grouped with SCA1 and SCA6. The slope of the 
HD regression curve (-0.029 ± 0.0022) did differ significantly from the slopes of SCA1, SCA2, 
SCA3, and SCA7, but not from the SCA6 slope. These data partly support the hypothesis 
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 that polyQ tracts or fragments have distinctive effects in different neurons or neuronal 
populations. 
 
Other factors 
Gender differences did not contribute significantly to the model, making gross hormonal 
factors unlikely modifiers. The sex of the transmitting parent did not significantly affect age at 
onset. Also, the length of the expanded CAG repeat was not related to the parental sex 
(numerical results not shown). 
Finally, we did not find a significant contribution of ‘origin’, which rules out relevant 
differences between the Dutch and French data (data not shown). 
 
 
Discussion 
The quest for genetic and non-genetic factors that explain the full range of age at onset 
variance is of great importance for the elucidation of the pathophysiology of SCAs and could 
also provide targets for therapeutic interventions. Based on a quantitative framework, we 
studied the data in a Dutch-French cohort of 802 SCA patients. Although the results of this 
study are purely mathematical, biological hypotheses can be generated.  
The length of the expanded CAG repeat has been reported to explain 50 to 80% of age at 
onset variance, which is largely confirmed by our results (44 to 75%).1,8-13 Although this 
would support a direct role of polyQ in neuronal dysfunction and death in these SCAs, less 
than 50% of variance in age at onset in SCA3 and SCA6 was attributable to the size of the 
expanded repeat, suggesting a major influence of other factors. 
SCAs share the main trigger of pathogenesis, namely the polyQ sequences. Because the 
protein that contains this polyQ strand is different for each SCA subtype, it might be expected 
that the consequences of this shared trigger are (slightly) different as well. This should then 
be reflected by different slopes of regression curves of age at onset versus CAG length. Our 
analysis of 802 SCA patients shows that slopes were similar for SCA1, 3, 6, and 7, which 
suggests that these SCA subtypes share similar basic mechanisms of polyQ-mediated 
neurotoxicity, despite differences in structure and function of the host proteins. Contrary to 
this, the slope of the regression curve in SCA2 was significantly different. This favours a role 
of protein context factors in the polyQ pathway of SCA2. The most likely factor for this is that, 
considering the relative steepness of the curve and the relative shortness of the CAG 
expansion in SCA2, the SCA2 gene product is more sensitive to polyQ expansions. This 
might be attributable to the fact that mutant ataxin-2 is less efficiently cleared by the cell than 
the other ataxins.2,21 In addition, true SCA2-specific mechanisms might exist, which would 
then be related to protein interactions and disturbances in the normal cellular function of the 
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disease protein. The main reason to consider the possibility of a differential pathogenesis in 
SCA2 is the fact that, contrary to SCA1, 3, 7, and HD, the cytoplasm rather than nucleus is 
the primary site of pathology in SCA2.21,22-25  
When comparing the various slopes shown in table 2, the slope of SCA6 also seems to be 
different, although the statistical analysis does not corroborate this observation. This may be 
due to the relatively small size of the SCA6 sample, to the low variation of CAG sizes, and to 
the large standard error of the slope. There is a biological justification for a different slope in 
SCA6 and a larger SCA6 sample size may ultimately confirm this.10 
We did find some support for the contribution of tissue context factors, as the main 
parameters in a dataset of HD, a CAG expansion disorder that mainly affects the basal 
ganglia rather than the cerebellum, were significantly different from the SCA data, except for 
SCA6. We cannot exclude the possibility that the findings in HD are not all related to tissue 
context factors but also to protein context, as the encoded protein, huntingtin, differs also in 
structure and function from the ataxins. 
In SCA1 and SCA6, the length of the non-expanded repeat was observed to have a modest 
but significant influence on the age at onset, although this effect is different for SCA1 and 
SCA6. While larger repeat sizes on the non-mutated allele produce a earlier onset in SCA6, 
the reverse appears to be the case in SCA1. This might be due to functional or 
conformational differences in the corresponding non-polyQ proteins or distinctive aggregation 
kinetics that lead to a differential pace in the disruption of normal protein function. This 
observation adds to the idea that the protein context influences age at onset.  
The effect of familial factors on age at onset variance has been intensively studied in HD,26-28 
but such studies are rare in SCAs.29,30 We found that interfamilial differences, due to yet 
unknown factors that cluster within families, accounted for 17.1 and 45.5% of the age at 
onset variance in SCA2 and SCA3, respectively. We can not rule out the possibility that 
similar results will also be obtained for the other SCA subtypes when larger subtype cohorts 
are studied that contain larger families. We postulate that such familial factors are most likely 
to be polygenic, which is supported by a small number of genes that have been found to 
modify age at onset, albeit to a very modest extent (ΔR2 = 0.004 - 0.07).15,16,31-35 
Although it is known that very early-onset cases in SCAs and HD only occur on paternal 
transmission, there remains debate about a true effect of the sex of the transmitting 
parent.27,36,37 Here, we did not find a significant effect of the sex of the transmitting parent on 
the age at onset or on the length of the repeat expansion.  
Several confounding factors may have influenced the results of this study. The assessment 
of the age at onset in a slowly progressive disease is known to be susceptible to biases and 
to be characterized by a low interobserver reliability. Different physicians use different key 
symptoms or signs to define disease onset. In addition, older patients have the tendency to 
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 recall a later onset age and although this affects all SCA subtypes alike, this might 
theoretically lead to an overestimation of the steepness of the regression curves. Other 
potential confounders include an overfitting of the regression curve, differences in the size of 
the data set for the various SCA subtypes, and errors in CAG repeat length assessment 
(carried out by different laboratories). Regarding the latter, in a previous study, we showed 
that the inter-laboratory variance in this assessment was one repeat unit for SCA1, SCA2, 
SCA3, and SCA6, and two repeat units for SCA7. Because there was no indication for a 
systematic error, we do not believe this has influenced results.10 
In conclusion, the following factors, besides the polyQ motif, were identified as age at onset 
modifiers: protein context (SCA2); familial factors (suggested to be genetic) in SCA2 and 
SCA3; and the length of the CAG repeat on the non-mutated allele in SCA1 and SCA6. 
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CHAPTER 3.3 
 
The infantile phenotype in spinocerebellar ataxia type 7: an 
example of genotype - phenotype correlations 
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Knoers NVAM, Kremer HPH. Striking anticipation in spinocerebellar ataxia type 7: 
the infantile phenotype. J Neurol 2001;248:911-914. 
 Abstract 
Autosomal dominant cerebellar ataxia (ADCA) type II, caused by pathologic CAG repeat 
expansions in the spinocerebellar ataxia type 7 (SCA7) gene, is clinically characterized by 
pigmentary macular degeneration in addition to signs and symptoms of spinocerebellar 
pathology. Anticipation usually accompanies paternal disease transmission. Infantile disease 
onset has been reported rarely and is characterized by marked multi-organ involvement. We 
report a severe infantile SCA7 phenotype in two siblings, encompassing additional 
hypotonia, patent ductus arteriosus, capillary leak syndrome, and hepatomegaly. In one 
infant, we detected the largest repeat expansion reported ever: 460 CAG repeat units. The 
infantile SCA7 phenotype should be included in the differential diagnosis of neonatal 
hypotonia. In unexplained neurological diseases of childhood, autosomal dominant disorders 
with extreme anticipation should always be considered, even when the parents are 
unaffected. 
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Introduction 
Autosomal dominant cerebellar ataxia type II (ADCA II) is characterized clinically by 
progressive cerebellar ataxia and pigmentary macular degeneration.1 Age-at-onset may be 
highly variable, ranging from 1 month to 76 years, with a mean age of 32 years.2-4 ADCA type 
II is genetically homogeneous and caused by a pathologic CAG repeat expansion in the 
spinocerebellar ataxia type 7 (SCA7) gene on chromosome 3.5 The gene encodes for the 
ataxin-7 protein, the function of which remains unknown.6,7 Pathologic repeat sizes range 
from 37 to 306 repeats, while normal alleles contain 4 to 35 CAG units.2,8 The expanded 
CAG repeat results in an elongated polyglutamine stretch in the ataxin-7 protein. SCA7 is 
therefore added to the growing list of polyglutamine tract diseases, that also includes 
Huntington’s disease (HD) and other SCAs. In all polyglutamine expansion diseases, an 
inverse relationship exists between repeat length and age-at-onset, i.e. the longer the repeat, 
the earlier the disease begins. These disorders also feature the phenomenon of anticipation: 
successive generations experience an earlier age-at-onset. This is largely due to expansion 
of the unstable repeat during meiosis. In SCA7, the expanded repeat is more unstable in 
paternal than in maternal transmission.9,10  
The rarely documented infantile SCA7 phenotype, characterized by additional 
extraneurological manifestations and a rapidly progressive course, is associated with 
enormous repeat expansions on paternal disease transmission.2,4,8,11 
Here we report a family, in which the onset of ataxia and subsequent detection of the SCA7 
mutation in the father retrospectively explained a fatal multisystem illness in two children who 
died young.  
 
 
Family report (figure) 
Proband III-3 presented with visual complaints at age 35, being specified as blurred vision for 
distant objects with clearer vision in dimmed light. An ophthalmologist diagnosed bilateral 
cone dystrophy. Because of consanguinity of the proband’s parents, an autosomal recessive 
pattern of inheritance was considered. 
Two years earlier, patient IV-3 (a girl) was born. Acute respiratory distress resulted in 
immediate admission to the neonatal Intensive Care Unit (ICU). Cardiological examination 
revealed an atrial septum defect and a patent ductus arteriosus, which were surgically closed 
at 7 months of age. Physical examination showed hepatomegaly, and multiple hemangiomas 
of the trunk, abdomen and right upper leg, without dysmorphic features. Her motor 
development was delayed from birth onwards due to generalized hypotonia. Eye contact was 
poor; an ophthalmologic examination at the age of 7 months revealed retinitis pigmentosa. A 
metabolic disorder was suspected, particularly as repeated episodes of low serum lactate 
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 levels (< 0.1 mmol/L) were reported. Extensive metabolic studies were performed in blood, 
cultured skin fibroblasts, liver, and muscle, which excluded peroxysomal disorders and 
defective glycogenolysis. Chromosomal analysis was normal. After cardiac surgery, the 
patient developed severe capillary leak syndrome. At age 8 months she suffered arterial 
hemorrhage complicating a liver biopsy, which led to fatal multi-organ failure. An autopsy 
was not permitted. In the follow-up genetic counselling, it was discussed that the girl most 
probably had suffered from a recessive metabolic disorder and that a twenty-five percent 
recurrence risk for future offspring was likely. Three years later (several months after the 
onset of visual disturbances in the father), patient IV-5, the three-month-old son, was 
admitted, because of persisting vomiting and failure to thrive. Physical examination showed 
tachypnea, a continuous cardiac murmur grade II-III, hepatomegaly, roving eye movements, 
and generalized hypotonia. No typical dysmorphic characteristics were present. 
Echocardiography indicated a patent ductus arteriosus and an atrial septum defect. An 
ophthalmologist, consulted because of decreased visual contact, again diagnosed retinitis 
pigmentosa. Evaluation of brainstem-evoked auditory potentials showed central conduction 
disturbances. Electroretinography showed no detectable retinal activity. Additional 
electrophysiologic investigations were normal.  
 
 
? 
I:1 
?
I:2
II:1 II:2 II:3 II:4 II:5 II:6 II:7
III:1 III:3 III:2
IV:1 IV:2 IV:3 IV:4 IV:5
 Figure: Family pedigree  
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Neuroimaging indicated cerebellar atrophy. Reconsidering the clinical features of the 
deceased sister, autosomal recessive metabolic disorders, including mitochondrial disease, 
peroxysomal disorders, and carbohydrate deficient glycoprotein syndrome, were suspected. 
However, biochemical analyses of blood, cerebrospinal fluid, bone marrow, and muscle, as 
well as endocrinological screening, chromosomal analysis, and muscle and renal biopsy 
were all normal, as was a sweat test.  
The patent ductus arteriosus and the atrial septum defect were operatively corrected. 
Postoperatively, the patient deteriorated due to severe capillary leak syndrome and was 
admitted to the ICU, where, at 5 months of age, he died due to multi-organ failure resulting 
from Klebsiella oxytoca sepsis. Autopsy examination revealed multi-organ involvement 
compatible with septic shock and bronchopneumonia. Microscopic examination of the eye 
showed alternating hyper- and hypopigmentation of the retinal pigment epithelium with focal 
photoreceptor degeneration, compatible with early-stage retinitis pigmentosa. 
Neuropathological studies revealed oedematous changes of cerebral cortex and a small 
focus of ischemia in the cerebellar cortex; gross structural abnormalities and migratory 
disturbances were absent. In the subsequent genetic counselling session the autosomal 
recessive pattern of inheritance of an unclassified systemic disorder was re-emphasized.  
At the age of 38 years, one year after the death of his son (patient IV-5), the proband III-3 
noticed gait difficulties and clumsiness of the hands. He recalled that his father (II-6) and an 
uncle (II-4) had walking difficulties as well. Neurological examination showed severe slowing 
of horizontal and vertical saccades, central scotoma, cerebellar dysarthria, limb and gait 
ataxia, and symmetrical hyperreflexia with indifferent plantar responses. Neuroimaging 
revealed marked cerebellar atrophy.  
A clinical diagnosis of ADCA type II was made. Genetic analysis revealed an expansion of 
the CAG repeat (49 repeats) in the SCA7 gene. Southern blot analysis of DNA extracted 
from stored peripheral leukocytes of patient IV-5 and from stored fibroblasts of patient IV-3 
using a SCA7 probe indicated enormous repeat expansions of 325 and 460 repeats, 
respectively, the latter constituting the largest ever reported. 
 
 
Discussion 
The infantile SCA7 phenotype has been reported previously. Benton et al. described an 
infant with the onset of congestive heart failure due to patent ductus arteriosus at the age of 
2 months.2 Additional irritability, mild hypotonia, acquired microcephaly, swallowing 
difficulties, inability to visually track objects, and cerebellar atrophy on neuroimaging were 
found. The infant died at the age of 6 months. His father had only mild tandem walking 
difficulty at the age of 45 years. The father’s SCA7 allele contained 43 repeats, while in the 
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 infant 306 repeat units were detected. The infant reported by Hsieh et al. was found to have 
nystagmus at 1 month of age and developed severe hypotonia, signs of visual impairment, 
and developmental delay.4 Aspiration pneumonia was the cause of death at age 17 months. 
SCA7 mutation analysis was not carried out. The father, 44 years old, was still asymptomatic 
with 41 CAG repeats in the SCA7 gene. Johansson et al. briefly described an infant with 
>200 repeat units, whose father noticed ataxia at the age of 35 years and was found to have 
49 CAG repeats.11 Clinical features in the child included poor weight gain, patent ductus 
arteriosus, breathing problems, and metabolic acidosis. The infant died at 7 months of age. 
Finally, Neetens et al. described an ADCA type II pedigree that included an infant with a 
cardiac anomaly, which caused death at the age of 6 weeks. The father was the transmitting 
parent.8 
Generalized hypotonia and retinal pigment abnormalities in the two siblings reported here, 
led to an extensive differential diagnosis that mainly included metabolic disorders. At that 
time, no one recognized the possible relationship with the retinopathy in the father.  
In the infantile form of SCA7, the neurological involvement is more severe and the clinical 
spectrum extends beyond neurological and ocular signs. Cardiac abnormalities, mainly 
patent ductus arteriosus, are reported in all but one infant. In addition, the infants reported 
here also showed hepatomegaly, multiple hemangiomas, and severe capillary leak syndrome 
after surgery. Apparently, large CAG repeat expansions that result in dysfunction of the 
ataxin-7 protein may lead to congenital abnormalities such as patent ductus arteriosus. The 
function of ataxin-7 and the way the polyglutamine sequence in the ataxin-7 protein exerts its 
cellular toxicity remain unknown. It is possible that mutant ataxin-7 accumulates into 
aggregates and resists ubiquitin-mediated proteolytic processes, with subsequent disruption 
of nuclear structure, nuclear stability and/or nuclear machinery. Ataxin-7 is also suggested to 
function as a transcription factor and, accordingly, the mutant ataxin-7 protein could interfere 
with transcriptional processes.6 Because SCA7 usually presents in adulthood with 
neurological and ophthalmological signs only, we postulate the existence of a dose-effect 
relationship and a decreased vulnerability to polyglutamine-mediated cytotoxicity in 
peripheral tissues. 
All infantile cases reported here and in the literature, occurred on paternal disease 
transmission with extreme anticipation (disease onsets of 35 to 45 years earlier) 
accompanied by enormous (4 to 9 fold) increases in repeat expansions. In SCA7, mean 
anticipation was found to be 17±14 years, but anticipation is significantly greater on paternal 
transmission.5 This is currently explained by the high repeat instability during 
spermatogenesis in SCA7, as is the case in other SCAs and HD.12 On paternal transmission, 
the mean increase in repeat size is 15±20 repeats, compared to 5±5 repeats on maternal 
transmission.13 To our knowledge, the CAG repeat expansions of 325 and 460 units in this 
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report are the largest ever detected. The differential diagnosis of neonatal hypotonia includes 
neuromuscular disorders (e.g. spinal muscular atrophy type I, congenital myopathies, 
congenital muscular dystrophies, and metabolic myopathies) and central nervous system 
diseases (e.g. Prader-Willi syndrome, Zellweger syndrome, and cervical myelopathy). 
Hypotonia is reported in most of the infantile SCA7 cases and in patient IV-3 the hypotonia 
was documented in the neonatal period. Therefore, the infantile form of SCA7 should be 
included in the differential diagnosis of neonatal hypotonia. 
We emphasize the importance of recognizing this phenotype, because of associated 
consequences regarding diagnostic efficiency, prognostic issues, and genetic counselling. In 
unexplained neurological diseases, autosomal dominant disorders with extreme anticipation 
should always be considered.  
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 Abstract 
Purpose – To report a Dutch family with autosomal dominant cerebellar ataxia (ADCA) based 
on a novel mutation in the PRKCG gene.  
 
Methods – The authors studied 13 affected members of a six-generation family. After 
exclusion of the known spinocerebellar (SCA) genes, a combination of the shared haplotype 
approach, linkage analysis, and genealogical investigations was used. Exons 4 and 5 of the 
candidate gene, PRKCG, were sequenced.  
 
Results – Affected subjects displayed a relatively uncomplicated, slowly progressive 
cerebellar syndrome, with a mean age-at-onset of 40.8 years. A focal dystonia in two 
subjects with an onset of disease in their early twenties suggests extrapyramidal features in 
early-onset disease. Significant linkage to a locus on chromosome 19q was found, 
overlapping the SCA14 region. Based on the recent description of three missense mutations 
in the PRKCG gene, located within the boundaries of the SCA14 locus, we sequenced exon 
4 and 5 of this gene and detected a novel missense mutation in exon 4, which involves a 
G→A transition in nucleotide 353 and results in a glycine-to-aspartic acid substitution at 
residue 118 (Gly118Asp).  
 
Conclusion – A SCA14-linked Dutch ADCA family with a novel missense mutation in the 
PRKCG gene was identified.  
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Introduction 
A major part of the genetic background of autosomal dominant spinocerebellar ataxias 
(ADCA) has been elucidated in the past decade.1 Twenty genetic loci have been detected by 
linkage studies in spinocerebellar ataxia ([SCA]1-8, SCA10-14, SCA16-19, and SCA21-23) 
and  ten of the corresponding genes have been identified to date.2-22 In approximately 60 to 
70% of Dutch ADCA families, a mutation is found in the SCA1, SCA2, SCA3, SCA6, or SCA7 
gene.23 The other genes and loci seem to be rare or seem to be confined to specific 
populations.24,25 Although the contribution of these genes in the Dutch ADCA population is 
unknown, novel mutations are likely present.   
We have recently identified two novel loci in two Dutch ADCA families, SCA19 and 
SCA23.19,22 In addition, a missense mutation in the FGF14 gene on chromosome 13q34 was 
found in another Dutch family.26 We reasoned that several of the Dutch mutation-negative 
ADCA families must have common origins and that, by combined linkage, haplotype and 
genealogical analyses, we should be able to link some of the small ADCA families in larger 
clusters. 
Here, we report a large six-generation Dutch ADCA family in which linkage to the SCA14 
locus on chromosome region 19q13.4-qter was found. Recently, missense mutations in exon 
4 of the PRKCG gene that encodes protein kinase Cγ (PKCγ) were reported in two ADCA 
families, one of which involved a SCA14-linked family reported previously, and one sporadic 
ADCA case.27,28 We therefore sequenced exon 4 and 5 of the PRKCG gene and identified a 
novel missense mutation (353G→A) in exon 4. This new family adds to the clinical and 
genetic characterization of PRKCG mutations in SCA14 patients. 
 
 
Subjects and methods 
After diagnostic screening, 24 Dutch ADCA families with affected individuals in multiple 
generations and without a mutation in the SCA1, SCA2, SCA3, SCA6, or SCA7 gene, were 
identified. By linkage, haplotype, and genealogical analysis (see below), three independently 
referred families (RF13, RF11, and RF17) were found to be linked and the pedigree of this 
combined large six-generation family is depicted in figure 1 (only the affected individuals are 
shown). Of this extended family, 22 family members from three generations were included in 
the study and all gave informed consent for additional research studies.  
In the past 18 months, all the affected family members received a full neurological 
examination and a comprehensive case history was taken. When appropriate, neurological 
symptoms were graded as absent, mild, moderate, or severe. Blood samples (20 mL EDTA) 
were taken later.  
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 Exclusion of the known SCA genes  
Diagnostic screening was performed to exclude a mutation in the SCA1, SCA2, SCA3, 
SCA6, and SCA7 genes in the 24 families. High molecular weight DNA was obtained from 
leukocytes by a routine salting out procedure. No repeat expansions were found in the 
affected individuals. Further testing with the more recently identified SCA genes, including 
SCA8, SCA10, SCA12, and SCA17 was carried out and proved to be negative (data not 
shown). These 24 families were subsequently used in a combined linkage, haplotype, and 
genealogical approach. 
 
Shared haplotype analysis 
Because most of the 24 ADCA families were too small to perform traditional linkage analysis, 
we used an alternative strategy to localize the disease-causing genes in these families: the 
shared haplotype analysis (SHA). 
 
 
Figure 1: The pedigree of the extended family RF13, RF11, and RF17. Haplotype analysis for seven 
chromosome 19 markers is shown. The ‘disease’ haplotype is boxed. Open figures = unaffected; 
closed figures = affected; square = male; circle = female; / = deceased. In order to maintain 
confidentiality, unaffected family members are not shown. 
 
This method is based on the assumption of a limited number of founder mutations in the 
Dutch ADCA families, which had already been observed in SCA3 and SCA6 families. For all 
24 ADCA families, we focused on the remaining reported SCA loci, namely SCA4, SCA5, 
SCA11, SCA13, SCA14, SCA16, SCA18, SCA19, SCA21, and SCA23. Polymorphic markers 
 68 
       CHAPTER 3.4 
within the candidate regions, with an average spacing of approximately 2.0 cM, were 
selected from the Marshfield database (http://research.marshfieldclinic.org/genetics/). The 
different marker alleles were defined using the CEPH 133101 control sample. Haplotypes 
were constructed using the program GENEHUNTER (v1.2) and were corrected manually. 
We searched for identical haplotypes within the reported SCA loci in these small ADCA 
families. For each SCA locus, we created 100 control haplotypes from the genotypes of 
unrelated persons from a series of families collected for other purposes (data not shown). 
The alleles that characterize the SCA14 haplotype are represented by: D19S206 allele 7, 
132 base pair (bp); D19S571: allele 1, 198 bp; D19S589: allele 2, 169 bp; D19S924: allele 3, 
201 bp; D19S927: allele 2, 142 bp; D19S926: allele 4, 105 bp; and D19S605: allele 2, 117 
bp. 
Meanwhile, an exhaustive genealogical analysis was initiated to explore possible links 
between the apparently unrelated ADCA families that were included in the SHA, since other 
studies have shown that families in the Netherlands are often interrelated several 
generations back.  
 
Linkage analysis 
Two-point and multipoint linkage analyses were performed with the programs MLINK and 
LINKMAP of the LINKAGE package (v 5.2). In our model, we applied a disease frequency of 
1.0 in 100,000 and equal allele frequencies. Both analyses were based on an affected-only 
strategy to avoid the problem with possible pre-symptomatic carriers.  
 
Mutation analysis 
Based on the recent report of three missense mutations in exon 4 of the PRKCG gene, we 
decided to screen exons 4 and 5 of this gene for mutations in affected individuals from all 24 
families.27 An additional 85 anonymous control individuals with no history of ataxia were also 
sequenced. Both exons were amplified using the primers described in the original report.27 
The template for the sequence reaction was amplified with Ampli Taq DNA polymerase, 
using a PCR mixture containing 10X Pol buffer (67mM Tris-HCl, 6.7mM MgCl2, 10mM β-
mercaptano-ethanol, 6.7mM EDTA [pH=8.0], and 16.6mM (NH4) 2SO4), 1.5mM dNTP’s, 0.15 
mg/mL bovine serum albumin, and 10% dimethylsulfoxide. The PCR protocol started with 4 
minutes of denaturation at 94°C, followed by 35 cycles of 1 minute denaturation at 94°C, 1 
minute of annealing at 56°C and 2 minutes of extension at 72°C, and ending with a final 
extension step of 7 minutes at 72°C. PCR fragments were purified with Manu 30 Multiscreen 
PCR filter plate (Millipore) and dissolved in 40μL of water. DNA sequencing was performed 
using the Big Dye Terminator cycle sequencing ready reaction kit (Applied Biosystems, 
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 Warrington, UK). Sequence products were purified with the ManuN45 multiscreen sequence 
reaction filter plates (Millipore) and then were run on a 3100 ABI automated Sequencer 
(Applied Biosystems Foster City, CA). Data were analyzed with Sequencing Analysis (v3.7) 
software. 
 
 
Results 
Shared haplotype analysis  
After all the markers were typed and haplotypes constructed, we identified a shared 
haplotype in 3 of the 24 ADCA families. In these families (RF13, RF17, and RF11), this 
shared haplotype covered almost the complete SCA14 locus. The genealogical 
investigations revealed that the RF17 and RF11 families could indeed be linked to the large 
RF13 family (see figure 1). The closest common ancestor in these three families was 
identified four generations back. A partially shared haplotype, which corresponded only to the 
lower part of the SCA14 region between marker D19S924 and marker D19S605, was found 
in two other families (data not shown).  However, the PRKCG gene turned out to be located 
outside this part of the haplotype. Therefore, this result was marked as false positive.  
The SCA14 haplotype was not observed in controls, where the allele frequencies were for 
marker D19S206: allele 7, 0.10; D19S571: allele 1, 0.38; D19S589: allele 2, 0.30; D19S926: 
allele 4, 0.18, allele; D19S927: allele 2, 0.41; D19S926: allele 4, 0.27; and D19S605: allele 2, 
0.32. 
 
Linkage analysis and haplotype analysis in the SCA14 locus 
The positive results from the SHA were followed up and confirmed by multipoint linkage 
analyses in the extended six-generation pedigree (figure 1). An affected-only strategy was 
used to perform the linkage analysis with seven markers in the SCA14 region. Significant 
linkage of 3.61 (two-point lod score) at theta = 0.00 was found with marker D19S924 and a 
multipoint lod score (Zmax) of 4.56 was obtained. Finally, haplotype analysis determined the 
upper and lower boundaries of the SCA14 candidate interval by recombination events for 
markers D19S206 and D19S926 (see figure 1). This resulted in a SCA14 candidate interval 
of approximately 9.54 cM and covering 10.2 Mb genomic DNA.  
 
Mutation analysis  
At the time we obtained our linkage results, three missense mutations in exon 4 of the 
PRKCG gene, located within the SCA14 region, were reported.27 Accordingly, we sequenced 
exons 4 and 5 of the PRKCG gene in affected individuals from all 24 ADCA families. In the 
extended six-generation family, we identified a G→A transition in nucleotide 353 resulting in 
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a base pair substitution from glycine to aspartic acid, as depicted in figure 2a, that replaces a 
non-polar for a charged polar amino acid.  
 
 
 
Figure 2A: Sequence electropherograms for a part of exon 4 of the PRKCG gene. The upper panel 
shows the DNA sequence of a normal control. The DNA sequence of an affected individual (lower 
panel) shows a heterozygous mutation at base pair position 353G→A (indicated by an asterisk). 
Figure 2B: Evolutionary conservation of the Cys2/C1B domain at the glycine residue 118 (boxed) in 
different isozymes of PRKCG and different organisms. 
 
The Gly118Asp mutation is present in the C1B domain of the PKCγ protein. This C1B domain 
is highly conserved during evolution and the original glycine residue is present in many 
organisms (see figure 2b). Subsequently, all related family members were sequenced and 
screened for the Gly118Asp mutation. The mutation cosegregated completely with the 
disease phenotype in the family. In addition, two individuals were identified who also carried 
the mutation, which was in agreement with the haplotype analysis, but did they not show 
signs of the disease phenotype. Neither unaffected individual is depicted in figure 1 in order 
to maintain confidentiality. No mutation was identified in any of the other 21 ADCA families. 
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 The Gly118Asp mutation was not detected in 85 control individuals (170 chromosomes), 
indicating that this change is unlikely to be a polymorphism. 
 
Clinical characteristics 
Thirteen family members of the extended six-generation family were found to be affected. 
The clinical features of affected family members are given in the table. The mean age-at-
onset was 40.8 ± 10.7 years (range 21 to 59 years). One family member (V-8), with an age in 
the onset range, was thought not to have any symptoms, but on examination he was found to 
have difficulty in turning, an upper limb action tremor, and slight abnormalities in the heel-to-
shin test. Findings were concluded to be too subtle to clearly indicate disease-onset. Life 
span appears to be unaffected, witnessed by the fact that three affected males are 80 years 
or older. Striking age-at-onset variability was observed in two of the four parent-child groups 
studied. In one pair (V-2 and VI-1), the disease manifested 25 years earlier in the child. The 
other pair involves an asymptomatic male family member (IV-11) who died at the age of 56 
years. His family did not recall any sign or symptom that suggested the presence of a 
cerebellar dysfunction at that age. However, the age-at-onset in his two sons (V-10 and V-
11) was 21 and 24 years, respectively. All subjects displayed cerebellar ataxia with a slowly 
progressive course, with a disease-onset after the age of 30 years in all but two subjects. 
The markedly earlier onset of the disease in subjects V-10 and V-11 was not accompanied 
by an increase in the rate of disease progression. A gait disorder was the presenting feature 
in all affected individuals. In addition to gait and limb ataxia, the neurological examination 
revealed cerebellar dysarthria in 11 subjects, slowing of saccadic eye movements in 6 and 
dysmetric saccades in 7 subjects, and hyperreflexia in 8 individuals. Two older subjects (IV-5 
and IV-7) showed marked hyporeflexia (with absent Achilles tendon reflexes), as well as 
absent sense of vibration below the knees, which suggest the coexistence of a peripheral 
neuropathy, either age-related or disease-related. Although hypotonia was not observed, 
individual V-7 showed rigidity of the upper limbs. A focal task-induced dystonia of the right 
hand (writer’s cramp) was observed in the two brothers with relatively early-onset disease (V-
10 and V-11). Individual IV-9 was very severely affected and completely immobilized, which 
prohibited a thorough neurological examination. 
However, bradyphrenia and the presence of frontal release signs could indicate additional 
diffuse involvement of the cerebral cortex. Cognitive decline or mental retardation was not 
encountered in other family members and no family member showed signs of autonomic 
disturbances, axial myoclonus, parkinsonism, tremor, or seizures. 
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Figure 3: T1-weighted sagittal 
MRI scan of brain, showing 
marked atrophy of cerebellar 
midline structures.  
 
 
A MRI-scan had been made in three family members (V-2, V-6, and VI-1) and showed 
marked atrophy of cerebellar vermis and hemispheres (figure 3), while no cortical atrophy, 
basal ganglia abnormalities, or white matter changes were observed. 
 
 
Discussion 
The Dutch SCA14 family reported here displayed a slowly progressive, relatively isolated 
spinocerebellar ataxia, with a mean age-at-onset of approximately 40 years. In addition to 
the cerebellar syndrome, hyperreflexia was frequently observed. In two older subjects, the 
clinical examination was suggestive of a peripheral neuropathy, but whether this represents a 
true disease characteristic or an age-related feature remains unclear. In two other subjects, 
the onset of disease in their early twenties and the presence of a focal task-induced dystonia 
of the right hand in both of them is noteworthy. Whether the dystonia is truly attributable to 
the disease itself remains to be established, but in this light it should be recalled that in the 
first SCA14 family reported by Yamashita et al., axial myoclonus was observed in five early-
onset subjects.14 Taking the upper limb rigidity in one of the family members reported here 
also into account, suggests that extrapyramidal features (in early-onset disease) could 
indeed be part of the phenotypic spectrum of SCA14. In addition, agu rats, which carry a 
homozygous nonsense mutation in the PRKCG gene that results in the complete absence of 
the catalytic domain of the PKCγ protein, display a parkinsonian phenotype.29 Thus, PRKCG 
gene mutations appear to lead to pathology in both the cerebellar and the extrapyramidal 
pathways. 
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In this extended family, clinical anticipation was suggested in two of the four parent-child 
combinations. In addition, the family pedigree details of one of the other SCA14 families also 
suggest anticipation.14,27 However, caution is needed, because the number of patients for 
studying the anticipation phenomenon is too small, the recorded age-at-onset is known to be 
affected by a recall bias in older individuals, and, regarding this specific missense mutation in 
the PRKCG gene, the biological correlate of anticipation, commonly an expanded 
trinucleotide repeat, is lacking. The absence of the usual indicator of anticipation also casts 
further doubts on the anticipation being present. We will therefore use the term ‘onset age 
variability’, which is remarkable in this SCA14 family, where the age-at-onset ranges from 21 
to 59 years. The descriptive characteristics of the other SCA14 families reported also reveals 
onset ranges of 10 to 51 years and 12 to 42 years, respectively.14,28 This clinical variability 
may be a reflection of true (but unexplained) anticipation, or of problems in assessing the 
age-at-onset, or it may reflect modifying genes in a common genetic background instead of 
anticipation via the SCA14 locus. 
Three ADCA families, originally believed to be independent, were found to be linked to a 
common ancestor four generations back and, with the shared haplotype analysis, a common 
haplotype covering the SCA14 locus was identified in these three families. Significant linkage 
in the combined family to the SCA14 locus was confirmed by multipoint linkage (Zmax = 
4.56) and haplotype analysis. The boundaries of the SCA14 region were determined by 
recombinant events with the markers D19S206 and D19S926, providing a candidate interval 
of approximately 9.54cM. At that time, mutations in the PRKCG gene were reported to be 
found in two SCA families and in one sporadic case.27 Interestingly, one of these families is 
partly of Dutch ethnicity. Based on these results, we screened exon 4 and 5 of the PRKCG 
gene and identified a novel missense mutation in exon 4 that involves a G→A transition in 
nucleotide 353, which predicts a glycine-to-aspartic acid substitution (Gly118Asp) and 
replaces a non-polar for a charged polar amino acid. The mutation cosegregated with 
disease in all affected family members. The subject who showed too subtle cerebellar signs 
on examination to clearly indicate disease onset also carried the mutation. In addition, the 
mutation was detected in two individuals, in whom the presence or onset of cerebellar 
disease was or could not be established. 
The PRKCG gene encodes PKCγ, an isoform of protein kinase C, which is a member of the 
family of serine/threonine kinases. These kinases are intermediates in second messenger 
signaling pathways and are involved in various cellular processes. PKCγ, one of the classical 
isoforms, is built up of a regulatory and a catalytic domain. The regulatory domain comprises 
a C1 subdomain, containing two tandem repeat cysteine-rich regions (C1A and C1B), and a 
C2 subdomain.30 The three missense mutations reported (His101Tyr, Ser119Pro, and 
Gly128Asp), as well as the Gly118Asp mutation we report here, are all located in the 
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 evolutionary conserved C1B-region of the C1 regulatory domain, illustrating the important 
role that mutations in this specific region must play in cerebellar degeneration.27 Two 
mutations seem to directly alter PKCγ function, as shown by protein-structure modeling 
studies, mainly by affecting zinc ion interaction and phorbol ester binding affinity.27,31 How 
this eventually results in the spinocerebellar degeneration remains to be elucidated, but the 
fact that PKCγ protein levels are reduced in Purkinje cells of SCA1 transgenic mice and that 
in one patient with the PRKCG mutation the majority of Purkinje cells did not show ataxin-1 
staining, points to a potential role of PKCγ in the ataxin-1 pathway.27,32 To address this issue, 
we investigated whether the age-at-onset in the affected family members correlated with the 
length of the CAG repeat on both alleles of the SCA1 gene, but no significant correlation was 
found (data not shown).  
A mutation in the SCA1, SCA2, SCA3, SCA6, or SCA7 gene is found in 60 to 70% of Dutch 
ADCA families.23 The identification of this SCA14 family will further contribute to the 
clarification of the genetic background of the remaining ADCA families. 
It is of particular interest that we were able to link three originally independent ADCA families 
by a combined linkage, haplotype, and genealogy analysis. This confirms our suspicion that 
there may only be a limited number of independent SCA mutations within the Dutch ADCA 
families. This assumption is reinforced by our unpublished results, which show a clear 
geographic distribution of given SCA mutations confirming close temporal and geographical 
links for many families. Although we were fortunate to be able to reconstruct such a large 
family as in this example of SCA14, the future challenge will be to obtain similar results with 
much smaller ADCA families.  
While the mutations in the first SCA genes identified are characterized by a tri- or 
pentanucleotide repeat expansion that probably leads to a toxic gain of protein function, it is 
missense mutations that have been found in the two most recent SCA genes. This opens up 
a new perspective for neuroscientists in the further unraveling of the complicated disease 
mechanisms of dominantly inherited spinocerebellar degenerations. 
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The Gly118Asp mutation in the PRKCG/SCA14 gene: a 
founder mutation in the Dutch spinocerebellar ataxia 
population 
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mutation in the Dutch ataxia population. Hum Genet 2005;117:88-91. 
Abstract 
Missense mutations in the PRKCG gene have recently been identified in SCA14 patients; 
these include the Gly118Asp mutation that we found in a large Dutch ADCA family. We 
subsequently screened the current Dutch ataxia cohort (approximately 900 individuals) for 
SCA14 mutations in the Cys2 region of the PRKCG gene. We identified the Gly118Asp 
mutation in another eight individuals from five small families. Haplotype analysis identified a 
shared chromosomal region surrounding the SCA14 gene, and genealogical research was 
able to link all these ADCA patients to a single common ancestor. We therefore conclude 
that the Gly118Asp mutation is a SCA14 founder mutation in the Dutch ADCA population.  
 82 
     CHAPTER 3.5 
Introduction 
Spinocerebellar ataxia 14 (SCA14) is one of the autosomal dominant cerebellar ataxias 
(ADCAs) and is characterized by a slowly progressive, more or less isolated cerebellar 
syndrome that evolves after the age of 20 years. Interestingly, the first reports describe 
disease-causing missense mutations in the strongly conserved Cys2 region of the C1 
domain of the protein kinase C γ (PRKCG) gene in families of Dutch/English, Dutch, and 
Japanese ancestry.1-4 These findings demonstrate that SCA14 is present in different ethnic 
populations and displays a heterogeneous mutation spectrum. The effect of these mutations 
on the activity and function of the kinase is yet unknown.  
In 2002, a national survey estimated the prevalence and frequency of the SCA1, 2, 3, 6 and 
7 mutations in the Dutch population to be 3.0 per 100,000 inhabitants.5 However, a molecular 
diagnosis could be made in only about two-thirds of the ADCA families, and the remaining 
one-third will therefore likely be due to novel or unknown SCA genes.  
After the identification of the SCA14 mutations, we decided to sequence the current panel of 
Dutch ADCA patients without a known genotype for mutations in the Cys2 domain of the 
PRKCG gene, in order to reveal the frequency and heterogeneity of SCA14 mutations in the 
Dutch ADCA population. We were able to link eight new patients from five small families to 
the large family (RF13, RF11 and RF17) we had already identified.3 Clinical characteristics 
were obtained for six of these new patients (table 1). 
 
 
Methods  
Patient collection 
The current SCA-negative cohort consists of DNA samples of approximately 900 
independently referred individuals with a clinical syndrome of cerebellar ataxia, with or 
without a positive family history for ataxia, and who were tested negative for CAG repeat 
expansions in the SCA1, 2, 3, 6 and 7 genes.  
The individuals came from three clinical genetic diagnostic centers in the Netherlands 
(Utrecht, Rotterdam, and Groningen) but the cohort represents all the geographic regions of 
the Netherlands.  
 
Mutation analysis  
Because all SCA14 mutations reported, at that time, were located in the Cys2 region of the 
C1 domain, we sequenced exons 4 and 5 of the PRKCG gene for mutations as described 
previously.3 
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Genealogical research 
Subsequently, we performed genealogical research to see if we could cluster the SCA14 
patients to particular regions of the Netherlands and whether we could link together some of 
the independently referred families.  
 
 
Figure 1: Pedigree of the seven-generation SCA14 family. Please note that not all the affected family  
members from our original published SCA14 family (RF13, RF11 and RF17) are shown. Haplotype  
analysis for seven chromosome 19 markers is shown. Open figures = unaffected; closed figures =  
affected; dotted figures = obligate carrier; square = male; circle = female; / = deceased. In order to  
maintain confidentiality, unaffected family members are not shown. 
 
 
The data for the genealogical research included: [1] family data forms completed by patients, 
[2] population registries for 1853-1920, [3] Dutch civil registries of births, marriages and 
deaths (1811-2004, www.genlias.nl), [4] church archives with baptism, marriage and death 
registers (before 1811), [5] notary archives, and [6] citizen books for various towns (1500 – 
1799).  
 
Shared haplotype analysis 
To estimate the size of the conserved SCA14 chromosomal region throughout the family 
(including some of the new patients), we typed the same seven polymorphic markers that 
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were used to confirm linkage in our initial SCA14 family (RF11, RF17, and RF13).3 The 
different marker alleles were annotated using the CEPH 133101. The alleles that 
characterize the SCA14 core haplotype are represented by: D19S571 allele 1, 198 base pair 
(bp); D19S589 allele 2, 169 bp; D19S924 allele 3, 203 bp; D19S927 allele 3, 138 bp; and 
D19S926 allele 4, 105 bp. 
 
Clinical examination 
The clinical data of our original SCA14 family (RF13, RF11 and RF17) has already been 
published.3 Six of the eight new patients underwent a comprehensive neurological 
examination (table 1). Age of onset data was obtained by structured history taking. 
 
 
Results 
Mutational analysis 
To identify additional SCA14 patients, we sequenced exons 4 and 5 of the PRKCG gene in 
our Dutch SCA-negative cohort, and identified another eight individuals who carried the 
Gly118Asp mutation. Of these eight patients, three were siblings while the other five were 
independent referrals (figure 1).  
 
Shared haplotype analysis 
To determine the conservation of the Dutch SCA14 haplotype, we typed seven polymorphic 
markers surrounding the PRKCG gene, and found that patients carried identical haplotypes. 
The smallest shared chromosomal region still covered ~6.9 cM (figure 1). This SCA14 
haplotype was not observed in controls, where the allele frequencies were for marker 
D19S206: allele 7, 0.10; D19S571: allele 1, 0.38; D19S589: allele 2, 0.30; D19S926: allele 4, 
0.18; D19S927: allele 2, 0.41; D19S926: allele 4, 0.27; and D19S605: allele 2, 0.32. 
 
Genealogical research 
Because we detected a shared haplotype surrounding the Gly118Asp mutation in our 
patients, we investigated their genealogy. Interestingly, all the grandparents of these patients 
originated from the Dutch province of North Brabant. Therefore, we were not very surprised 
when we identified a common ancestor born in 1722, who linked all the independently 
referred individuals together into a large seven-generation family (figure 1).  
Not all the affected family members from our original SCA14 family (RF13, RF11 and RF17) 
are shown because this has already been published.3  
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Clinical characteristics 
Clinical characteristics from six of the new family members are summarized in table 1. In the 
complete family of 22 individuals, the age of onset ranged from 21 to 59 years (mean 38.3 ± 
9.9 years). Gait difficulties, speech disturbances, cycling difficulties, or myoclonic jerks (in 
one subject) were reported as initial symptoms. The core phenotype showed to be a slowly 
progressive, uncomplicated cerebellar ataxia. However, overt extrapyramidal features were 
observed in four patients: a focal task-induced dystonia of the dominant hand in two patients, 
and rigidity of the arms and myoclonic movements of the limbs, each in one patient. Other 
non-cerebellar signs included distal sensory disturbances in eight patients, primitive reflexes 
in one, hyperreflexia in ten, and hyporeflexia in five patients. MRI scans were available from 
seven patients and revealed: cerebellar atrophy in all, most prominently in the vermis; mild 
frontal or diffuse cerebral cortical atrophy in two; subcortical white matter lesions that were 
considered to be vascular in two; but no basal ganglia or brainstem abnormalities as was 
shown previously.3 
 
 
Patient Sex Age 
(yrs) 
AO 
 
Presenting 
feature 
Gait 
ataxia 
Limb 
ataxia 
Dysarthria Saccade 
slowing 
Ocular 
dysmetria 
Distal 
sensory 
disturbance 
Tendon 
reflexes 
VII:6 M 56 29 D ++ +/++ ++ + - - N 
VII:7 M 55 32 D ++ + ++ + + + N/↓ 
VII:8 F 52 43 G + + - - - - ↑ 
VII:5 M 59 32 D/G/C ++ + + + - ++ ↑ 
VII:9 M 52 30 G ++ ++ + + + - N/↓ 
VI:9 M 76 30 My ++ + ++ - - - N 
Table 1: Clinical characteristics of six of the affected family members (M = male, F = female, AO = 
age-at-onset, D = dysarthria, G = gait difficulties, C = cycling difficulties, My = myoclonus, - = absent, + 
= present or mild, ++ = moderate, +++ = severe, ND = not determinable, ↑ = increased, ↓ = 
decreased, N = normal). 
 
 
Conclusions 
We have demonstrated through a haplotype study and a genealogical research that the 
Gly118Asp SCA14 mutation is a founder mutation in the Dutch ADCA population that 
originated from a common ancestor born in the early 18th century. Haplotype studies have 
already provided evidence for the existence of founder mutations in SCA2, 3, 6 and 7 in 
different ethnic populations.6-10 Recently, we also showed that founder mutations for the 
SCA3 and SCA6 genes are present in the Dutch ADCA population and that ADCA families 
can be traced back to common ancestors in specific parts of the Netherlands.11  
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Out of approximately 900 independently referred diagnostic requests that proved to be SCA-
negative, we have identified a further eight individuals who carry the Gly118Asp mutation, 
which brings the total to 22 diagnosed SCA14 patients in the Netherlands. Furthermore, 
genealogical research was able to link the independently referred patients and showed that 
the SCA14 ancestor originated from the Dutch province of North Brabant. These twenty-two 
SCA14 patients explain almost 2% of the ataxia patients in the SCA-negative cohort. Even 
more, these 9 (6 new identified families, and RF13, 11 and 17) originally independently 
referred families account for approximately 4% of the estimated total ADCA families (n=227) 
in the Netherlands.5   
Clinical findings in the SCA14 patients reported here illustrate that, in addition to the slowly 
progressive cerebellar ataxia, SCA14 patients can display or even present with 
extrapyramidal features such as focal dystonia or action myoclonus, particularly in cases with 
a disease onset before the age of 30 years.4 Interestingly, the SCA14 mutation spectrum 
seems not to be confined to the Cys2 region of the C1 domain. Only recently Stevanin et al. 
identified a missense mutation (F643L) in the catalytic domain of the PRKCG gene.2 
However, the phenotype of their SCA14 patients seems to differ, since symptoms included 
also cognitive impairment, which was not detected in any of the other SCA14 families. 
Further studies will reveal whether a particular SCA14 phenotype with cognitive impairment 
indeed exists and, accordingly, to what extent mutations in the catalytic domain of the 
PRKCG gene contribute to the molecular genetics of ataxia patients. 
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 Abstract 
We report upon a Dutch autosomal dominant cerebellar ataxia (ADCA) family, clinically 
characterized by a late-onset (> 40 years), slowly progressive, isolated spinocerebellar ataxia 
(SCA). Neuropathological examination in one affected subject showed neuronal loss in 
Purkinje cell layer, dentate nuclei, and inferior olives, thinning of cerebellopontine tracts, 
demyelination of posterior and lateral columns in the spinal cord, as well as ubiquitin-positive 
intranuclear inclusions in nigral neurons that were considered to be Marinesco bodies. 
Data obtained from the genome-wide linkage analysis revealed a maximal lod score of 3.46 
at θ = 0.00 for marker D20S199. This new SCA locus, on chromosome region 20p13-p12.3, 
was designated SCA23 after approval by the HUGO Nomenclature Committee. Currently, 
candidate genes are being screened for mutations within the SCA23 interval. 
In addition to the recently identified SCA14, SCA19, and FGF14 families, SCA23 is yet 
another novel SCA locus in the Dutch ADCA population, which further defines the genetic 
heterogeneity of ADCA families in the Netherlands. 
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Introduction 
The autosomal dominant cerebellar ataxias (ADCAs) are a group of seriously invalidating 
disorders characterized by gait and limb ataxia, disturbances of speech and oculomotor 
control, in combination with variable other clinical features and usually with an adult age at 
onset.1 Harding’s classification of ADCAs into type I-III, based on the differential clinical 
features, is gradually being substituted by a classification based on molecular-genetic 
characteristics. 
Since 1993, 11 spinocerebellar ataxia (SCA) genes have been cloned (SCA1-3, 6-8, 10, 12, 
14, 17 and fibroblast growth factor-14 (FGF14)) and an additional 12 SCA loci (SCA4, 5, 11, 
13, 15, 16, 18-21, 24 and 25) have been identified.2-25 
In SCA1-3, 6, 7, and 17, the mutational mechanism is known to be a repeat expansion of 
coding CAG stretches leading to elongated polyglutamine tracts in the otherwise unrelated 
encoded proteins. However, in the SCA8, 10, and 12 genes, the mutation involves a non-
coding CTG, ATTCT, and CAG repeat expansion, respectively.6,11,26 Interestingly, the most 
recently identified mutations in the FGF14 gene and the SCA14 (protein kinase C γ) gene 
turned out to be missense mutations.2,27-30 
Based on results of diagnostic testing of ADCA families, the estimated prevalence of ADCA 
in the Netherlands is about three per 100,000 individuals.31 In ~30% of the Dutch ADCA 
families, no repeat expansion is identified in the SCA1-3, 6, and 7 genes. So far, the SCA10, 
12 or 17 repeat expansions have not been reported in the Netherlands and the contribution 
of FGF14 mutations remains to be established. In addition, the contribution of the SCA14 
mutations is currently being explored further in our laboratory. So far, the SCA14 mutations 
seem to be restricted to the Cys2 region of the C1 domain indicating a particular role for this 
part of the gene or the mutations that were identified. Still, we hypothesize that yet 
unidentified SCA genes are present in Dutch ADCA families. 
Here, we present a Dutch ADCA family, clinically characterized by a late-onset (> 40 years), 
slowly progressive, isolated SCA. Linkage analysis localized the disease gene to 
chromosome region 20p13-p12.3, and this locus was designated SCA23 (approved by the 
HUGO Nomenclature Committee). The identification of SCA23 further adds to the genetic 
heterogeneity of Dutch ADCA families. 
 
 
Methods 
The patients 
The pedigree of the three-generation family that participated in this study is shown in figure 
1. In order to maintain confidentiality, some individuals are depicted with the symbol sex 
unknown. All participating family members signed an informed consent. The study was 
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 approved by the University Medical Center Utrecht (Utrecht) Medical Ethical Committee. 
DNA samples were available from nine affected individuals and five presumptive unaffected 
relatives. Five of the affected family members were subjected to a thorough neurological 
examination. One asymptomatic carrier was detected.  
 
Neuropathology and immunohistochemistry 
The brain of subject II:11, who died in 1996 at the age of 80 years, was available for 
neuropathological examination and immunohistochemical studies. After formalin fixation and 
external neuropathological examination, the brain and spinal cord were examined at the cut 
surface, and multiple samples were taken and embedded in paraffin for histology. 
 
 
 
 
 
Figure 1: The pedigree of the SCA23 family. Haplotype analysis is shown for 19 chromosome 20 
markers. In order to maintain confidentiality, some individuals are depicted with the symbol sex 
unknown. The disease haplotype is boxed. Open figures = unaffected; closed figures = affected; 
dotted figures = asymptomatic carrier; square = male; circle = female; diamond = unknown sex; / = 
deceased.  
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The following tinctorial stainings were performed on 4 μm histological sections of these 
samples: hematoxylin and eosin (H&E), Bodian silver, and a combined luxol fast blue and 
H&E (LFB-H&E) staining. In addition, on sections of relevant areas (brain stem, spinal cord, 
cerebellum, hippocampus) immunohistochemical stainings were performed for ubiquitin 
(DAKO Cytomation, Heverlee, Belgium), tau (Innogenetics, Gent, Belgium), β-amyloid 
(DAKO Cytomation, Heverlee, Belgium), α-synuclein (Neomarkers/Labvision, Fremont CA, 
USA), 1C2 (Chemicon International, Temecula, CA, USA), and ataxin-3.32 
 
Mutation analysis of known SCA genes 
High molecular weight genomic DNA was isolated from peripheral blood leukocytes using 
routine salting-out procedures. Direct mutational analysis of trinucleotide repeat expansions 
of the SCA1-3, 6-8, 12, and 17 genes was performed, but no repeat expansions were 
observed (data not shown). The other SCA loci  (SCA4-6, 10, 11, 13, 14, 16, and 19) were 
excluded by two-point linkage analysis (lod score < -2.0).  
The polymorphic markers used were selected from the Marshfield database: http:// 
research.marshfieldclinic.org/genetics/Map_Markers/maps/IndexMapFrames.html. 
 
Genome-wide genotyping analysis 
After excluding the known SCA loci as candidates, a genome-wide scan was performed. The 
screening set consisted of 350 polymorphic markers, covering the whole genome. The 
average spacing between two adjacent markers was 10-15cM.  
The protocol used to amplify the polymorphic markers has been described previously.20  
Multiplex PCR products with HEX and FAM or HEX and TET labels were pooled.  Finally, 1μl 
of these pools were mixed with 4 μl HIDItm (highly deionized formamide) including the internal 
lane standard ROX (Applied Biosystems Foster City, CA, USA), and run on an automated 
high-throughput capillary electrophoresis ABI3700 machine (Applied Biosystems). 
Subsequently, fragment analysis and genotyping were performed using Genescan (v3.5 NT) 
and Genotyper (v2.1) software (Applied Biosystems). Two raters scored all genotypes 
independently. 
 
Linkage analysis 
Two-point LOD scores were calculated for each marker with the program MLINK of the 
software package FASTLINK (v5.2),33 using an affected-only strategy assuming an 
autosomal dominant mode of inheritance, a disease frequency of 1:100,000, and equal allele 
frequencies of the markers. Two-point lod scores > 1.0 were considered to indicate regions 
of interest.  
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 These genomic regions were further fine mapped by testing additional markers and 
haplotype analysis. With the program LINKMAP of the LINKAGE (v5.2) package,33 a multi-
point analysis was performed to confirm the size of the candidate region. 
 
 
 
Results 
Clinical characteristics 
In the five family members examined, the age at onset ranged from 43 to 56 years (mean 
50.4  ±  4.9 years) and disease duration varied from 1 to 23 years (mean 10.2  ±  8.4 years) 
(table 1). The presence of clinical anticipation could not be studied because we were only 
able to examine affected subjects from the third generation. The age at onset of individual 
II:11, of whom blood and brain tissue was preserved, could not be extracted accurately from 
the clinical records. Gait difficulties were the presenting feature in three subjects, while 
cycling difficulties and a simultaneous deterioration of gait and speech were the presenting 
signs in two others. After onset of disease, all displayed a slowly progressive, isolated SCA.  
In addition to gait and/or limb ataxia, which were present in all subjects, the neurological 
examination revealed dysarthria in three, slowing of saccades and ocular dysmetria in three, 
decreased vibration sense below the knees in three, hyperreflexia in four, and Babinski’s 
sign in two affected subjects.  
 
 
Patient Sex Age  AO 
 
Disease 
duration  
PS Gait 
ataxia 
Limb 
ataxia
Dysarthria Saccade 
slowing 
Ocular 
dysmetria 
Sensory 
disturb. 
distally  
Tendon 
reflexes 
III:6 F 62 53 9 G ++ ++ - + - ++ ↑ 
III:1 M 61 56 5 G/S + + + + + ++ ↑ 
III:2 M 64 51 13 G + + + - - - N 
III:4 M 66 43 23 G +++ +++ +++ + + ++ ↑ 
III:12 M 50 49 1 C - ± - - ± - ↑ 
Table 1: Clinical characteristics of affected family members (M = male, F = female, AO = age-at-onset, 
PS = presenting symptom, G = gait difficulties, C = cycling difficulties, S = speech difficulties, - = 
absent, ±  = subtle, + = present or mild, ++ = moderate, +++ = severe, ↑ = increased, N = normal). 
 
Clinical severity grossly correlated with the duration of the disease and subject III:4, with a 
disease duration of 23 years, was wheelchair-bound outdoors. Cognitive deterioration or 
mental retardation, epilepsy, extrapyramidal features, signs of peripheral nerve involvement, 
or sphincter abnormalities were not present. Neurophysiological studies were not conducted. 
An MRI-scan of the brain in subject III:4 at the age of 60 years showed severe cerebellar 
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atrophy, normal brainstem structures and basal ganglia, no cerebral cortical atrophy, and 
multiple small subcortical white matter lesions in the cerebral hemispheres that resembled 
vascular disease. 
 
Neuropathology 
The brain weight was 930 g (normal for age = 1100-1400 g). Macroscopically, the cerebrum, 
cerebellum, brain stem, and spinal cord showed generalized, moderate to severe atrophy. 
The atrophy was most pronounced in the frontotemporal region of the cerebrum, the vermis 
of the cerebellum, the basis pontis, and the spinal cord. On the cut surface, marked dilatation 
of the cerebral ventricles was found with moderate, generalized atrophy of the central nuclei. 
The substantia nigra and locus ceruleus showed normal pigmentation.  
Microscopically, pronounced neuronal loss was present in the Purkinje cell layer, especially 
in the vermis (figure 2a and b) and in dentate nuclei and inferior olives, accompanied by 
variable gliosis and myelin loss in the surrounding white matter. In the basis pontis, both the 
longitudinal and transverse white matter tracts were well myelinated, but the latter (i.e. 
cerebellopontine) tracts were relatively small.  
No neuronal loss was observed within the pontine nuclei. The substantia nigra and locus 
ceruleus contained an ample number of pigmented neurons with sparse loose neuromelanin 
pigment and an occasional Lewy body in the substantia nigra. In the spinal cord, especially in 
the posterior and lateral columns, moderate, dispersed loss of (staining for) myelin was found 
without inflammatory infiltrate or gliosis; there was no clear loss of motorneurons.  
On thorough microscopic examination only a few neurons in the substantia nigra contained 
striking intranuclear inclusions (figure 2c). These inclusions were round, 2-5 μm in diameter, 
strongly ubiquitin positive, but negative in the other immunohistochemical stainings (including 
1C2 and ataxin-3) and therefore interpreted as Marinesco bodies. No other ubiquitin positive 
inclusions were found. In the α-synuclein staining, no cortical Lewy bodies were found. In the 
Bodian silver staining and in the immunohistochemical stainings for tau and β-amyloid, other 
‘neurodegenerative depositions’ were generally scarce (neurofibrillary tangles, neuritic 
plaques) or absent (amyloid angiopathy, Pick bodies, oligodendroglial inclusions). In the tau-
staining, some micro- and astroglial cells in and around central nuclei, dentate nuclei, and 
substantia nigra were positive.  
Vascular damage was present in the form of moderate to severe atherosclerosis of the circle 
of Willis and its major branches, with large recent ischemic necrotic areas in the left insular 
region (maximum 8cm; territory of the left medial cerebral artery) and left occipital lobe 
(maximum 5 cm; territory of left posterior cerebral artery), and dispersed old ischemic 
necrotic lesions (cerebral white matter, hypothalamus, cerebellar cortex and white matter, 
basis pontis; maximum 1cm).  
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 General autopsy revealed severe cachexia, emphysema, contractures of especially the lower 
limbs, and severe atherosclerosis of the large and middle-sized arteries with dispersed old 
infarcts in kidneys and spleen, myocardial hypertrophy, and atheromatous plaques in the 
pulmonary artery (the latter indicating pulmonary hypertension). 
 
Linkage analysis 
The SCA loci were excluded in the initial analysis with two-point lod scores (data not shown). 
Next, a genome-wide screen was performed and only two genomic regions showed two-point 
lod scores of >1.0, including regions on chromosome 20 and 22. In addition, because 
analysis of our data might be hampered by the presence of possible asymptomatic mutation 
carriers, an affected-only strategy was performed. This resulted in a maximal lod score (Zmax) 
of 3.46 at θ = 0.00 for marker D20S199 (table 2).  
The order and distance between the markers are based on the Marshfield database from 
April 2002 (http://research.marshfieldclinic.org/genetics/). 
 
 
Figure 2: Neuropathological findings. The cerebellar folia, especially of the rostral vermis (a,b), show 
severe atrophy with (sub)total loss of myelin in some parts (lighter staining, loosely textured area of 
white matter, indicated by arrowhead in a) and relative preservation of myelin in other parts of the 
white matter (darker staining for myelin in more compact area, indicated by arrow in a). Panel b 
represents a higher magnification of the area indicated by the rectangle (a); it illustrates severe 
Purkinje cell loss, accompanied by Bergmann gliosis in the affected cerebellar cortex (arrows). 
Occasional neurons in the substantia nigra contain up to four round, intranuclear inclusions in 
(arrowheads in c, maximum diameter = 5 μm). These are strongly ubiquitin-positive but negative in the 
1C2 and ataxin-3 staining and therefore interpreted as Marinesco bodies. No pathological neuronal 
intranuclear inclusions were encountered in the CNS of this patient. 
a,b: LFB-H&E staining; c: Ubiquitin staining; Original magnification x 12.5 (a), 100 (b) and 400 (c). 
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Haplotype and multi-point linkage analysis 
Haplotypes were constructed by minimizing the number of possible recombination events 
(figure 1). The candidate interval directly starts from the tip of the short arm of chromosome 
20, because no recombination events were detected with the most proximal marker 
D20S1155.  A recombination event was observed in affected individual III:5 with marker 
D20S194 located at 18.2cM, which determined the lower boundary of the interval. Multi-point 
linkage analysis (figure 3) based on the affected-only strategy was performed and resulted in 
a Zmax of 3.56. Due to computer restraints, the multi-point analysis was calculated with three 
markers at the same time. The overlapping parts of the interval showed identical values, 
indicating that the analysis was performed correctly. The 95% candidate interval (maximum 
lod = –1) from the multi-point analysis is flanked by marker D20S1155 and marker D20S835, 
and spans around 15cM. 
 
Lodscore at recombination rate (θ)   
Markers 
0.00 0.10 0.20 0.30 0.40 Zmax θ = 
D20S1155 2.22 1.82 1.36 0.84 0.3 2.22 0.00 
D20S103 1.48 1.19 0.85 0.49 0.15 1.48 0.00 
D20S117 2.49 2.06 1.56 0.99 0.38 2.49 0.00 
D20S199 3.46 2.82 2.1 1.32 0.5 3.46 0.00 
D20S473 0.39 0.34 0.25 0.14 0.04 0.39 0.00 
D20S867 1.66 1.2 0.75 0.36 0.09 1.66 0.00 
D20S835 2.02 1.68 1.25 0.76 0.27 2.02 0.00 
D20S194 -4.57 0.53 0.46 0.26 0.07 0.53 0.10 
D20S907 -0.08 -0.04 -0.02 -0.01 -0.01 -0.01 0.30 
D20S901 1.27 1.08 0.8 0.48 0.16 1.27 0.00 
D20S160 -6.50 -1.01 -0.45 -0.17 -0.04 -0.04 0.40 
 
Table 2: Two-point lod scores between the disease locus and eleven chromosome 20 markers. 
 
Candidate gene analysis 
The SCA23 interval is located between the tip of the short arm of chromosome 20 and 
D20S194, and is ~18.2 cM in size, corresponding to ~6.1 Mb, and contains around 100 
genes. Our first attempt focused on candidate genes that contain coding triplet repeats. This 
resulted in the identification of two coding (CTG)5/6 stretches in the GFR receptor alpha 4 
(GFRA4), and the Attractin (with dipeptidylpeptidase IV activity, (ATRN)) gene. Only one 
coding CAG repeat was identified; this was located in the ubiquitin-conjugating enzyme 7 
interacting protein 3 gene. Four other non-coding intronic CAG repeats were located within 
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 the boundaries of the genes including β-neoendorphin-dynorphin precursor [PDYN; (CTG)7)], 
KIAA1442 protein [Q9P2A6; (CTG)5], ring finger protein 24 [RNF24; (CTG)5], FK506 binding 
protein peptidyl prolyl cis trans isomerase [FKBP1A; (CAG)7], and signal-regulatory protein β-
1 precursor [SIRP-β-1; (CAG)6]. Four other CAG and CTG repeats with a maximal length of 
five repeats were identified, but it remained unclear whether these repeats are coding or non-
coding sequences. However, no repeat expansions for any of these genes were observed 
(data not shown). Secondly, only three other genes were selected for missense mutation 
screening including neuronal cell death inducible kinase (SKIP3), major prion protein 
precursor (PRNP), and the prion gene complex downstream (PRND). Overexpression of 
Doppel (Dpl), the paralog of the mammalian prion protein (PrP), is correlated with ataxia and 
death of cerebellar neurons in mice. All these genes were excluded as candidates based on 
our sequence data results. 
 
 
Figure 3: Multi-point analysis with eleven chromosome 20 markers. 
 
 
Discussion 
The genome scan in this three-generation Dutch ADCA family resulted in the identification of 
a novel SCA locus, designated SCA23, on chromosome region 20p13-p12.3. Clinically, the 
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affected family members displayed a late-onset (> 40 years), slowly progressive, isolated 
SCA. Features mainly included gait and limb ataxia, disturbance of oculomotor control, 
dysarthria, and hyperreflexia. As distinctive extracerebellar disease features are absent, the 
SCA23 phenotype is clinically indistinguishable from other SCA subtypes; relatively pure 
cerebellar syndromes have also been described in SCA5, SCA6, SCA11, SCA14, SCA15, 
SCA16, and SCA22.34 
Genome-wide linkage analysis revealed a maximal two-point lod score (Zmax) of 3.46 at θ= 
0.00 with marker D20S199. The SCA23 interval is located between the tip of the short arm of 
chromosome 20 and D20S194 and is ~18.2cM in size, corresponding to ~6.1 Mb, and 
contains ~100 genes. 
Our candidate genes analysis was unable to identify the SCA23 disease-causing mutation. 
We focused on candidate genes that contain coding triplet repeats, since this is the most 
common mutation in the ADCAs worldwide. We also searched for missense mutations in 
genes that correlated with ataxia and death of cerebellar neurons in mice, considering the 
fact that the two most recently identified SCA mutations were point mutations. 
The neuropathological findings in subject II:11 grossly correspond to previous observations 
in this group of disorders, although we did not observe the neuronal intranuclear inclusions 
typically encountered in polyQ-associated ADCAs.34,35 Some nigral neurons were found to 
contain ubiquitin-positive intranuclear inclusions, very much reminiscent of Marinesco bodies. 
In addition, Lewy bodies were occasionally present in nigral neurons. Substantia nigra 
involvement has been reported in SCA2 and SCA3 patients.36,37 Unfortunately, it is not 
known whether subject II:11 displayed additional parkinsonian features. Marinesco bodies 
are non-specific ubiquinated intranuclear inclusions in nigral neurons, observed in, for 
example, normal ageing and Alzheimer’s disease. Interestingly, wild-type ataxin-3, the 
mutated protein in SCA3, was recently found to be recruited to Marinesco bodies in both 
non-human primates and in myotonic dystrophy patients.38,39 In our case, we did not find the 
Marinesco bodies to be immunopositive for ataxin-3, but this may be due to the fact that 
different antibodies were used. How this finding of Marinesco bodies relates to the 
pathogenic processes involved in SCA23 and whether this also indicates failure of protein 
homeostasis mechanisms remains to be established (mainly by identifying the mutated gene 
product).  
In conclusion, the SCA23 locus is a novel locus identified in the Dutch ADCA population. The 
candidate interval is located on chromosome region 20p13-12.3 and is ~18.2cM. In an 
attempt to refine the size of the candidate interval, we are currently trying to identify 
additional ADCA families that also link to the SCA23 locus. 
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Abstract 
Background - In autosomal dominant cerebellar ataxias (ADCAs), it is unclear whether the 
associated peripheral nerve involvement is always a typical length-dependent axonopathy 
rather than a primary neuronopathy due to neuronal degeneration in the spinal anterior horns 
and/or dorsal root ganglia. 
 
Objective - To study the nature and extend of peripheral nerve pathology in ADCA patients. 
 
Patients and methods - Standardized clinical and electrophysiologic studies of 27 genotyped 
ADCA patients were conducted prospectively, with special emphasis on the distinction 
between primary neuronopathy and dying-back axonopathy. 
 
Results - Electrophysiologic evidence of involvement of the peripheral nervous system was 
present in 70% of patients. Findings were compatible with a dying-back axonopathy in 30%, 
while in 40% of patients a neuronopathy was diagnosed. Patients with spinocerebellar ataxia 
(SCA)1 and SCA2 mostly displayed features of a neuronopathy, while both neuronopathies 
and axonopathies were encountered in SCA3 and SCA7. In SCA6, no significant peripheral 
nerve involvement was demonstrated. We did not observe an influence of age, disease 
duration, or ataxia severity on the presence or type of peripheral nerve involvement. 
 
Conclusions - Peripheral nerve involvement in ADCA manifests not only as a distal axonal 
neuropathy, but also as a primary neuronopathy. Electrodiagnostic studies in this group of 
patients should be conducted in such a way, that primary neuronopathy is detected.  
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Introduction 
Autosomal dominant cerebellar ataxias (ADCAs) share features of progressive, usually adult-
onset, spinocerebellar degeneration, including gait and limb ataxia, dysarthria, and 
oculomotor control impairment. Genetic studies have identified twenty-one genetic loci 
(SCA1-8, SCA10-19, and SCA21-23) and ten of the corresponding genes 
(http://www.gene.ucl.ac.uk/nomenclature). Still, about two thirds of Dutch ADCA families map 
to one of the five most common loci: SCA1, SCA2, SCA3, SCA6, and SCA7.1 In these five 
genes, the common mutation is an expanded coding CAG repeat that results in an elongated 
polyglutamine (polyQ) tract in the encoded proteins. How this polyQ-sequence induces 
neuronal loss in selected regions is currently unknown. 
Although the cerebellum is predominantly affected, the mutated gene also causes 
dysfunction in other neuronal populations. The presence of peripheral nerve involvement in 
ADCAs has been reported, suggesting that disease mechanisms are not solely confined to 
the central nervous system compartment.2-8 However, none of these studies were developed 
to systematically investigate whether the peripheral nerve involvement is a typical distal-
dominant axonopathy or a primary neuronopathy due to the degeneration of neurons in the 
anterior horns and/or dorsal root ganglia.  
To study the nature and extend of the peripheral nerve involvement in ADCAs and to obtain 
electrophysiologic data that support the presence of either a neuronopathy or a dying-back 
axonopathy, we prospectively conducted standardized clinical examinations, nerve 
conduction studies, and electromyography (EMG) in twenty-seven genotyped ADCA 
patients. 
 
 
Methods 
Patients and clinical evaluation 
Twenty-seven ADCA patients with a mutation in the SCA1, SCA2, SCA3, SCA6, or SCA7 
genes were recruited from our outpatient clinic and gave informed consent. 
Age at ataxia onset, disease duration, and the presence of symptoms suggesting 
involvement of the peripheral nervous system (paresthesias, pain, numbness, muscle 
cramps, weakness, fasciculations, and muscle wasting) were recorded. To quantify ataxia 
severity, the International Cooperative Ataxia Rating Scale was used, which ranges from 0 
(no ataxia) to 100 (very severe ataxia).9 We did not attempt to identify an additional sensory 
component of the ataxia. Examination of the peripheral nervous system was carried out by 
the same investigator (BW) in all patients and performed according to a standardized 
protocol.10  
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The Medical Research Council scale (0-5) was used to measure muscle strength of seven 
muscles or muscle groups in both arms and legs. Summation of muscle strength could result 
in a maximum Medical Research Council sum score of 140. Sensory function was examined 
in all extremities and included rating of pinprick, touch, vibration, and joint position sense 
according to a distal to proximal distribution. Summation of all sensory modalities could lead 
to a maximum sensory sum score of 56. Clinically, involvement of the peripheral nervous 
system was considered in case of (spinothalamic) sensory disturbances, muscle weakness, 
amyotrophy, and/or markedly decreased or absent tendon reflexes.  
 
Electrophysiologic studies 
A Medelec Synergy EMG system (Oxford Medical Instruments, Surrey, England) was used 
for neurophysiologic studies. Nerve conduction studies were conducted according to 
standard techniques. Motor nerve conduction studies included the median, peroneal, and 
posterior tibial nerves, and sensory nerve conduction studies encompassed antidromic 
stimulation of the left median, radial, and ulnar nerves, and both sural nerves. Compound 
muscle action potentials (CMAPs) below 7 mV in the upper extremities and below 5 mV in 
the lower extremities were considered abnormal; for sensory nerve action potentials 
(SNAPs), these values were 10 µV and 5 µV, respectively. The CMAPs and SNAPs of all 
nerves examined were summated into a sum score.11 The sural/radial amplitude ratio 
(SRAR) was calculated by dividing the highest sural nerve SNAP by the left radial nerve 
SNAP.12 In our laboratory, a sural/radial amplitude ratio greater than 0.30 was found to have 
a predictive value of 90% (females) and 100% (males) for the absence of a dying-back 
axonopathy (BW and MZ, unpublished data, 2003). Concentric needle electrode EMG 
studies were performed in the left extensor hallucis longus and rectus femoris muscles, using 
a standard method of visual, semi-quantitative measurement of insertional activity and 
spontaneous activity at rest, and assessment of motor unit morphology (duration, amplitude, 
and recruitment pattern) during slight, intermediate, and maximum voluntary contraction.13 
An axonal neuropathy was considered to be present when there was a reduction of CMAPs 
and/or SNAPs, with or without neurogenic muscle changes and spontaneous muscle fiber 
activity, all in a distal to proximal gradient. Neuronopathy was defined as electrophysiologic 
evidence of an axonal neuropathy without a distal to proximal gradient. A sural/radial 
amplitude ratio greater than 0.30 was used as an additional tool to demonstrate the absence 
of such a gradient. 
 
Statistical analysis 
The means of the group with and the group without EMG abnormalities were compared with 
a t-test. Multiple comparisons of means per SCA subtype were corrected with the Bonferroni 
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rule. Linear regression analysis was applied to assess the correlation between sum of 
CMAPs and SNAPs and age, disease duration, or the International Cooperative Ataxia 
Rating Scale score. All analyses were carried out by using the SPSS computer package, 
version 9.0 (SPSS Inc, Chicago, Ill). 
 
 
Results 
Clinical characteristics  
Patient characteristics are presented in the table. Symptoms or complaints that suggested 
peripheral nervous system involvement were present in 78% of patients. The presence of 
distal paresthesia and/or numbness was reported by eight patients. None of the six patients 
with subjective muscle weakness reported predominant involvement of proximal muscles, 
although one patient did notice wasting of proximal leg muscles. Eight patients observed 
fasciculations that (also) occurred in the proximal muscles of arms and legs in three of them. 
Fifteen patients complained of muscle cramps, which involved proximal muscles in four.  
On examination, vibration sense was found to be abnormal in twenty-two patients. In three 
patients, a total absence of lower extremity vibration sense was observed. Joint position 
sense was diminished but preserved in five patients. Other findings compatible with 
peripheral nerve pathology were present in 56% of patients. Muscle weakness was found in 
nine patients. Proximal muscle weakness was present in two patients, with weakness of the 
quadriceps femoris and iliopsoas muscles in a SCA1 patient and weakness of only the 
intrinsic hand muscles in one SCA7 patient. In thirteen patients, decreased or absent tendon 
reflexes were observed, which affected only the ankle jerks in five. Sensory disturbances, 
when present, always showed a distal to proximal gradient. 
 
Electrophysiologic studies 
Electrophysiologic evidence of peripheral nerve pathology was found in 19 (70.3%) of 27 
patients. In eight patients, abnormalities were compatible with a typical dying-back axonal 
neuropathy, which was purely sensory in one and mixed sensorimotor in seven patients. 
However, in eleven patients, the findings were indicative of a neuronopathy involving dorsal 
root ganglion and/or anterior horn cells (table).  
In four of the five SCA1 patients, electrophysiologic studies were abnormal, indicating a 
motor and sensory neuronopathy in three and an axonal sensorimotor dying-back 
neuropathy in one patient.  
Sensory neuronopathy was found in all three SCA2 patients. In one patient, neurogenic 
muscle changes without a distal to proximal gradient indicated additional involvement of 
spinal motorneurons. 
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Only one of eight SCA3 patients showed normal neurophysiologic studies. An axonal 
sensorimotor neuropathy was diagnosed in four and a neuronopathy in three. The 
neuronopathy involved both motor and sensory neurons in two, and only motor neurons in 
one patient. 
Of the seven SCA6 patients, electrophysiologic abnormalities were observed in one patient 
only and interpreted as an axonal sensorimotor neuropathy.  
 
  
 SCA1 SCA2 SCA3 SCA6 SCA7 
Patient characteristics      
Number of patients 5 3 8 7 4 
Number of males 4 3 3 3 2 
Age, yrs 59.4 (53-69) 48.3 (43-58) 56.1 (40-66) 54.0 (39-72) 39.0 (19-49) 
Age-at-onset, yrs 46.8 (40-66) 33.0 (25-39) 47.0 (38-56) 39.6 (35-53) 25.0 (8-36) 
Disease duration, yrs 12.6 (3-16) 15.3 (5-23) 9.1 (1-21) 14.4 (4-36) 14.0 (7-20) 
Length expanded CAG repeat 44.5 (42-49) 40.5 (38-43) 67.9 (61-72) 22.4 (22-23) 50.5 (48-53) 
      
ARS score 44.0 (26-80) 32.0 (27-36) 29.6 (7-60) 22.5 (2-60) 41.0 (27-75) 
      
Sensory symptoms      
Paresthesia 1 / 5 0 / 3 2 / 8 2 / 7 0 / 4 
Numbness 1 / 5 0 / 3 3 / 8 2 / 7 0 / 4 
      
Motor symptoms      
Cramps 3 / 5 3 / 3 6 / 8 3 / 7 0 / 4 
Weakness 1 / 5 0 / 3 2 / 8 2 / 7 1 / 4 
Muscle wasting 0 / 5 0 / 3 1 / 8 2 / 7 1 / 4 
Fasciculations 1 / 5 1 / 3 4 / 8 2 / 7 0 / 4 
      
      
Motor signs      
Proximal paresis 1 / 5 0 / 3 0 / 8 0 / 7 0 / 4 
Distal paresis 2 / 5 0 / 3 4 / 8 2 / 7 1 / 4 
MRC sum score < 140 2 / 5 0 / 3 4 / 8 2 / 7 1 / 4 
MRC sum score 135.2 (119-140) 140 138.9 (136-140) 138.7 (134-140) 138.3 (138-140) 
      
Hypo/areflexia 2 / 5 2 / 3 7 / 8 2 / 7 0 / 4 
      
Sensory signs      
Touch 2 / 5 0 / 3 3 / 8 1 / 7 2 / 4 
Pinprick 2 / 5 1 / 3 2 / 8 0 / 7 2 / 4 
Vibration sense 5 / 5 3 / 3 6 / 8 4 / 7 4 / 4 
Joint position sense 1 / 5 0 / 3 2 / 8 1 / 6 1 / 4 
Sensory sum score < 56 5 / 5 3 / 3 6 / 8 4 / 7 4 / 4 
Sensory sum score 48.0 (38-54) 52.3 (51-54) 49.8 (42-56) 52.9 (46-56) 50.3 (34-54) 
      
      
Neurophysiologic studies      
Normal 1/5 0/3 1/8 6/7 0/4 
Distal axonopathy         
     sensory 0/5 0/3 0/8 0/7 1/4 
     sensorimotor 1/5 0/3 4/8 1/7 1/4 
Neuronopathy       
     anterior horn 2/5 1/3 3/8 0/7 1/4 
     dorsal root ganglion    2/5 3/3 2/8 0/7 1/4 
Sum-score CMAP/SNAP (mV) 33.9 (± 18.6) 54.0 (± 7.2) 38.9 (± 25.5) 67.6 (± 24.7) 65.6 (± 24.2) 
Sum-score SNAP (µV) 39.7 (± 30.6) 38.7 (± 19.0) 42.9 (± 25.2) 146.0 (± 59.8) 66,3 (± 34.4) 
 
Table: Patient characteristics, overview of peripheral symptoms and signs, and results of 
electrophysiologic studies. The number of patients with a particular symptom or sign is displayed as a 
fraction of the total SCA subtype population; the other numbers represent means of data with the 
range or standard deviation between brackets; ARS = ataxia rating scale; maximum MRC sum score 
is 140; maximum sensory sum score is 56. 
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Electrophysiologic studies were considered abnormal in all four SCA7 patients studied. A 
mild axonal sensorimotor neuropathy and an axonal sensory neuropathy were diagnosed 
both in one patient. Neuronopathy affecting motor neurons was deemed likely in another 
patient, while findings were interpreted as an early-stage sensory neuronopathy in the fourth 
SCA7 patient.  
Overall, no signs of demyelinating peripheral nerve pathology were present. 
 
Clinical characteristics vs. electrophysiologic findings 
The fact that some patients without EMG abnormalities were found to have vibration sensory 
disturbances implicates that this can as likely be due to posterior column degeneration as to 
peripheral nervous system degeneration. Therefore, in the following, we disregarded 
vibration sensory disturbances.  
Some patients without electrophysiologically confirmed peripheral nerve pathology did, 
however, have signs and symptoms that suggested peripheral neuropathy clinically, which 
was most evident in the SCA6 group. Alternatively, several patients with electrophysiologic 
abnormalities had no peripheral symptoms or signs at all. Peripheral symptoms were present 
in 68% of patients with established peripheral nerve involvement, and peripheral signs were 
also present in 68%. In patients with normal electrophysiologic studies, these percentages 
were 63% and 25%, respectively.  
Of all eleven patients with neuronopathy, four did not have any symptom and three had no 
objective signs suggestive of involvement of the peripheral nerves. In the eight patients with 
axonopathy these numbers were two and one, respectively. 
 
Statistical analysis 
There was no significant correlation between the sum of CMAPs/SNAPs and age, disease 
duration, or ataxia severity, although the correlation between age and the sum of 
CMAPs/SNAPs (r = -0.34) almost reached significance (p = 0.09), indicating an age-related 
decline in nerve action potentials. Similar results were obtained by summating SNAPs only. 
There was no significant difference in age, disease duration, or ataxia severity between the 
group with (n=19) and the group without (n=8) peripheral nerve involvement, nor between the 
neuronopathy (n=11) and axonopathy group (n=8).  
Multiple comparison tests indicated that, compared to SCA1, SCA2, SCA3, and SCA7, the 
sum of SNAPs was significantly higher in SCA6 (p = 0.002). 
Groups were too small to study the effect of the length of the CAG repeat expansion.  
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Discussion 
The issue of whether the peripheral nerve involvement manifests as a typical distal-dominant 
axonopathy or as a primary neuronopathy has not been systemically addressed. Solving this 
issue seems relevant to understand the pathophysiologic mechanisms of polyQ-induced 
neurodegeneration. In addition, the peripheral neuropathy in SCA patients is a putative 
candidate surrogate disease marker in future therapeutic trials, which makes the 
determination of the true nature and pattern of peripheral nerve pathology even more 
important. Here, we confirm the high prevalence (about 70%) of peripheral nerve 
involvement in ADCAs. Dying-back axonal neuropathy was found in 29.6%, while 
neuronopathy was observed in 40.8% of patients.  
Some findings deserve comment. Our SCA2 patients all had abnormalities compatible with a 
sensory neuronopathy, mainly affecting the upper limbs. That the ‘axonal neuropathy’ in 
SCA2 preferentially affected the arms was already known, and it has been suggested that 
this most likely resulted from a motor and sensory neuronopathy.3,8 The axonal neuropathy in 
only one 72-year-old SCA6 patient may not represent a disease-related polyneuropathy, but 
rather a chronic idiopathic axonal polyneuropathy.10 Although the presence of an axonal 
neuropathy has been reported in SCA6, the fact that the sum score of SNAPs in our SCA6 
population was found to be significantly higher compared to the other SCA subtypes, 
strengthens our idea that peripheral nerve pathology is not a prominent disease feature, if at 
all, in SCA6. 7 There is accumulating evidence that SCA6 indeed behaves differently from the 
other SCAs that carry a CAG repeat expansion.1 In a previous study of five SCA7 patients, 
electrophysiologic abnormalities were not observed, while the four patients we studied all 
showed peripheral nerve pathology.5 
Remarkably, some patients with electrophysiologically confirmed peripheral nerve 
involvement were found not to have any accompanying sign or symptom, suggesting that the 
peripheral nerve pathology is often mild and subclinical. The slow progression of disease 
may also contribute to this observation. In the ADCA patients studied here, neuronopathy 
and axonopathy are clinically almost indistinguishable, and in only two cases, weakness of 
predominantly proximal muscles provided a clue for a lower motor neuron lesion.  
Neuropathologic examinations have revealed degenerative changes and reductions in the 
number of neurons in the anterior horns and/or dorsal root ganglia of patients with SCA1, 
SCA2, SCA3, and SCA7, and we are not aware of such findings in SCA6.14-16 Based on 
these observations, one would expect the peripheral nerve pathology to manifest as 
neuronopathy and not as typical dying-back axonopathy.  
On the other hand, recent studies on cell and animal models of polyQ diseases show that 
neuronal cell death is preceded by neuronal dysfunction that involves dendrites and 
axons.17,18 In this way, the presence of dying-back axonopathy is to be expected, with 
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neuronopathy representing end-stage disease. However, the findings in SCA2 patients, in 
whom the sensory neuronopathy was mainly observed in the upper extremities, argue 
against this sequence of events. We also did not observe a difference in disease duration 
between the neuronopathy and axonopathy groups. 
In agreement with others, we hypothesize that the primary event in peripheral nerve 
pathology in ADCAs is dysfunction of motor neurons in the anterior horn and sensory 
neurons in the dorsal ganglions.8,19 This is supported by the fact that the primary site of 
degeneration in trinucleotide repeat expansion diseases is supposed to be nuclear. The 
dysfunction thus involves the soma itself but can then result in either a motor and/or sensory 
neuronopathy or in a length-dependent (dying-back) distal axonopathy. In which of these two 
downstream disease pathways the neuron finds itself is probably related to the SCA gene 
and gene product characteristics and to yet unidentified modifying genes or environmental 
factors. Such contributing factors might also explain the possible absence of peripheral nerve 
pathology in some patients.  
We did not find any correlation between the sum of CMAPs/SNAPs and age, disease 
duration, or ataxia severity. Previously, the severity of the axonal polyneuropathy in SCA3 
patients was found to be related to age and not to CAG repeat length or disease duration.4 
Moreover, in SCA3 patients, the CAG repeat was shown to be shorter in those with an 
axonal neuropathy.5 SCA2 patients with a later age-at-onset (> 40 years) and small CAG 
repeat expansions, both suggesting milder disease, were found to display a more severe 
peripheral neuropathy.20 We recently reported a SCA3 family, carrying intermediate repeat 
expansions, with a syndrome encompassing restless legs, fasciculations, and a sensorimotor 
axonal polyneuropathy.21 Apparently, peripheral nerve involvement, both neuronopathy and 
axonopathy, can be an early disease feature, can occur in patients with relatively small 
repeat expansions, and is not related to disease progression. This would suggest that the 
pathways resulting in dorsal root and anterior horn neuronal dysfunction differ from the 
disease mechanisms in the central nervous system, or that the vulnerability of the peripheral 
and central nervous system for polyQ toxicity differs. 
In conclusion, peripheral nerve pathology in SCA patients manifests not only as a distal 
axonal neuropathy, but also as a primary neuronopathy. Electrophysiologic studies in this 
group of patients that aim to examine additional peripheral nerve involvement should include 
nerve conduction studies of upper extremity nerves and EMG studies in proximal muscles as 
well in order to detect a neuronopathy.  
One might argue that the distinction between axonopathies and neuronopathies is rather 
trivial in this group of diseases, but we believe that it is essential for understanding disease 
mechanisms and for the accurate evaluation and follow-up of ADCA patients. 
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Falls in degenerative cerebellar ataxias 
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Abstract 
We retrospectively and prospectively assessed the frequency and characteristics of 
falls in patients with degenerative cerebellar ataxias. The results show that falls occur 
very frequently in patients with degenerative cerebellar ataxias and that these falls 
are serious and often lead to injuries or a fear of falling.  Clinicians should be aware 
of this problem in ataxia patients and should try to prevent falls.
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Introduction 
Late-onset degenerative cerebellar ataxias, which include the autosomal dominant cerebellar 
ataxias (ADCA), idiopathic late-onset cerebellar ataxias (ILOCA), multiple system atrophy 
type C (MSA-C), and late-onset forms of autosomal recessive cerebellar ataxias, share 
features of adult-onset, usually moderately to slowly progressive gait and limb ataxia, 
dysarthria, and disturbances in oculomotor control. For affected patients, the disturbance of 
gait and balance is the most devastating, as this leads to reduced mobility and the resultant 
physical and social consequences.1 In addition, during medical interviews ataxia patients 
often report one or more falls, which are accompanied frequently by serious injuries. Falls 
may also induce a fear of falling and, therefore, contribute to a vicious cycle of 
immobilisation.  
At present, there is a lack of studies on the clinical epidemiology of falls in ataxia patients. To 
investigate the frequency, severity, and impact of falls in patients with a degenerative ataxia, 
we conducted a retrospective and prospective fall assessment in ADCA and ILOCA patients. 
In addition, we aimed to identify patient or fall characteristics that might be amenable to 
intervention. 
 
 
Methods 
Subjects 
Patients were recruited from our outpatient ataxia clinic. We excluded patients with MSA-C, 
because falls in these patients may be attributable to coexisting parkinsonism or autonomic 
dysregulation.2 The source population consisted of 86 patients with a diagnosis of ADCA or 
ILOCA. After chart review, 23 patients were excluded because of severe visual disturbances, 
significant cognitive decline, or documented inability to walk and stand. Of the 63 eligible 
patients that were invited to participate, 10 refused, 2 had died, 4 were completely immobile, 
and 5 could not be reached, and thus, 42 patients (32 ADCA and 10 ILOCA patients) were 
included in the retrospective study. Of these 42 patients, 26 (18 ADCA and 8 ILOCA 
patients) also agreed to participate in the prospective survey. Informed consent was obtained 
from all participants. Ataxia severity was assessed with the international cooperative ataxia 
rating scale (ICARS).3 Retrospective data on healthy subjects (n=82) who had participated in 
previous studies of falls in Parkinson’s disease (PD) served as a control population for this 
study; follow-up data were available for 76 control subjects.4,5 
 
Retrospective analysis of falls 
To evaluate prior falls, patients received a standardized questionnaire that had to be self-
completed. The details of this questionnaire have been published previously.4 In brief, the 
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questionnaire spanned a period of 12 months and addressed conditions of living, current use 
of medication, first fall after disease onset, accounts of falls during the preceding 12 months 
(including frequency, circumstances, direction of falls, and fall-induced injuries), fear of 
falling, restriction in daily or social activities, the occurrence of near falls, and an estimation of 
self-perceived confidence in one’s own balance (0, no confidence; 100, full confidence).5 
Patients were classified as ‘fallers’ if they reported one or more falls in the preceding 12 
months. 
 
Prospective assessment of falls 
For a 3-month period, patients were instructed to document all falls in a diary. At the end of 3 
months, fall diaries were returned to us by mail. In addition, patients had to fill out details of 
the first three falls on a standardized form immediately after the fall had occurred. They were 
asked to describe the fall and the assumed cause in their own words and to check off 
prespecified answers to questions about the circumstances and consequences of the fall.4,5 
Based on these data, patients were categorized as ‘fallers’, ‘recurrent fallers’, ‘injurious 
fallers’, or ‘serious fallers’ (subjects with recurrent falls, injurious falls, or both).4 In addition, 
according to established classification schemes, falls were firstly classified as extrinsic, 
intrinsic, nonbipedal, or nonclassifiable falls,6 and, secondly, as ‘base-of-support’, ‘centre-of-
mass’, no obvious perturbation, or nonclassifiable falls.7  
 
Statistical analysis 
Student’s t-test and χ2-test were used for comparison of data between patients and controls. 
Logistic regression analysis was performed to evaluate whether a variable or a combination 
of variables obtained by the retrospective study could identify the patients that displayed 
serious falls in the follow-up period, as this variable encompasses falls that are clinically most 
relevant.4 Multiple comparisons were corrected with the Bonferroni rule. 
 
 
Results 
Baseline characteristics and fall questionnaire 
The mean age of patients and healthy controls was comparable (table). There tended to be 
more women in the control group. All control subjects but only 40% of the ataxia patients 
were able to walk without support or walking aid. More ataxia patients used antidepressants. 
Disease duration in the ataxia group ranged from 1 to 50 years, and ataxia severity, as 
assessed with the ICARS, ranged from 6 to 48. 
Based on the self-reports of falls in the 12 preceding months, 93% of ataxia patients were 
identified as fallers compared with 24% of control subjects (table; figure).  
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 QUESTIONNAIRE Patients (n=42) Controls (n=82) Significance 
Descriptives  
Age (years) 56.6 ± 9.4 59.4 ± 14.2  N.S. 
Men 52.4% 34.1% N.S. 
Living in own, unadjusted home 85.7% 100% N.S. 
Walking without support or walking aid 40.5% 100% p<0.01 
Medication  
   anticholinergics 2.4% 0%* N.S. 
   benzodiazepines 12.2% 3.7% N.S. 
   antidepressants 17.1% 0%* p=0.04 
ICARS 23.9 ± 12.2 - N.A. 
  
Falls questionnaire  
Fallers (≤ 12 months) 92.9% 24.0% p<0.01 
Fall frequency  
   never to once a year 54.8% 100%*
   every month 16.7% 0%
   every week 16.7% 0%
   every day 11.9% 0%
 
p<0.01 
Injurious fallers 84.6%** 38.9%** p<0.01 
   fracture/dislocation 30.8%** 27.2%** N.S. 
Fear of falling 42.9% 1.5% p<0.01 
Restriction of activities 78.6% 11.1% p<0.01 
Near falls 97.6% 22.2%* p<0.01 
Confidence in balance 44.9 ± 26.3 95.4 ± 9.7 p<0.01 
  
FOLLOW-UP STUDY Patients (n=26) Controls (n=76)  
Fall rates and consequences  
Number of falls 22 5 - 
Fallers (≥1 fall) 13/26 5/76 p<0.01 
Recurrent fallers (≥2 falls) 7/26 0/76 p<0.01 
Injurious fallers 5/26 2/76 p=0.01 
Serious fallers 8/26 2/76 p<0.01 
Number of falls with:  
   injury 7/22 2/5 N.S. 
   inability to get up 5/22 0/5 - 
Falls indoors 14/22 0/5 p=0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table: ICARS = International Cooperative Ataxia Rating Scale; N.S. = not significant; N.A.  
= not applicable; * = complete documentation available for 27 control subjects; ** = expressed  
as a proportion of the fallers. 
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The mean estimated interval between ataxia onset and first fall was 6.5 years, but varied 
from 2 to 23 years. The fall frequency was significantly higher in the patient group (P<0.01; 
figure). Patients fell backwards, forwards, or sideways equally frequent. While falls in control 
subjects occurred mostly outside, most falls in ataxia patients took place inside their home. 
Almost 85% of the ataxia patients identified as fallers reported injurious falls, encompassing 
a fracture or dislocation in about 30%. Patients expressed a fear of falling significantly more 
often than control subjects (table). A restriction in daily activities was also more common in 
patients. In addition to true falls, near falls were reported by almost all ataxia patients. Finally, 
patients perceived a significantly lower confidence in their balance than healthy subjects did. 
 
Prospective fall assessment 
There were no significant differences in retrospective fall data between the 26 patients that 
did and the 16 patients that did not complete the follow-up study. During the 3-month follow-
up of 76 healthy controls, 5 subjects reported one fall each (6.6%; table; figure). Two of these 
five falls were injurious. Falls in control subjects were exclusively extrinsic, either base-of-
support or centre-of-mass, following an unexpected and overwhelming environmental hazard 
that occurred outdoors.  
In the patient group, 22 falls were reported by 13 of the 26 patients (50.0%; relative risk 7.6, 
P<0.001; table). Of the 13 fallers, 7 were recurrent and 5 were injurious fallers, which 
culminated in 8 serious fallers. In 5 of 22 falls, patients were unable to get up without help 
and 7 falls were injurious, with an ankle joint distortion in one. Most falls in the patient group 
occurred indoors. In contrast to control subjects, falls in ataxia patients were mostly intrinsic, 
centre-of-mass falls.  
 
Prediction of falls 
Age, disease duration, prior falls, the use of psychotropic medication, or a fear of falling (or a 
combination of these parameters) did not predict the patients that proved to be serious fallers 
in the prospective analysis.  
 
 
Discussion 
In a recent study of falls in a neurological in-patient population, the prevalence of falls was 
found to be high and to be attributable to an underlying gait disorders, such as Parkinson’s 
disease, motor neuron disease, or peripheral neuropathy, in 55% of cases.8  
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To our knowledge however, this is the first study of falls in patients with degenerative 
cerebellar ataxias. The main conclusion is that falls are very common in patients with 
degenerative cerebellar ataxias, as 93% recalled one or more falls in the last 12 months. In 
the 3-month prospective assessment period, 50% of ataxia patients experienced one or more 
falls. Based on the self-reported fall frequency, an even larger number of fallers and falls 
might have been expected during the prospective period. This suggests that patients might 
have overestimated the number of falls in the questionnaire or might have underreported falls 
in the follow-up period, or, alternatively, somehow managed to reduce falls. 
Another important finding was the high rate of injurious falls. About 85% of ataxia patients 
identified as fallers by the retrospective questionnaire reported injuries, which mostly 
involved soft tissue, but 31% of fallers suffered a fracture or joint dislocation. In the follow-up 
period, one-third of reported falls was injurious. We also observed a high rate of injuries in 
control subjects, which is not surprising because falls in the healthy subjects were typically 
high-energy falls caused by external hazards. 
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More than 40% of ataxia patients volunteered a fear of future falls. Besides being associated 
with a further decrease in mobility and social isolation, a fear of falling may lead to further 
deterioration of balance control.9 
Development of adequate preventive measures calls for data on how and where ataxia 
patients fall. Most, but not all, falls were classified as intrinsic and as centre-of-mass falls, 
pointing to the underlying disturbance of balance as the cause in most falls. In addition, most 
falls occurred indoors.  
Falls were found to occur as early as 2 years after disease onset, thus physicians should pay 
attention to falls early in the course of the disease and should be aware of the fact that, in our 
experience, patients often do not report falls spontaneously. 
We were not able to identify patient characteristics that could be used to predict which 
patient would turn out to be a recurrent or injurious faller.  
Our study had several shortcomings. The number of patients in this study was relatively 
small. Nevertheless, most results were highly significant and a larger number of patients will 
probably only strengthen the main conclusion of our study. We did not correlate falls with 
semiquantitative measures of gait and stance disturbances such as the number of deviations 
on 10 tandem gait steps or Tinetti’s Mobility Index.10  
It was not our purpose to study the precise underlying pathophysiological mechanisms of 
falls in cerebellar ataxias, but such studies are underway. In addition, it is unknown whether 
peripheral neuropathies, (extra)pyramidal features, or vestibular disturbances, which may 
occasionally be present in degenerative cerebellar ataxias, contribute to the falls. 
We think this study is of practical relevance for physicians involved in the care for patients 
with these types of currently untreatable cerebellar degenerations, as it alerts them to this 
serious source of morbidity. 
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 Abstract 
Purpose - We investigated whether quantified measurements of trunk sway during stance 
and gait tests in patients with autosomal dominant spinocerebellar ataxias (SCA) could be a 
useful approach to assess ataxia, which is highly relevant for adequate follow-up and future 
intervention studies.  
 
Methods - Eleven SCA patients and 11 age-matched healthy controls were examined. 
Postural and balance control were quantified using peak-to-peak measurements of trunk 
angle and angular velocity, in the roll (lateral) and pitch (anterior-posterior) directions, during 
a battery of stance and gait tasks.  
 
Results - In all stance tasks, trunk angle displacement and angular velocity in both the pitch 
and roll planes were significantly larger in the SCA group compared with the control group. 
Among the ataxia patients, instability was more increased in the pitch than in the roll direction 
for two-legged stance tasks, especially when standing on foam with pronounced oscillations 
in the pitch plane at 1.4 and 2.5 Hz. A similar dominance of pitch over roll instability was also 
observed in most gait tasks, especially for tandem gait and while walking with simultaneous 
head rotations.  
 
Conclusions - Trunk sway measurements were effective in detecting and quantifying the gait 
and balance abnormalities in SCA patients, suggesting that this method might be used for 
follow-up studies of SCA patients. Furthermore, the method might help to identify early-
symptomatic individuals and those patients at risk of falling. The postural instability in SCA 
was found to be multi-directional, although there is generally more pitch than roll instability 
corresponding with the predominant involvement of the spinocerebellum. 
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Introduction 
Disturbances of gait and balance are the core features of autosomal dominant 
spinocerebellar ataxias (SCAs). The gait and balance difficulties progressively affect mobility 
and also contribute to falls that already occur early in the course of the disease.1 
Insights into the pathophysiology that underlies the gait and balance disturbances in 
cerebellar disease may provide new knowledge about the role of the cerebellum and its 
neural connections in the control of posture and movement. Quantitative analysis of trunk 
sway during everyday gait and stance tasks is one possible way to achieve this.  
Prior studies of patients with cerebellar diseases used either static or dynamic 
posturography.2-5 These detailed analyses underscored the importance of the cerebellum in 
postural control, but the methods applied in these studies also had some disadvantages. The 
force-measuring platforms used in static posturography provided only indirect measures of 
body sway and then only during stance tasks. In addition, most posturography studies mainly 
focused on leg responses, whereas analysis of trunk motion and/or muscle responses has 
been shown to yield additional information on balance regulation.6,7 Finally, the results 
obtained by these prior studies have poor ecological validity.8  
A simple, but accurate and quantitative assessment of the posture and gait pathologies in 
freely moving SCA patients in a more clinical setting would have important clinical 
implications. A relatively easy to use tool to quantify trunk sway could be employed to detect 
early symptomatic individuals, to identify those patients that carry a high risk of future falls, 
and to document disease progression for the follow-up of patients. Such issues are likely to 
become clinically relevant because the first line of drugs aimed to retard disease progression 
in SCAs may start to be investigated in the next years. Furthermore, for future therapeutic 
trials with these drugs, quantitative markers of disease progression are needed, as the 
current clinical ataxia rating scales have not been studied for their sensitivity to detect small 
but appreciable changes over relatively short periods of time. 
In this study, abnormalities in trunk sway during gait and stance tasks were assessed in SCA 
patients using a novel device that consists of two angular-velocity transducers mounted on 
the lower back, allowing quantitative measurements of trunk movements in the pitch 
(anterior-posterior) and roll (lateral) plane near the centre of body mass.  
This technique of trunk sway measurement has previously been used in the detection of 
ageing effects on postural instability, in studies of balance in patients with Parkinson’s 
disease (PD) and in patients recovering from an acute unilateral peripheral vestibular 
deficit.6,9,10 
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 Subjects and methods 
Subjects 
Patients with autosomal dominant SCA based on a mutation in one of the known SCA genes 
(see table 1) were recruited from the outpatient ataxia clinic of the Department of Neurology 
of the University Medical Center Nijmegen. Loss of independent ambulance, severe visual 
disturbances, or cognitive impairment were exclusion criteria. Eleven patients and 11 age-
matched healthy subjects agreed to participate in the study. Mean age of the patients was 
49.5 ± 8.9 (standard deviation) years and of the healthy controls 48.5 ± 7.8 years. Both 
groups consisted of 3 females and 8 males. All signed informed consent prior to the study, 
which was approved by the medical ethical committees of the University Medical Centre 
Nijmegen and University Hospital Basel. 
Ataxia severity was assessed by the International Cooperative Ataxia Rating Scale (ICARS), 
which ranges from 0 (no ataxia) to 100 (severe ataxia).11 Balance and gait were scored 
according to Tinetti’s Mobility Index.12 
 
 
 
 
Figure 1: Illustration of the measurement system. The sensors measured trunk pitch (forwards-
backwards) and roll (side-to-side) angular movements as indicated by the arrows. The belt was placed 
around the patient so that the sensors were positioned at the lumbar level 2-3. 
 
 
Analysis of trunk movements 
Trunk sway analyses were carried out at the Department of Otorhinolaryngology, University 
Hospital Basel, based on a previously described protocol.6 In brief, trunk sway was measured 
during eleven stance, gait and retropulsion tasks in order of increasing difficulty. The tasks 
were: standing on both legs separated at shoulder width on a normal surface for 20 seconds 
with eyes open or closed; standing on a foam support for 20 seconds with eyes open or 
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closed; walking eight tandem steps; walking three meters with rotating or pitching head 
movements; walking three meters with eyes closed; walking over four barriers that were one 
meter apart; a retropulsion (a straight backward shoulder pull applied from behind while 
standing, preceded by a warning); and a ‘get up and go’ task (getting out of a chair and walk 
for three meters). Task duration, defined as the time needed to complete a task or as the 
time until loss of balance occurred, was recorded. 
For trunk sway measurements, the SwayStarTM system (Balance International Innovations 
GmBH, Switzerland) was used. This system comprises two digital angular-velocity 
transducers attached to the lower back by a belt (figure 1). One transducer was placed to 
measure angular velocity deviations in the pitch plane, the other to measure deviations in the 
roll plane. The transducers were connected by a long cable to a computer for data storage 
and online analysis. Angular displacements were calculated using trapezoid integration of 
angular velocities. Angular velocity over a range of ±327 deg/sec was sampled at 100 Hz 
with 16 bit resolution. Inherent transducer drift was equal to the rotation of the earth, about 
0.01 deg/sec.  
 
Data analysis 
Peak-to-peak excursions in trunk angular displacement and trunk angular velocity in both the 
roll and pitch planes were calculated (see figures 2 and 3). In addition, the amplitude of trunk 
sway velocity in the pitch and roll plane at the various frequencies was examined. Group 
means were compared using parametric testing. Parameters within the group of ataxia 
patients were studied with the paired sample t-test or with multicomparison testing. Linear 
regression analysis was applied to study correlations with clinical rating scales. The level of 
significance was set at p<0.05, which was corrected with the Bonferroni rule for 
multicomparisons.  
 
 
Results 
Baseline details and disease characteristics of the SCA patients are shown in table 1. There 
was evidence of non-cerebellar disease features in some patients but these were not 
uniformly present. We observed significant differences in trunk sway measurements during 
the various stance and gait tasks (examples of these differences are shown in figures 2 – 4 
and table 2). 
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 Stance tasks 
In all stance tasks, trunk angle displacement and velocity in both the pitch and roll planes 
were significantly larger in SCA patients compared to controls (table 2). In the group of SCA 
patients, the trunk sway abnormalities were significantly greater in the pitch than in the roll 
direction. For ataxia patients, standing on a normal surface lead only to a highly significant 
increase in pitch angle and velocity measures. Standing on foam support induced significant 
increases in all measurements. Eye closure on foam support was accompanied by a further 
increase of pitch relative to roll angle displacement (see figures 2 and 3). In ataxia patients, 
the increases in trunk sway while standing on foam support and upon eye closure were 
markedly larger than in controls. Task duration was significantly shorter in the SCA group for 
stance on foam support with eyes closed (15.0s ± 7.1s versus 20.6s ± 1.0s in controls, 
p=0.026). The cause was a loss of balance before the routine end of the task (at 20s) in five 
ataxia patients (see Figure 2). For other stance tasks duration was the full 20s of the task. 
 
 
 
Patient SCA 
type 
Age/Duration ICARS NCS/EMG Pyramidal 
tract signs 
VOR Imaging, atrophy of: 
1-male SCA1 54 / 12 26 normal + normal cerebellum 
2-male SCA2 49 / 14 36 neuronopathy of 
UE 
+ low cerebellum, 
pons (subtle) 
3-female SCA2 56 / N.D. 26 neuronopathy of 
UE/LE 
- normal cerebellum 
4-female SCA3 63 / 15 38 neuronopathy of 
UE/LE 
+ low N.D. 
5-male SCA3 41 / 3 5 mild axonal 
neuropathy 
- normal cerebellum (vermis) 
6-female SCA3 32 / 13 25 N.D. - normal cerebellum (vermis) 
7-male SCA6 48 / 12 39 normal - normal  
8-male SCA7 45 / 8 28 mild axonal 
neuropathy 
+ low cerebellum, brainstem 
9-male SCA14 60 / 21 34 N.D. - normal N.D.  
10-male SCA14 44 / 23 29 N.D. + normal N.D. 
11-male SCA14 55 / 26 12 normal - normal cerebellum (vermis) 
mean±SD  49.5±8.9/13.8±6.7 27.1±10.6     
Table 1: Disease characteristics of the participating patients, including non-cerebellar features (ICARS 
= international cooperative ataxia rating scale; NCS/EMG = nerve conduction studies and 
electromyography; UE = upper extremity, LE = lower extremity; VOR = vestibulo-ocular reflex; N.D. = 
no data) 
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Gait tasks 
Consistent with our observations for the stance tasks, the ataxia patients demonstrated more 
severe instability in the pitch compared to the roll plane for all gait tasks except while walking 
over barriers (table 2). For all gait tasks, task duration was significantly longer in the SCA 
group. 
In the tandem gait task, pitch and roll angular displacement and velocity were significantly 
larger in the ataxia patients, again with the largest increase in the pitch direction (figures 4 
and 5). The regular oscillation observed in the pitch movements of controls with each step 
became irregular with the unstable lengthened task duration of the patients (figure 4). 
Walking three meters with eyes closed and with pitching head movements showed significant 
differences in angle displacement and velocity in only the pitch plane. Rotating head 
movements while walking induced similar changes in the pitch plane and also an increase in 
the roll angular velocity. The only significant difference in the ‘get up and go’ task was a 
smaller velocity in pitch movements of the trunk in the patients (table 2). The large (ca. 150 
deg/s) pitch velocities are elicited during the get-up phase of the task. 
 
 
Figure 2: Example of extensive pitch oscillation of a typical SCA patient while standing with eyes 
closed on foam. Backward pitch and leftward roll is represented by a negative (downward) deflection 
of the traces. The lower set of traces is from a normal subject of the same age and sex. Between the 
two sets of traces, columns indicate the mean stance durations for the SCA and control populations. 
Horizontal bars to the right of the columns indicate standard errors of the means.  
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Figure 3: Extent of sway for typical SCA and control subjects (same subjects as in figure 2). Each 
recording from figure 2 is shown as an x-y plot of either pitch versus roll angle (upper row) or pitch 
versus roll velocity (lower row). An envelope has been drawn around the excursions. The maximum 
peak-to-peak excursions in each direction were analyzed. Notice the relatively larger pitch than roll 
angle deviations. To the right of the x-y plots columns indicating population average and standard 
errors of the mean of pitch and roll angle and pitch and roll velocity excursions are shown. Notice how 
the SCA means are larger than normal for pitch more than for roll. 
 
 
 
Retropulsion (Pull) task 
Trunk movements were analyzed during a five-second period that commenced just before 
the pull. None of the SCA patients lost their balance. Compared to controls, pitch angle 
displacement and both pitch and roll angular velocity were larger in ataxia patients. The 
ataxia patients displayed more pitch than roll instability. The effect of the pull led, however, 
also to larger pitch velocities and angles in the controls. 
 
Analysis of frequency spectra 
When the low-frequency bands (up to 5 Hz) of velocity spectra were examined for stance 
tasks, increases in trunk angular velocity of the ataxia patients occurred significantly in all the 
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bands for both pitch and roll planes (table 3).  
 
 
Figure 4: Examples of trunk angle sway for the task of walking 8 tandem steps. The layout of the 
figure is identical to that of figure 2. 
 
 
Correlation with clinical scales 
Overall, the results of trunk sway analyses were not strongly correlated with ataxia severity 
as assessed by the ICARS and with Tinetti’s Mobility Index. The total ICARS score 
correlated with: pitch angular velocity while walking over barriers (r=0.709; p=0.032); pitch 
angle displacement while walking 3 meters with eyes closed (r=0.725; p=0.0027); and pitch 
angle displacement while walking 3 meters with pitching head movements (r=0.806; 
p=0.009). The ICARS kinetic subscore correlated with: pitch angular velocity while standing 
on foam with eyes open (r=0.672; p=0.048) and while walking barriers (r=0.746; p=0.021); 
pitch angle displacement while walking 3 meters with eyes closed (r=0.749; p=0.020); and 
roll angle displacement following the shoulder pull (r=0.729; p=0.026). The ICARS 
posture/gait subscore correlated with: roll angular velocity while walking 8 tandem steps 
(r=0.754; p=0.019); and with pitch angle displacement while walking 3 meters with pitching 
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 head movements (r=0.757; p=0.018). All other correlations between trunk sway and ataxia 
severity were small and non-significant. 
Tinetti’s Mobility Index was correlated with: pitch angular velocity while walking 3 meters with 
rotating head movements (r=0.705; p=0.034); and roll angular velocity for the retropulsion 
test (r=0.673; p=0.047).  
The number of patients with a specific non-cerebellar feature was too small to study a 
possible contribution of extracerebellar pathology to the results. 
 
 
Figure 5: Example of the extent of sway in typical subjects and mean values of trunk sway for the task 
of walking 8 tandem steps. The subjects are those of figure 2 and the layout of the figure is identical to 
that of figure 3. 
 
 
Discussion 
The study demonstrated significant differences in trunk sway between ataxia patients and 
control subjects. Because we studied clearly affected SCA patients, these differences were 
expected, but the magnitude and the form of the differences we observed offer promise for 
follow-up studies and detection of early-symptomatic patients.  
The main result we noted was that SCA patients display more pitch than roll instability.
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 ROLL PITCH 
 1.2 Hz 2.4 Hz 3.6 Hz 4.8 Hz 1.2 Hz 2.4 Hz 3.6 Hz 4.8 Hz 
Stance tasks 
Normal surface 
  eyes open 
  eyes closed 
Foam surface 
  eyes open 
  eyes closed 
 
 
 
0.042 
0.021 
 
0.004 
ns 
 
 
 
0.025 
0.012 
 
0.008 
0.006 
 
 
 
0.003 
0.015 
 
0.005 
0.026 
 
 
 
0.097 
0.036 
 
0.004 
0.033 
 
 
 
0.030 
0.007 
 
0.002 
0.003 
 
 
 
0.007 
0.013 
 
0.006 
0.002 
 
 
 
0.020 
0.026 
 
0.002 
0.001 
 
 
 
ns 
0.035 
 
0.007 
0.012 
 
 
Table 3: P-values of t-test comparisons between the mean amplitudes of sway in ataxia patients and 
healthy controls for pitch and roll frequencies below 5 Hz; ns = not significant. 
 
 
 
Increases in trunk sway during stance and during almost all gait tasks were more 
pronounced in the pitch compared to the roll plane. This increase in both directions though 
greater in the pitch plane for stance and gait is distinctly different from sway instabilities in 
other patient groups we have studied.10,13 
More pitch than roll instability most likely reflects the predominant involvement of the 
spinocerebellum in SCAs. As patients were allowed to assume a comfortable standing 
position, which may have been more wide-based (shoulder-wide) than their natural pre-
symptomatic position, they may have (partially) compensated for lateral instability. However, 
we also found more pitch than roll trunk instability during the tandem gait test where such 
compensation is presumably absent. This finding illustrates that quantitative analysis can 
reveal unexpected differences that are difficult to observe clinically. 
The increase in trunk sway when patients stood on foam with either eyes open or closed 
compared to the increase in sway when eyes are open or closed on a normal surface 
demonstrate that both an absence of visual control and distortion of proprioceptive inputs 
induce an increase in postural sway in SCA patients. The magnitude of the changes under 
these conditions suggests, however, a relatively greater preservation of proprioceptive 
balance control compared to visual control of balance.14 
When walking over barriers, roll angle displacement was larger in the ataxia patients than in 
controls. In the pitch plane no difference was observed.  This task will induce more trunk roll 
instability due to a relatively longer single-leg phase when stepping over a barrier, and the 
simultaneous counter phase roll trunk movements are necessary to walk over the barriers.  
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In the ‘get-up-and-go’ test, the angular velocity of the trunk movement in the pitch plane was 
decreased in the SCA group. As this task requires fast trunk movements in mainly the 
antero-posterior direction, this could be interpreted as a decreased ability to generate such 
fast trunk movements in ataxia patients or as a compensatory strategy to prevent truncal 
instability. Interestingly, this decrease did not lead to increased trunk roll as in patients with 
PD.15  
Previous static posturography studies suggested a cerebellar topography in the 
abnormalities in body sway, because the direction and frequency of postural tremor in ataxia 
patients depended on the cerebellar regions affected.3 When the anterior lobe 
(spinocerebellum) was affected, as is seen in chronic alcoholics, a spontaneous antero-
posterior directed postural tremor was observed, with a frequency of about 3 Hz. Lesions to 
the vestibulocerebellum induced an omnidirectional, low-frequency (<1 Hz) sway. 
Involvement of mainly the spinocerebellar afferents, as in Friedreich’s ataxia, produced a 
lateral body sway with a large amplitude and low frequency (1.1 Hz). Damage to the 
cerebellar hemispheres alone did not result in alterations of postural sway. A more recent 
study showed, however, that lesions of the pontine tegmentum, deep cerebellar nuclei, and 
cerebellar hemispheres all resulted in a 3 Hz body oscillation, and these results thus argue 
against such a cerebellar topography in body sway abnormalities.4 The presence of body 
oscillations in cerebellar disease has been explained by an increased gain of posturally 
stabilizing (long loop) reflexes that involve cerebellar control.2,4,5 
Although we observed increases at 3 Hz, the greatest increases in pitch tremor were noted 
at lower frequencies (1.2 and 2.4 Hz) during stance tasks in SCA patients. This postural 
tremor corresponds to previous observations in cerebellar ataxia patients, occurring at 
frequencies below 5 Hz, but nonetheless the frequency of the tremor is somewhat lower than 
the 3 Hz usually observed. This is may be due to differences in technique and 
measurements used (static posturography measures oscillations registered at the feet rather 
than trunk sway) or a greater involvement of vestibular cerebellar pathways in our patients. 
In general, our results of trunk sway analyses correlated poorly with clinical rating scales of 
posture and gait. This may be caused by the small sample size of the ataxia group and in 
particular by the relative narrow window of ataxia severity in this group (all but one patient 
had an ataxia severity score, as assessed by ICARS, between 10 and 30). In addition, the 
sensitivity for the detection of trunk sway abnormalities with our system is significantly 
greater than for the rating of clinical items. 
Due to the small sample size and the fact that extracerebellar disease features were found to 
be invariably present, we were not able to address whether the abnormalities of trunk sway 
in these SCA patients reflect pure cerebellar disease and not also possible coexisting 
disease such as peripheral nerve pathology. Although such studies are necessary from a 
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 pathophysiologic point of view, the follow-up of these patients requires the clinical 
assessment of ‘net’ gait and balance problems. 
In conclusion, the postural instability in SCA was found to be bidirectional, but with generally 
more pitch than roll instability, which corresponds to the predominant involvement of the 
spinocerebellum. The method of trunk sway analysis presented here showed to be an 
adequate tool to detect and quantify the gait and balance abnormalities in SCA patients. In 
addition, this method might be used to detect early-symptomatic patients and help to identify 
those patients at risk of falling. This method has already been used to identify fallers among 
PD patients and the elderly.15,16
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Abstract 
In recent years, molecular genetic research has unraveled a major part of the genetic 
background of autosomal dominant and recessive spinocerebellar ataxias. These advances 
have also allowed insight in (some of) the pathophysiologic pathways assumed to be 
involved in these diseases. For the clinician, the expanding number of genes and genetic loci 
and the enormous clinical heterogeneity of specific ataxia subtypes complicate management 
of ataxia patients. 
In this review, the clinical and neuropathologic features of the recently identified 
spinocerebellar ataxias are described, and the various molecular mechanisms that have 
been demonstrated to be involved in these disorders are discussed. 
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Introduction 
The problem of a rational nosological classification of the degenerative cerebellar ataxias has 
haunted clinicians for about 150 years. The problem was conceptually resolved by Anita 
Harding when she proposed a genetic subdivision into dominant, recessive, and sporadic 
spinocerebellar ataxias.1 The development of statistical and molecular genetic analytic tools 
has resulted in the identification of the loci and mutated genes associated with the various  
spinocerebellar ataxias, allowing us to unravel the underlying mechanisms of cerebellar 
neurodegeneration. However, the expanding number of genes has created novel challenges, 
such as defining the most efficient diagnostic approach and how to pursue the ultimate goal 
of finding rational therapies.  
We will review the various spinocerebellar ataxias that have now unambiguously been 
identified, present data on the corresponding clinical and neuropathologic features, and 
examine the various molecular mechanisms that have been demonstrated to be involved in 
these particular neurodegenerative disorders.  
 
Autosomal dominant cerebellar ataxias (ADCAs) 
Since the identification of the first gene involved in dominant ataxia, Spinocerebellar Ataxia 
(SCA) 1, in 1993, 24 genetic loci and 9 genes have been described (table 1).2 The first SCA 
genes (SCA1, 2, 3, 6, and 7) identified all share as their mutational mechanism an expanded 
repeat of coding CAG sequences.2-6 These repeats are translated into an expanded 
polyglutamine (polyQ) stretch in the cognate proteins, which are termed ataxines but which 
are otherwise unrelated. SCA8, 10, and 12, are caused by a noncoding CTG, ATTCT, and 
CAG repeat expansion, respectively,7-9 although the pathogenicity of the SCA8 mutation is 
still under debate. The SCA10 and SCA12 mutations seem to be confined to specific 
populations.10-12 
Because of significant clinical overlap between the various SCAs and the phenotypic 
variability of single subtypes, it is hazardous to clinically predict the SCA genotype in 
individual patients. There are, nevertheless, some specific clinical clues that can be used to 
adopt a rational first-line genetic testing strategy (table 1).13 Characteristics of the most 
recently identified SCA loci and genes are discussed below. SCA subtypes discovered 
earlier have been reviewed previously.13,14 
 
Novel SCA subtypes 
SCA12 (OMIM 604326) 
This very rare genotype has been described in a pedigree of German descent, as well as in 6 
families from India.7,10,11 Onset varies between age 8 and 55 years, although an insidiously 
progressive postural tremor precludes exact onset determination. Progressive ataxia, 
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extrapyramidal features, and ultimate dementia are characteristic. SCA12 is caused by an 
expanded noncoding CAG repeat in the PPP2R2B gene that encodes a brain-specific 
regulatory subunit of the phosphatase PP2A.7 
 
SCA13 (OMIM 605259) 
To date, only a single French family linked to this chromosome 19q13.3-13.4 locus has been 
described.15 The clinical features clearly distinguish SCA13 from the other SCA subtypes: 
onset of ataxia in early childhood (although with very slow disease progression), delay of 
motor milestones, and mild mental retardation or deterioration. Additional signs include 
pyramidal tract signs, swallowing difficulties, urinary urgency, and extrapyramidal features 
like torticollis or bradykinesia.  
 
SCA14 (OMIM 605361) 
A small number of families with linkage to the SCA14 locus on chromosome 19q13.4-qter 
have been reported. A slowly progressive isolated cerebellar syndrome with a markedly 
variable age at onset was reported, with extrapyramidal features, such as focal dystonia or 
axial myoclonus, in early onset disease.16-18 Five different missense mutations have been 
described in exon 4 of the PRKCG gene that encodes protein kinase Cγ (PKCγ): c.301C→T, 
355T→C, 383G→A, 353G→A, and 380A→G.18-20 These 5 mutations all affect the regulatory 
domain of PKCγ. Recently, a mutation in exon 18 that affects the catalytic domain of the 
protein was identified in a French SCA14 family with additional cognitive disturbances and 
myoclonus.21 Neuropathologic examination has shown patchy Purkinje cell loss without glial 
proliferation, mild gliosis in the medulla oblongata and inferior olives, without neuronal loss, 
and with normal findings in the basis pontis, basal ganglia, and cerebral cortex.17,20 
 
SCA15 (OMIM 606658) 
Pure cerebellar ataxia in an Australian family was linked to the 3p24.2-pter region.22 A 
Japanese SCA family was reported recently with possible linkage to a locus on 3p26.1-25.3, 
which partly overlaps the SCA15 locus.23 Most of the affected subjects in this family showed 
additional postural and action tremor of the trunk and hands. 
 
SCA16 (OMIM 606364)   
Linkage to a locus on 8q22.1-24.1 has been found in a large Japanese ADCA family with a 
late-onset isolated cerebellar ataxia and coexisting rotatory head tremor in 3 subjects.24  
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SCA17 (OMIM 607136) 
This rare SCA subtype is caused by an expanded CAG/CAA repeat in the TATA Binding 
Protein (TBP) gene that results in an expanded polyQ tract in the encoded TATA-binding 
protein, a transcription factor. Normal alleles carry 29 to 42 CAG/CAA repeats; expansions 
between 46 and 66 are associated with spinocerebellar ataxia.25-27 
Controversy exists about the meiotic stability of the SCA17 repeat and the occurrence of 
nonpenetrance, complicated by marked variability in the age at onset, ranging from 18 to 55 
years.26,28-30 Clinical features encompass a variable combination of progressive cerebellar 
ataxia, psychiatric disturbances, dementia, and extrapyramidal features such as 
parkinsonism, dystonia, and chorea.25,26,28 A Huntington’s disease-like phenotype has been 
documented.31 Hyperreflexia is frequently present, and some patients develop seizures, 
spasticity, dysphagia, sphincter abnormalities, or an axonal neuropathy.25,26,30 Imaging 
studies revealed cerebellar and cerebral cortical atrophy.25,29,30  
Neuropathologic examination has demonstrated 1) marked cerebellar atrophy with mild 
cerebral cortical atrophy, 2) moderate to severe Purkinje cell loss, 3) moderate loss of 
neurons in the caudate nucleus, putamen, locus ceruleus, and in thalamic and hippocampal 
regions, 4) neuronal loss with spongiotic changes in various cerebral cortical regions, 5) 
relatively mild brainstem involvement, 6) and the presence of extensive intranuclear 
ubiquitinated polyQ-containing neuronal inclusions in a wide range of both affected and 
nonaffected brain regions.25,26,28,31 
 
SCA18 (OMIM 607458) 
This 7q22-q32 locus was mapped in an Irish-American family. Onset of disease, which 
consisted of a sensory ataxia due to a sensory axonal neuropathy, was mostly before the 
age of 20 years. Later, some individuals developed cerebellar ataxia with mild cerebellar 
atrophy on neuroimaging, pyramidal tract signs, and neurogenic muscle weakness and 
atrophy.32 Phenotypically, this family seems to present an overlap between the SCAs and the 
hereditary sensory neuropathies.  
 
SCA19 and SCA22 (OMIM 607346) 
The SCA19 locus on chromosome 1p21-q21 was identified in one Dutch family.33 Affected 
individuals displayed a late-onset mild cerebellar ataxia, hyporeflexia, and frontal executive 
dysfunction.34 Tremor and myoclonic movements were occasionally observed. Before the 
SCA19 locus had been published, the name SCA22 was assigned to a 1p21-q23 locus that  
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Mutational mechanism Locus Gene Gene product Distinctive clinical feature 
 
Coding CAG repeat expansion
    
SCA1 6p22-23 SCA1 Ataxin-1  
SCA2 12q23-24.1 SCA2 Ataxin-2 Marked slowing of saccades; pontine 
atrophy on neuroimaging 
SCA3 14q24-qter SCA3/MJD Ataxin-3 Pronounced parkinsonism, spasticity, 
neuropathy, or motor neuron disease 
SCA6 19p13 CACNA1A α1-subunit of voltage-gated 
Ca2++-channel type P/Q 
Relatively late-onset (>50 yrs); may be 
found in ‘sporadic’ ataxia 
SCA7 3p12-21.1 SCA7 Ataxin-7 Macula degeneration 
SCA17 6q27 TBP TATA box binding protein Marked dementia, chorea, 
parkinsonism, and/or psychiatric 
symptoms; may resemble Huntington’s 
disease 
 
Non-coding repeat expansion
    
SCA12 (CAG) 5q31-33 PPP2R2B Brain-specific regulatory 
subunit phosphatase PP2A 
Action tremor head and arms as first 
feature 
SCA8 (CTG) 13q21 SCA8 Antisense RNA-transcript 
(KLHL1) 
 
SCA10 (ATTCT) 22q13-qter SCA10 ? Seizures; all families reported so far are 
of Mexican descent 
 
Point mutations
    
SCA6 19p13 CACNA1A α1-subunit of voltage-gated 
Ca2++-channel type P/Q 
 
SCA14 19q13.4-qter PRKCG Protein kinase C type γ  Dystonia or axial myoclonus if onset < 
30yrs 
‘FGF14’/SCA27 13q34 FGF14 Fibroblast growth factor 14 Childhood hand tremor; orofacial 
dyskinesias 
 
 
Unknown
    
SCA4 16q22.1 ? ? Coexisting sensory axonal neuropathy 
SCA5 11p11-q11 ? ?  
SCA11 5q14-21.3 ? ?  
SCA13 19q13.3-13.4 ? ? Onset <10 years, psychomotor 
retardation 
SCA15 3p24.2-pter ? ?  
SCA16 8q23 ? ? Rotatory head tremor 
SCA18 7q22-q32 ? ? Onset <20 years, marked sensory 
neuropathy 
SCA19 / SCA22 1p21-q23 ? ? Holmes-like tremor, myoclonus, frontal 
executive dysfunction 
SCA20 (SCA5?) 11 ? ? Dysphonia, palatal or lip tremor, 
calcifications of dentate nucleus 
SCA21 7p21.3-p15.1 ? ? Extrapyramidal features 
SCA23 20p13-p12.2 ? ?  
SCA25 2p15-p21 ? ? Occasional very early onset, prominent 
sensory neuropathy 
Table 1:  Dominant genotypes ordered according to type of mutation 
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resulted from a linkage study in a Chinese SCA family.35 Although extracerebellar signs were 
absent in the Chinese family, these 2 loci might represent the same condition.36 
 
SCA20 (OMIM 608687) 
This locus on the pericentromeric region of chromosome 11 covers the SCA5 locus.37 
Clinically, this Australian family is clearly different from the original SCA5 family. Disease 
onset varied from 19 to 64 years and dysarthria was a relatively frequent presentation. 
Besides ataxia, subjects displayed dysphonia, palatal or lip tremor, and bradykinesia. 
Neuroimaging disclosed calcifications in the area of the dentate nucleus. SCA5 and SCA20 
may be allelic or phenotypic variants of the same mutated gene or are indeed distinct genetic 
disorders. 
 
SCA21 (OMIM 607454) 
Linkage to 7p21.3-15.1 was described in a single French family.38 Ataxia onset ranged from 
6 to 30 years. Mild akinesia with or without limb rigidity, resting and postural limb tremor, mild 
cognitive impairment, and hyporeflexia were observed.  
 
SCA23 
SCA23, its locus on 20p13-p12.2, is clinically characterized by an isolated cerebellar ataxia 
that starts after age 40 years. Neuropathology in one affected subject showed the following: 
neuronal loss in the Purkinje cell layer, dentate nuclei and the inferior olives; thinning of 
cerebellopontine tracts; demyelination of the spinocerebellar afferent tracts; and ubiquitin-
positive intranuclear inclusions in substantia nigra neurons.39 
  
SCA24 (OMIM 607317) 
The SCA24 designation has been assigned to a family with late-onset spinocerebellar ataxia, 
increased saccadic speed, pyramidal tract signs, axonal neuropathy, mild pes cavus, and 
myoclonic jerks.40 However, the pedigree of the family referred to suggests an autosomal 
recessive mode of inheritance. 
 
SCA25 (OMIM 608703) 
A 2p15-p21 locus has been mapped in a French family.41 Age at onset varied from 17 
months to 39 years. In addition to cerebellar ataxia, sensory neuropathy was a prominent 
feature and some subjects showed severe neuropathy with only little cerebellar involvement. 
Scoliosis, facial tics or myokymia, and gastric pain were noted in some subjects. Like 
SCA18, SCA25 seems to lie within a spectrum of SCAs and hereditary sensory 
neuropathies. 
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SCA26 
This locus on 19q13.2 has been mapped in a Norwegian American family with a pure 
cerebellar ataxia (personal communication, MJ Howell, 2004). 
 
FGF14 (SCA27; OMIM 601515) 
The fiboblast growth factor 14 (FGF14) mutation associates an unexpected category of 
genes / proteins with spinocerebellar ataxia.42 Affected members of the single Dutch FGF14 
family showed ataxia onset between 28 and 40 years, but most patients had hand tremor 
since childhood. Head tremor, orofacial dyskinesias, low cognitive performances, and 
aggressive outbursts were frequently present. The FGF14 mutation on chromosome 13q34 
consists of a missense mutation (c.434T→C) in exon 4. The function of wild-type Fgf14 is 
unclear; how this mutation induces neurodegeneration is unknown. Functional studies 
indicate that the mutation might affect Fgf14 protein stability.   
 
Recessive and sporadic early onset ataxias 
The group of recessive ataxias is clinically even more heterogeneous than the dominant 
forms and often manifest as multisystem disorders. However, the various genotypes can be 
grouped into recognizable and more or less specific phenotypes (table 2). We will review 
autosomal recessive diseases with cerebellar ataxia as the core feature; recessive diseases 
with ataxia as an additional feature (e.g. Refsum’s disease) are not discussed. 
 
Syndromal phenotype Clinically defined disease Locus Gene 
    
Friedreich’s disease (FA) 9q12 Frataxin  Ataxia with 
neuro(no)pathy FRDA2 9p23-p11  
 Hereditary ataxia with Vitamin E deficiency 8q13.1-q13.3 Alpha-tocopherol transfer protein
 X-linked sideroblastic anaemia with ataxia Xq13.1-q13.3 ATP-binding cassette (ABC) 
transporter 
 Infantile onset spinocerebellar ataxia  10q24  
 Cayman type ataxia 19p13.3 Atcay (Caytaxin) 
 Spinocerebellar Ataxia with Axonal neuropathy 
(SCAN1) 
14q31-q32 Tyrosyl-DNA phosphodiesterase 
1 (TDP1) 
 Early Onset Cerebellar Ataxia (EOCA)   
    
Spastic ataxia Autosomal Recessive Ataxia of Charlevoix-
Saguenay 
13q12 SACS (Sacsin) 
    
Ataxia Telangiectasia (AT) 11q22.3 ATM Ataxia with oculomotor 
apraxia hMRE11 associated AT 11q21 MRE11 
 Ataxia with Oculomotor Apraxia (AOA1) 9p13.3 APTX (Aprataxin) 
 Ataxia with Oculomotor Apraxia (AOA2) 9q34 SETX (Senataxin) 
    
Ramsay Hunt 
syndrome 
Various n.a. n.a. 
 
Table 2: Recessive genotypes ordered according to phenotype (n.a. = not applicable). 
 152 
     CHAPTER 5 
Ataxias with neuro(no)pathy 
A large group of recessive ataxias is characterized by prominent peripheral nerve 
involvement that accompanies the spinocerebellar ataxia. This peripheral nerve involvement 
encompasses a more or less typical dying-back axonopathy that mainly affects the lower 
limbs. Less commonly, a nongradient neuronopathy or ganglionopathy of both upper and 
lower limb is encountered.  
 
Friedreich’s ataxia (OMIM 229300) 
The most common and best known recessive ataxia is Friedreich’s Ataxia (FA); its estimated 
prevalence in the western world is about 2 in 100,000. The estimated gene carrier frequency 
is about 1:100.43-45 FA is the sole example of an intronic expanded trinucleotide (GAA) 
repeat, located in intron 1 of the 9q12 frataxin gene.46 In most control alleles, the repeat 
length ranges from 6 to 9. A small subset of large-normal alleles (14-34 repeats) exists that 
may be the unique source of further expansions into an intermediate (up to 90 repeats) or 
clearly disease causing range (90 to 1,700 repeats).44,46-48 Frataxin gene point mutations 
have been described, but such alleles may only be pathogenic in conjunction with a GAA-
expanded allele.49 
For a detailed overview of the clinical hallmarks of FA we refer to the paper of Dürr.45 
Apparently, the clinical spectrum of FA is much wider than initially defined and currently 
includes onset ages over 30 years, a much milder disease course than usually recognized, 
spastic ataxia, and even extrapyramidal movement disorders such as myoclonus or chorea.50 
Cardiomyopathy is present in most cases, although its manifestations are variable and may 
often remain undetected.51 
 
FRDA2 (OMIM 601992)
A second locus, on 9p23-p11, was found to cosegregate with a disorder that was 
phenotypically described as classic Friedreich’s disease.52 No progress has been reported 
on this entity. 
 
Hereditary ataxia with vitamin E deficiency (AVED – OMIM 277460) 
This rare condition clinically resembles Friedreich’s ataxia: early onset progressive 
spinocerebellar ataxia with marked proprioceptive loss and areflexia due to prominent 
peripheral nerve pathology.53 The crucial lab finding is a very low serum concentration of 
vitamin E/tocopherol. The molecular defect turned out to be mutations in the alpha-
tocopherol transfer protein gene (alpha-TTP), which is localized on chromosome 8q13.54 
Most known patients originate from Tunisia where the prevalence may be as high as 1 per 
100,000.55  
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Another, extremely rare form of recessive ataxia with dystonia is encountered on one of the 
Cayman Islands only. The mutated protein, called caytaxin (OMIM 601238), shares a so-
called CRAL-TRIO domain with the alpha-TTP protein.56 This motif binds small lipophilic 
proteins like vitamin E, retinal, and squalene, a cholesterol precursor. Thus, vitamin E may 
not be the only culprit in the pathogenesis of these types of ataxia. Still, vitamin E should be 
supplemented to patients with AVED as trials have suggested a stabilization of neurological 
decline after treatment initiation.57 Apart from AVED, other causes of low serum vitamin E 
concentration may lead to cerebellar ataxia, spinal chord degeneration, and neuropathy.58 
  
X-linked sideroblastic anaemia with ataxia (OMIM 301310)
This very rare disorder consists of juvenile onset non-progressive ataxia, pyramidal tract 
signs, and a sideroblastic anaemia in affected males. Heterozygote women may show ring 
sideroblasts on bone marrow examination, a dimorphic peripheral blood smear, and raised 
free red cell protoporphyrin.59 Missense mutations have been found in a nuclear 
mitochondrial ATP-binding cassette transporter (ABC7).60,61 
 
Infantile onset spinocerebellar ataxia (IOSCA - OMIM 271245) 
IOSCA has been described exclusively in a small founder group of Finnish patients. Onset is 
between 1 and 2 years of age. Features are: progressive ataxia, athetosis, muscle 
hypotonia, areflexia, ophthalmoplegia, hearing loss, and sensory neuropathy.  Female 
hypogonadism and epilepsy are late manifestations.62 The IOSCA locus was mapped to 
10q24 but a gene has not been found yet.63 Two published autopsy cases showed the 
following: patchy cerebellar cortical and severe dentate nuclear atrophy; extensive 
involvement of brainstem structures such as the cerebellar peduncles, inferior olives, the 
eighth cranial nerve and nucleus, the tegmental nuclei and tracts, the oculomotor nuclei, and 
periaqueductal gray matter; severe atrophic changes in the spinal cord, particularly the 
dorsal roots, the posterior columns and the posterior spinocerebellar tracts; and a severe 
axonal loss in the sural nerve.64  
 
Spinocerebellar ataxia with axonal neuropathy (SCAN1- OMIM 607250) 
This recessive ataxia, recently described in a Saudi Arabian family, is characterized by mild 
ataxia and cerebellar atrophy, axonal mixed neuropathy, distal muscle atrophy, pes cavus, 
and a steppage gait as is seen in Charcot-Marie-Tooth disease.65 A homozygous 1478A→G 
transition mutation in the Tyrosyl-DNA phosphodiesterase 1 (TDP1) DNA repair enzyme was 
identified.65 
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Early Onset Cerebellar Ataxia (with retained Tendon Reflexes) 
This designation was, again, introduced by Anita Harding in 1981 as a denominator for 
patients with a phenotype that is distinct from classical FA: a slower rate of progression, less 
(or no) cardiac abnormalities, absence of scoliosis, and prominent cerebellar atrophy on 
MRI.66-68 Contrary to the name, arelfexia may evolve during the course of the disease. The 
prevalence of EOCA is unknown, but estimates yielded about half of the prevalence of FA.66 
As most of the publications date from prior to the discovery of the FA gene and given the 
clinical heterogeneity associated with the FA mutation, inclusion of FA cases in these series 
must be suspected. These cases are now considered to represent a clinically and genetically 
heterogeneous group of recessive ataxias with in general a slower disease course and a 
better prognosis than classical FA.69 
 
Spastic ataxias 
In some ataxias, lower limb spasticity is so prominent that a separate phenotype may be 
recognized. At least 1 dominant form, SAX1,70 as well as recessive forms are currently 
recognized. 
 
Autosomal recessive ataxia of Charlevoix-Saguenay (ARSACS - OMIM 270550) 
This disorder was first described in 1978 in a group of families from the two eponymic 
Quebec regions that were both related to a common founder.71 Clinical features of the 
original families included cerebellar ataxia, lower limb spasticity, distal muscle wasting, and 
foot deformities. Specific features appeared to be retinal striation reminiscent of early Leber's 
atrophy, mild mental retardation, and frequent mitral valve prolapse. Disease onset was very 
early and none of the patients ever walked normally, but little disease progression was noted 
after age 20 years. Shared homozygosity analysis identified a locus on 13q11 and 2 distinct 
ancestral haplotypes were revealed.72 The mutated gene, SACS, encodes a novel protein, 
called sacsin. Additional families have been reported from Turkey, Tunisia, Italy and Japan.73-
78 It now appears that neither retinal striation nor mitral valve prolapse are as specific as 
initially reported. 
 
Ataxia telangiectasia-like disorders 
This group of ataxias is characterized by early onset cerebellar ataxia, muscle wasting, 
prominent extrapyramidal features, and a rather specific eye movement abnormality called 
oculomotor apraxia. Ataxia telangiectasia is the best known of these disorders, but at least 
two novel forms have been identified. 
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Ataxia telangiectasia (AT – OMIM 208900) 
The incidence of AT has been estimated at about 0.3 to 1.0 per 100,000 live births.79 The 
AT-mutated gene carrier frequencies in western populations may be 0.5 to 1.0%, but 
percentages as high as 3.5 have been suggested.79,80 
The disease typically starts in early childhood with progressive cerebellar ataxia. Oculomotor 
apraxia with absent opticokinetic nystagmus is highly characteristic. Chorea, dystonia, and 
related extrapyramidal features occur in many patients. Deep tendon reflexes become 
diminished or absent by age 8 and patients later develop diminished large-fiber sensation.81 
Progressive spinal muscular atrophy that affects mostly hands and feet debuts at an older 
age and leads to striking combined flexion-extension contractures of the fingers. 
Nonneurological manifestations in homozygotes consist of conjunctival telangiectasias, 
frequent respiratory tract or other infections, radiosensitivity, and a predisposition to various 
forms of cancer. The most common malignancies associated with homozygous AT are 
leukemia and B-cell lymphomas. Diagnostic laboratory features are elevated serum alpha-
fetoprotein and carcinoembryonic antigen concentrations, dysgammaglobulinemias, and 
impairment of cellular immunity. The gene responsible for ataxia telangiectasia is called ATM 
(AT-mutated).82 The neuropathology of AT is not very specific. In advanced cases the 
cerebellum is severely atrophic due to thinning of the molecular layer, granule cell depletion, 
and loss of Purkinje cells. Additional affected structures include the dorsal root ganglia and 
the spinal cord, where dorsal column demyelination with neuroaxonal dystrophy, astrocytic 
proliferation and anterior horn cell degeneration may be observed. Abnormalities may also 
occur in brain stem nuclei such as the trigeminal mesencephalic nucleus and the substantia 
nigra.83-85 Intracerebral vascular abnormalities have been described that may be part of the 
pathobiology of the disease.86 
Two families have been described in which affected individuals suffered from an AT-like 
disease and in whom, instead of ATM mutations, a mutation in the hMRE11 gene was 
detected.87  
 
Ataxia with Oculomotor Apraxia type 1 (AOA1 – OMIM 208920) 
Another AT-like phenotype consists of oculomotor apraxia, with added features of early onset 
cerebellar ataxia, choreoathetosis, peripheral nerve involvement and, in a subset of patients, 
mental retardation.88,89 Telangiectasias or frequent infections were specifically absent, while 
hypoalbuminemia and hyperlipidemia were present in many patients. The gene was mapped 
to 9p13 and the mutated protein that causes AOA1 was called aprataxin (APTX).90,91  
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Ataxia with Oculomotor Apraxia type 2 (AOA 2 – OMIM 606002) 
A second locus on 9q34 was identified in two nonrelated families.92 Clinically, these patients 
had late childhood or adolescent onset ataxia, inconsistent oculomotor apraxia, and elevated 
levels of serum creatine kinase, gamma-globulin, and alpha-fetoprotein.92,93 The gene 
associated with this disorder has been designated senataxin.94  
 
Ramsay Hunt syndrome (dyssynergia cerebellaris myoclonica) 
This entity basically constitutes a syndrome that consists of ataxia and myoclonus, with or 
without epilepsy. Many different diseases may manifest as a Ramsay Hunt syndrome, such 
as mitochondrial disorders, sialidosis type I, Friedreich’s ataxia, celiac disease, or the various 
progressive myoclonic epilepsies.95-99 This syndromal diagnosis may thus be a useful step in 
restricting the search for the underlying molecular pathology.  
 
Putative disease mechanisms  
Reviewing the various mutations that cause the spinocerebellar ataxias, a limited number of 
disease mechanisms seem to emerge that underlie the degeneration of spinocerebellar 
pathways (table 3). These mechanisms have been implied in other forms of 
neurodegeneration, but by studying the spinocerebellar degenerations, their interplay may be 
illustrated.  
 
Disease mechanism affects… (May be) involved in… 
 
Transcriptional (dys)regulation 
 
Mitochondrial function 
 
Calcium signaling 
 
Phosphorylation 
 
DNA repair 
 
Ubiquitin / proteasome function 
 
Protein misfolding and chaperone function 
 
Growth factors 
 
 
SCA17, SCA7 
 
FA, AVED, X-SAA 
 
SCA6, (SCA14) 
 
SCA12, SCA14 
 
AT, AOA1, AOA2, SCAN1 
 
SCA3 
 
ARSACS 
 
FGF14 
 
Table 3: Putative disease mechanisms in dominant and recessive ataxias (FA = Friedreich’s ataxia; 
AVED = ataxia with vitamin E deficiency; X-SAA = X-linked sideroblastic anaemia with ataxia; AT = 
ataxia telangiectasia; AOA = ataxia with oculomotor apraxia; ARSACS = autosomal recessive ataxia 
of Charlevoix-Saguenay; FGF14 = fibroblast growth factor 14.) 
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Trinucleotide repeat expansions 
Expanding trinucleotide repeats represent the most common cause of spinocerebellar 
degeneration. The CAG repeats in SCA1, 2, 3, 6, 7, and 17 are expressed as expanded 
polyQ sequences in the cognate proteins. The mechanism by which these polyQ proteins 
cause neurodegeneration is still unknown. Relevant data, however, also comes from work on 
two other polyQ-associated neurodegenerative diseases: Huntington’s disease (HD) and 
spinal bulbar muscular atrophy (SBMA). A hallmark of polyQ diseases is the presence of 
nuclear or cytoplasmic inclusions that reflect the propensity of polyQ proteins to aggregate.100 
Ubiquitinated polyQ–containing aggregates have been found in neuronal nuclei of SCA1, 3, 
7, and 17 and in the cytoplasm of SCA2.101,102 In SCA6 brains, non-ubiquitinated aggregates 
have been found exclusively in the cytoplasm of Purkinje cells.103 Many issues are still 
unresolved. Does pathology depend on the polyQ stretch only, on a (partial) loss of wild-type 
protein function, or on a toxic ‘gain of function’ of the wild-type protein? Are polyQ 
aggregates themselves toxic, or are soluble polyQ-containing protein fragments the culprits? 
Which downstream cellular mechanisms are affected by polyQ proteins? By now a large 
number of such possible downstream mechanisms have been proposed; these are described 
below.  
 
Transcriptional regulation  
The function of some transcription factors or transcriptional coactivators has been found to 
be impaired by an interaction with polyQ proteins or by being sequestered into the polyQ 
aggregates.104 Examples are the interaction between ataxin-7 and the homeodomain 
transcription factor Crx, interactions between polyQ and TAFII-130, and the sequestration of 
the CREB-binding protein CBP into polyQ aggregates.105-107 This may result in transcriptional 
shutdown and subsequent neuronal degeneration.108 Current data suggest that the normal 
function of some of the ataxins is transcriptional regulation.109 SCA17 is caused by a 
mutation in the TATA-binding protein TBP, an important general transcription initiation 
factor.27 Wild-type ataxin-7 may be a subunit of TFTC-like transcriptional factor.110 Therefore, 
the term ‘transcriptionopathies’ for polyQ diseases has been advocated.  
 
Mitochondrial dysfunction 
Mitochondrial dysfunction may cause spinocerebellar ataxia. This is not only demonstrated 
by (spino)cerebellar ataxia as (part of) the phenotype of mitochondropathies,111 but also by 
the molecular pathology of FA, AVED, and X-linked sideroblastic anaemia with ataxia. The 
large GAA expansions in the frataxin gene suppress gene expression, thus causing a 
classical recessive genotype and loss of function of the frataxin protein, a mitochondrial 
matrix protein.112 In vitro deletion of a yeast frataxin homologue YFH1 resulted in 
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considerable oxidative damage to both mitochondrial and nuclear DNA.113 FA must therefore 
be considered as a nuclear encoded mitochondrial disorder. 
Ataxia with vitamin E deficiency may result from a similar mechanism. Alpha-TTP is 
responsible for selective retention of alpha-tocopherol from dietary vitamin E. The alpha-
TTP-mediated transfer of alpha-tocopherol into nascent VLDL constitutes the major 
determinant of plasma alpha-tocopherol levels in humans. AVED patients have an impaired 
ability to incorporate alpha-tocopherol into lipoproteins secreted by the liver. The resulting 
loss of vitamin E-dependent free radical scavenging and anti-oxidant capabilities may lead to 
mitochondrial dysfunction, similar to FA. 
Finally, in X-linked sideroblastic anaemia with ataxia, the mutated gene ABC7 is a nuclear 
mitochondrial ATP-binding cassette (ABC) transporter that localizes to the mitochondrial 
inner membrane and is involved in iron homeostasis.60,61 Thus, as in FA, mitochondrial iron 
homeostatic impairment may be linked to cerebellar dysfunction. 
 
Defective intracellular calcium signaling.  
The SCA6 expanded CAG repeat is found in the CACNA1A gene that encodes the α1A-
subunit of a voltage-gated calcium channel. Contrary to SCA1 or SCA3, polyQ containing 
aggregates in SCA6 neurons are nonubiquitinated and exclusively cytoplasmic.103 Episodic 
or progressive cerebellar ataxia have also been described in patients with point mutations 
rather than repeat expansions in the CACNA1A gene.114 Thus, rather than being caused by a 
polyQ-dependent toxic insult to Purkinje cells, SCA6 may result from an alteration of normal 
calcium channel function.115 In a study of HD patient cell lines and transgenic mice, the 
mitochondrial calcium homeostasis was found to be impaired in such a way that 
depolarization occurred more rapidly when the mitochrondria were challenged repeatedly.116 
Also, specific interactions have been observed between mutant huntingtin and the type 1 
inositol(1,4,5)-triphosphate receptor, an intracellular calcium release channel involved in 
neuronal calcium signaling. These data clearly link alterations in intracellular calcium 
signaling to polyQ diseases. 
 
Dysregulation of phosphorylation  
SCA12 and SCA14 imply interference with protein phosphorylation and its associated 
signaling alterations as another possible mechanism of cerebellar degeneration. The 
expanded SCA12 CAG repeat is located in the promotor region of the PPP2R2B gene that 
encodes a brain specific regulatory subunit (B) of the PP2A trimeric holoenzymes.7 These 
are protein serine/threonine phosphatases that regulate phosphorylation in a large number of 
cellular processes.117 Evidence suggests that the CAG repeat alters PPP2R2B gene 
expression.117  
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PRKCG, the mutated SCA14 gene, encodes PKCγ, a member of a serine/threonine kinase 
family and a mediator of second messenger signaling pathways involved in multiple cellular 
processes, particularly calcium-sensitive second messenger signaling pathways.19,118 PKCγ 
may be linked to the ataxin-1 disease pathway, as SCA1 transgenic mice showed reduced 
PKCγ protein levels in Purkinje cells, while the majority of Purkinje cells in the single 
autopsied SCA14 patient showed absence of ataxin-1 staining.19,119  
 
Axonal transport impairment 
Some studies in HD and SBMA suggest that the onset of neurological symptoms does not 
reflect loss of neurons but rather neuronal dysfunction due to dendritic and axonal pathology 
following obstruction of axonal transport by cytoplasmic polyQ-containing proteins.120-122  
 
DNA repair 
AT, AOA1, AOA2, and SCAN1 are all caused by mutations in DNA repair proteins. ATM is a 
protein kinase that belongs to a highly conserved family of phosphatidyl-inositol 3-kinase 
(PI3K)-like protein kinases (PIKKs) with serine/threonine-kinase activity.82 ATM appears to be 
functionally located at the top of the response cascade that senses, responds to, and repairs 
DNA damage. Its role has been particularly well described in the very rapid response to 
double strand DNA breaks, initiating a large number of various protein phosphorylation 
pathways.82,123 ATM may also play a role in processes such as telomere length maintenance, 
V(D)J recombination, cell cycle checkpoint regulation, and oncogenesis.123 Mutations in the 
AT-phenocopy hMRE11 affect a protein that complexes with the hRad50 and the Nbs1 
proteins, apparently impairing the same DNA damage response pathway as the ATM 
mutations.87  
Aprataxin, the gene associated with AOA1, turned out to be a member of the histidine triad 
(HIT) superfamily.91 A long-form splice variant of aprataxin has been found to interact with 
XRCC1 (x-ray repair cross-complementing group 1), constituting a multiprotein complex that 
is involved in single-strand DNA break repair.124 
Senataxin, associated with AOA2, shares extensive homology to fungal Sen1p proteins that 
are involved in splicing and termination of tRNA, small nuclear RNA, and small nucleolar 
RNA. Senataxin may have RNA and DNA helicase activity and act in the DNA repair 
pathway.94 Finally, the homozygous A1478G transition mutation in the Tyrosyl-DNA 
phosphodiesterase 1 (TDP1), a DNA repair enzyme, was identified as the cause of SCAN1.65 
 
Ubiquitin–proteasome pathways 
PolyQ aggregates may affect protein clearance. Important components of the 
ubiquitin/proteasome system are sequestrated into polyQ aggregates. This impairs the 
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proteolytic capacity of the system needed to maintain normal protein homeostasis.125,126 In an 
attempt to degrade polyQ proteins, accumulation of polyQ fragments within the proteasome 
may inactivate the proteasome.127 Recently, ataxin-3 has been shown to be a poly-ubiquitin 
binding protein, which implicates a direct role of ataxin-3 in protein clearance.31  
 
Protein misfolding and chaperone dysfunction 
PolyQ aggregates have been considered to be misfolded proteins, and inadequate 
chaperone function may contribute to this misfolding. Overexpression of the chaperone 
protein HDJ-2/HSDJ in HeLa cells decreases the frequency of ataxin-1 (SCA1) 
aggregation,128 and SCA1 transgenic mice that overexpress the molecular chaperone 
inducible Hsp70 were protected against neurodegeneration.129 The sacsin gene, mutated in 
ARSACS, contains heat-shock domains, which suggests a function for sacsin in chaperone-
mediated protein folding.130 
 
Growth factor alterations 
Missense mutations in the FGF14 gene suggest growth factors as candidate culprits involved 
in neurodegeneration. They have been implicated previously in HD, albeit secondary to 
transcriptional alterations.131,132 
 
 
Conclusion 
The clinical overlap between the various ataxias, the unexpected genetic heterogeneity, and 
the occasional atypical presentation of some subtypes truly complicates the clinical 
management of patients with cerebellar ataxia. On the other hand, the recent advances of 
molecular research have now provided us a glimpse at the complex pathophysiology of these 
diseases. Extensive functional studies are needed in order to identify the most important 
mechanisms of disease. Novel genes will add data to unravel the molecular pathways of 
cerebellar degeneration. The ultimate challenge will be the development of disease 
modifying drugs that is awaited most by the patients suffering from these devastating 
diseases.  
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Autosomal dominant cerebellar ataxias (ADCAs) comprise a group of hereditary 
degenerative cerebellar diseases with variable non-cerebellar features. The genetic 
background has proven to be markedly heterogeneous, with 24 genetic loci and 11 mutated 
genes identified so far. The most common genetic subtypes are SCA1, SCA2, SCA3, SCA6, 
and SCA7, which all share as the mutational mechanism a coding CAG repeat expansion 
that is translated into an elongated polyglutamine tract in the encoded proteins.  
Although the correlation between the length of the CAG repeat and the age at disease onset, 
as well as the neuronal intranuclear aggregates of polyglutamine as the pathological 
hallmark, both suggest a prominent role of expanded polyglutamine stretches in the 
pathophysiology of these disease, the exact mechanisms are still unclear. For this reason, 
there is currently no drug available that is able to prevent or retard disease progression in 
ADCA patients. 
 
The main goals of the studies described in this thesis were: to assess the prevalence of 
ADCAs in the Netherlands; to study genotype – phenotype correlations, or more specifically 
the relation between CAG repeat length and age at disease onset, in the most common SCA 
subtypes; to identify novel SCA loci or genes involved in Dutch ADCA families; and to 
perform clinical and physiologic studies in Dutch ADCA patients. 
 
 
Prevalence estimation 
In chapter 3.1, the prevalence estimate of ADCA in the Netherlands is described.  
 
Summary first part of chapter 3.1: 
The estimate was based on the databases of the three DNA-diagnostic laboratories that 
perform mutation analysis of the SCA1, SCA2, SCA3, SCA6, and SCA7 genes. By
studying the family pedigrees of the patients identified, the total number of families and 
affected individuals per SCA subtype was assessed. We collected 145 ADCA families (14 
SCA1, 16 SCA2, 64 SCA3, 34 SCA6, 17 SCA7 families) and 391 affected individuals. By
incorporating the assumption that in about 36% of ADCA patients and families no mutation
in the aforementioned genes can be found, an extrapolated minimal prevalence of 3.0 per 
100,000 (range 2.8 to 3.8 per 100,000) was calculated. SCA3 was the most frequent
mutation, followed by SCA6.  
This study represents the first prevalence assessment of ADCA in the Netherlands and the 
only nationwide inventory of ADCA published so far.  
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This prevalence is likely to be an underestimation, because there are still unidentified or 
unrecognized patients and families and because the extrapolation was based on the safe 
assumption that a family consists of only one affected subject. The prevalence number is 
higher than most previous estimates, except in certain relatively isolated populations, but 
these previous studies were conducted prior to the discovery of SCA genes.1-5  
There is a marked geographical and ethnical variability in the relative frequency of the 
different SCA mutations worldwide. Globally, SCA3 is the most frequent mutation and 
accounts for 20 to 25% of ADCA cases;6 this percentage is 28.2 in the Dutch population. 
However, SCA3 is responsible for 84% of cases in Portuguese/Azorean ADCA families.7 In 
Cuba, Korea, Italy, and India, SCA2 is relatively more prevalent.8,9,10,11 While SCA6 is 
frequently found in German and Japanese ADCA families, this subtype seems to be rare in 
Chinese and Indian families.12-14 The relative frequency of the various SCA subtypes in the 
Netherlands is more or less comparable to the distribution that was found among German 
kindreds.15 It is possible that in Dutch and German ADCA families common founder effects 
are involved. Such founder effects have already been demonstrated in Dutch SCA3 and 
SCA6 families.16 
The prevalence estimation of a rare disease like ADCA is relevant for several reasons. First, 
such data are essential for the basic epidemiology of rare diseases. Second, it provides 
information on the potential source population for future research studies, mainly therapeutic 
trials. And finally, for public relations and funding issues of the lay organisation, the ability to 
provide the number of patients the organisation is representing is very useful. 
 
 
Genotype – phenotype correlations 
It was already known that, in trinucleotide repeat diseases in general, an inverse relation 
exists between the length of the repeat and the age at disease onset.15,17 This proves a 
fundamental and dominant role of the length of the polyglutamine (polyQ) tract (as 
determined by the CAG repeat length) in the pathophysiology of these diseases. However, 
the true contribution of the CAG repeat length in the various SCAs was under debate. Such 
data can give important insight into the magnitude of the contribution of non-CAG dependent 
factors.  
Also, resolving the issue of whether the relation between CAG repeat and onset age is 
similar or different for the various SCA subtypes reveals whether the protein context (i.e. the 
function, conformation, interactions, and regional distribution of the protein that contains the 
polyQ expansion) is relevant for the disease process. 
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We first sought to address these issues in the Dutch ADCA population. The results of this 
study are also described in chapter 3.1.  
 
 
Summary second part of chapter 3.1: 
Of the patients retrieved from the various DNA-databases, individual CAG repeat length 
on the normal and expanded allele were documented and onset ages were extracted from
the clinical records. Regression analysis was applied to study the relationship between
CAG repeat length and age at onset per SCA gene. The slopes of the different regression 
curves were compared. CAG repeat length was found to contribute to 52 to 76% of age at
onset variance. Regression curve slopes for SCA1, SCA2, SCA3, and SCA7 did not differ
significantly. This suggests that the relationship between age at onset and CAG repeat 
expansion is similar for SCA1, SCA2, SCA3, and SCA7 and that these SCAs share similar
mechanisms of polyQ-induced toxicity. This relation and hence the polyQ-related disease 
mechanism in SCA6 is significantly different, which is consistent with what we know from 
SCA6 biology. 
These results were more or less contradictory to our assumption that, because of the 
heterogeneity in mutated proteins, differences in the relation between age at onset and CAG 
repeat would be identified.  
On the other hand, the observation that this relation is different for SCA6 only, implicated a 
logical biologic explanation. The distinctive disease features in SCA6 include: a relatively late 
onset of disease; absence of significant non-cerebellar features; relatively small repeat 
expansions (19-25 repeats in SCA6 versus 32-85 in the other SCA subtypes); and the 
absence of polyQ-containing intranuclear inclusions, which are present in SCA1, SCA3, and 
SCA7, as well as in Huntington’s disease. In SCA6, the function of the mutated gene 
(CACNA1A) is known; it codes a voltage-gated calcium channel.18 It still remains unclear 
whether SCA6 is due to channel dysfunction (loss of function) or polyQ-mediated neurotoxic 
pathways (gain of function), but the results described above (combined with the clinical and 
genetic features of SCA6) do suggest different disease pathways in SCA6.19   
However, because the number of subjects per SCA subtype was highly variable and rather 
low for some of the SCA types, the possibility that data of larger numbers of patients would 
ultimately yield differences between the various SCA subtypes could not be excluded. 
 
For this reason, we also collected the data of ADCA patients from the Hôpital de la 
Salpétrière (Paris, France) for an extension of this first age at onset variance analysis study. 
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The results of the second age at onset variance analysis study, conducted in a large Dutch – 
French patient cohort, are described in chapter 3.2. 
 
Summary chapter 3.2: 
Data on SCA subtype, age at onset, normal and expanded CAG repeat length, sex of the
patient and transmitting parent, and family details were available from 802 Dutch and
French ADCA patients. The size of the expanded CAG repeat was found to explain 44.3
to 74.9% of the variance in age at onset. However, this was less than 50% in SCA3 and
SCA6, which implicates a large effect of non-CAG factors. The relation between age at 
onset and CAG repeat length was now similar for SCA1, 3, 6, and 7, but different for 
SCA2, which points to different polyQ effects in SCA2. For SCA2 and SCA3, 17.1% and 
45.5% of the age at onset variance, respectively, was explained by yet unidentified familial
factors, most likely cis-acting or trans-acting genetic factors. We found a significant 
contribution of the non-expanded CAG size to the age at onset in SCA1 and SCA6. 
Because partially similar results were obtained in a small sample of Huntington disease
patients, a possible effect of neuronal tissue context factors cannot be excluded. 
The statistical analysis in this study was based on a hypothetical model, in which age at 
onset in CAG expansion diseases is determined by: the size of the polyQ expansion in the 
mutated protein (determined by the size of the coding CAG repeat); the protein context 
(function and interaction profile of the host protein); cis-acting and trans-acting genetic 
factors, (partially) recognizable as familial or ethnic factors (the CAG size on the normal 
allele should be considered as one of these); the neuronal tissue context in which the 
cognate protein is expressed; and potential environmental factors. Indeed, with this analysis 
the following age at onset modifiers were identified: the length of the polyQ tract; protein 
context in SCA2; familial factors in SCA2 and SCA3; and the CAG repeat length on the non-
mutated allele in SCA1 and SCA6.  
Contrary to the results obtained through the analysis of the Dutch data only, there was now 
evidence for a different effect of the polyQ expansion in SCA2 (and not in SCA6). The larger 
number of SCA6 patients and the fact that relatively larger repeat expansions were present 
in the French SCA6 patients most likely account for the different results concerning SCA6 in 
this study. Nevertheless, the slope of the SCA6 curve also seemed to be different, but this 
was found not to be statistically significant. Also, the size of SCA6 sample was relatively the 
smallest and there was a low and non-normally distributed variation of CAG sizes. As stated 
earlier, there is still a biological justification for a different pathogenesis (and thus slope) in 
SCA6 and a larger SCA6 sample size may ultimately confirm this. 
Again, also for SCA2 there are some biological data that might lead to slightly different 
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effects of expanded polyQ stretches. SCA2 seems to be more sensitive to polyQ expansions 
(steeper curve and smaller pathologic repeat ranges), which can be due to the fact that 
ataxin-2 is less efficiently cleared from the cell. Recent data indicate that in SCA2 the 
cytoplasm rather than the nucleus is the primary site of disease development: ataxin-2 is 
involved in Golgi-complex function and instead of nuclear inclusions (encountered in other 
SCA subtypes) cytoplasmic polyQ-inclusions can be observed.20,21 
The finding of a significant contribution of familial (genetic) factors to age at onset is 
extremely important, as this supports the attempted search for genetic age at onset 
modifiers. The identification of such factors is likely to provide targets for potential drugs that 
are consequently capable of influencing disease onset or progression. The quest for 
modifying factors necessitates large number of patients, because the contribution of any 
individual factor to age at onset is probably small.22  
 
In chapter 3.3, an illustration is given of the genotype – phenotype correlations in the SCA 
subtypes caused by an expanded coding CAG repeat.  
 
Summary chapter 3.3: 
In this chapter, a severe infantile SCA7 phenotype in two siblings is reported, consisting of
generalized hypotonia and retinal pigment abnormalities, with additional patent ductus 
arteriosus and atrial septum defect, capillary leak syndrome, and hepatomegaly, resulting
in early death (within the first year of life). The CAG repeat expansions of 325 and 460
units in this sibling are the largest ever detected. The father, who started to display ataxia 
after his two children had died, carried 49 repeats.  
This family history illustrates several interesting features of trinucleotide repeat expansion 
diseases. First, the relation between CAG repeat length and age at onset (and disease 
severity) is demonstrated. In this case, extremely expanded repeats resulted in a very early 
onset and a very severe phenotype that also included non-neurological manifestations. 
Second, the phenomenon of anticipation (an earlier age at onset in the successive 
generation) in these diseases is illustrated: onset in the father at 35 years, but in the first year 
of life in his children. This is caused by the meiotic instability of the CAG repeat expansions 
(mainly in spermatogenesis) leading to larger expansions in the next generation (49 repeats 
in the father, 325/460 repeats in his offspring). Third, cases like these present potential 
counselling difficulties, because the possibility of an autosomal dominant disorder with 
extreme anticipation (i.e. diseased children in yet unaffected parents) is usually not 
considered. 
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Novel SCA genes and loci 
From the literature and from our own clinical experience, we know that in 30 to 40% of ADCA 
patients or families no mutation in the SCA1, SCA2, SCA3, SCA6, or SCA7 gene can be 
found. Therefore, ADCA families with linkage to one of the other SCA loci or with a yet 
unknown locus or gene mutation had to be present in the Dutch ADCA population. Two 
ADCA families, large enough to perform linkage analysis, were identified and enrolled in a 
genome-screening program. 
 
The results of the linkage study and subsequent mutation analysis in the first family are 
described in chapter 3.4. 
 
Summary chapter 3.4:  
Initially, after excluding all known SCA genes and loci, a genome screen in a large three-
generation family was performed but found to be negative. Subsequently, a shared 
haploptype approach was used in a combined sample of 24 small and large ADCA
families, in which mutations in the known SCA genes were excluded. Priority was given to
the SCA loci for which no gene mutation was yet identified. In three families, a shared 
haploptype covering the previously reported SCA14 locus on chromosome 19q13.4-qter 
was found. Genealogical investigations linked these three families together, culminating in
a large six-generation family with 13 affected individuals. The affected subjects displayed 
a relatively pure, slowly progressive cerebellar syndrome, with a mean age at onset of
40.8 years. A focal dystonia in two subjects with an onset of disease in their early twenties
suggested extrapyramidal features in early-onset disease. At that time, mutations in exons 
4 and 5 of the PRKCG gene, which encodes protein kinase Cγ (PKCγ), were reported in 
SCA14-linked families. We subsequently sequenced these exons of this gene and 
detected a novel missense mutation in exon 4, which involves a G→A transition in 
nucleotide 353, resulting in a glycine-to-aspartic acid substitution at residue 118 
(Gly118Asp).  
The unfortunate initial exclusion of the SCA14 locus in the original family was caused by 
recombinants that were picked up with a marker used for the upper boundary of the SCA14 
region, which explained the negative lod score. 
The finding of PRKCG/SCA14 gene mutations in ADCA will prove to be an important one 
and will probably divert and direct future research, mainly because the mutated gene 
implicates a totally new group of proteins and mechanisms involved in the pathophysiology of 
these diseases. In addition to point mutations in the FGF14 gene that have been found in a 
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Dutch ADCA family,23 SCA14 is only the second SCA subtype in which point mutations 
instead of expanded triplet repeats constitute the mutational mechanism (although SCA6 
point mutations have occasionally been observed in progressive ataxia).24 The intriguing 
question is: how does a dominant missense mutation lead to disease, what is the gain of 
function mechanism? Cellular model experiments have demonstrated that missense 
mutations such as the Gly118Asp result in an increased translocation of PKCγ to the cellular 
membrane and in an increased activity of the kinase. The regulatory domain, which is 
affected by the Gly118Asp mutation, normally functions as an autoinhibitory substrate for the 
catalytic domain and this pseudosubstrate function is hypothesized to be disrupted. How this 
eventually leads to Purkinje cell dysfunction and death is unknown, but interference with 
crucial trophic signal propagation is postulated.25 
 
The PKCγ mutation has refocused attention to the possible central role of phosphorylation 
processes in the pathophysiology of SCAs. SCA14 is not the only subtype in which a protein 
involved in phosphorylation is directly affected. SCA12 is associated with a mutation (an 
expanded CAG repeat) in the promotor region of the PPP2R2B gene that encodes a brain-
specific regulatory subunit of the phosphatase PP2A, although the mechanism by which this 
mutation induces cerebellar pathology remains to be clarified.26 There are indications that 
PKCγ itself is linked to the ataxin-1 disease pathway. PKCγ is predicted to phosphorylate the 
serine-695 residue of ataxin-1.25 Moreover, the majority of Purkinje cells in the single 
autopsied SCA14 patient showed absence of ataxin-1 staining, while SCA1 transgenic mice 
showed reduced PKCγ protein levels in Purkinje cells.27 This seems to point to a reciprocal 
relation between ataxin-1 and PKCγ and both may be central elements in the same final 
common pathway. Also, for disease features to become manifest, phosporylation of ataxin-1 
by Akt kinase at the serine–776 residue is essential.28 In another CAG repeat expansion 
disease, Huntington’s disease, Akt-phosphorylation of serine-421 impairs toxicity of the 
polyQ-containing huntingtin fragments.29 These data indicate that phosphorylation of amino 
acid residues that flank the polyQ stretch in the mutated proteins modify neurotoxicity and 
also suggest that disturbances in phophorylation processes may be the primary cause of 
neurodegeneration. 
In future studies, we will attempt to 1) demonstrate that phophorylation of polyQ proteins 
involved in the known SCA subtypes indeed modify neurotoxicity of these polyQ fragments in 
various model systems; 2) demonstrate that chemically influencing phosphatase / kinase 
activity modifies disease in transgenic animal models; 3) polymorphisms in various 
phosphatase / kinase genes can modify age at onset in SCA patients; and 4) explore the 
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possibility that mutations in specific phosphatase / kinase genes are causative in ADCA 
families with a yet unknown genotype. 
 
The SCA14/PRKCG findings lead us to screen for this mutation in other ADCA patients in 
whom the other SCA gene mutations were excluded. 
 
 
Summary chapter 3.5:  
A sample of the Dutch SCA-negative patient cohort (n=900) was screened for mutations in 
exons 4 and 5 of the PRKCG/SCA14 gene. We identified the Gly118Asp mutation in
another eight individuals from five different small families. In addition to a slowly
progressive, relatively uncomplicated spinocerebellar ataxia in all of these patients, a 
severe action myoclonus of the limbs was seen in one patient. Haplotype analysis again
identified a shared haplotype involving the chromosomal region that surrounds the
PRKCG/SCA14 gene, and genealogical research was able to link all these new patients
(together with the family described in chapter 3.4) to a single common ancestor.
Therefore, the Gly118Asp mutation is a PRKCG/SCA14 founder mutation in the Dutch 
ADCA population. The SCA14 subtype is partly characterized by the occasional presence
of extrapyramidal features.  
Based on the previously generated epidemiological data, SCA14 mutations are involved in 
approximately 4% of the Dutch ADCA population. Still, even more SCA14 families are likely 
to be present. One reason for this is the fact that, as stated earlier, an unknown number of 
ADCA patients or families are unrecognized. Second, routine SCA gene mutation analysis 
for diagnostic purposes currently includes sequencing of only exons 4 and 5 of the 
PRKCG/SCA14 gene. However, mutations in other exons (18 and 10) have recently been 
reported in French and German families, respectively.30 This implies that, for diagnostic SCA 
mutation analysis, the entire PRKCG/SCA14 gene (or at least all exons in which mutations 
have been reported) should be sequenced.  
We have recently identified a second SCA14/PRKCG family (unpublished data) with a 
Val138Glu mutation in the Cys2 domain of the PKCγ protein. While most patients in this 
family display an uncomplicated spinocerebellar ataxia with an onset after 25 years of age, 
one subject showed early-onset (3 years) non-progressive mild cerebellar ataxia with 
additional subtle limb and truncal myoclonus. This corroborates previous observations that 
myoclonic movements may be a prominent feature in SCA14, especially in early-onset 
disease, but also expands the cerebellar phenotype in this particular SCA subtype. 
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A genome screen in another large Dutch ADCA family resulted in the identification of a new 
locus: SCA23. 
 
 
Summary chapter 3.6:  
Clinically, the affected family members displayed a late-onset (after 40 years), slowly 
progressive, pure spinocerebellar ataxia. Neuropathological evaluation of one subject
showed neuronal loss in Purkinje cell layer, dentate nuclei, and inferior olives, thinning of
cerebellopontine tracts, demyelination of posterior and lateral columns in the spinal cord,
and intranuclear ubiquitin-positive inclusions in substantia nigra neurons that were
reminiscent of Marinesco bodies. A genome-wide linkage analysis revealed a 18.2cM 
locus on chromosome region 20p13-p12 that was designated SCA23. Mutation analysis
excluded the neuronal cell death inducible kinase (SKIP3) gene, the major prion protein 
precursor (PRNP) gene, and the prion gene complex downstream (PRND) gene, as well 
as genes that contain coding and non-coding triplet repeats.  
The SCA23 locus adds to the genetic heterogeneity of the Dutch ADCA population. The 
present list comprises: SCA1, SCA2, SCA3, SCA6, SCA7, SCA14, and FGF14 gene 
mutations and the loci SCA19 and SCA23.  
The pure spinocerebellar ataxia phenotype is indistinguishable from some other SCA 
subtypes, such as SCA5, SCA6, SCA11, SCA14, SCA15, SCA16, and SCA22, and 
underlines the inability to predict the genotype based on the clinical presentation in many 
cases.  
The SCA23 locus is quite large, ~18.2cM, which corresponds to ~6.1 Mb, and contains 
approximately 100 genes. Gene finding strategies necessitate the detection of new affected 
family members or, ideally, of another family with linkage to the same locus. Regarding the 
latter, international research collaboration has been initiated within the European Ataxia 
Consortium, which facilitates the exchange of families to investigate possible linkage to the 
SCA23 locus.  
 
In the assignment of novel loci and genes, the core clinical features determine to which 
category of genes the novel locus or gene belongs to. However, in the group of hereditary 
ataxias, an unclear clinical overlap of the various genetic classifications has evolved. For 
example: SCA with prominent neuropathy (SCA18, SCA25) versus hereditary sensory 
neuropathies; and SCA with spasticity versus hereditary spastic ataxia or hereditary spastic 
paraplegia with cerebellar ataxia. Thus, the classification schemes based on recent genetic 
advances cannot be used for practical purposes, as the clinical syndrome of the patient 
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confronted with may be found under different groups of genes. Ultimately, a new 
classification based on the various clinical syndromes (and the overlapping features), with 
the possible underlying gene mutations listed per clinical entity, seems warranted. 
 
 
Peripheral nerve involvement  
The advances in the molecular genetic knowledge within the field of dominant cerebellar 
ataxias have been paralleled by a decrease in the clinical studies in this group of diseases. 
However, detailed clinical data remain important for clinical practice and for follow-up in 
future drug trials, and can also guide fundamental research. One of the clinical issues 
characterized by conflicting previous reports was the prevalence, type, and cause of 
peripheral nerve involvement.  
 
Summary chapter 4.1: 
Standardized clinical and electrophysiologic studies were conducted prospectively in 27
genotyped ADCA patients. Electrophysiologic evidence of involvement of the peripheral
nervous system was present in 70% (n=19) of patients, compatible with a dying-back 
axonopathy in 30% (n=8) and a neuronopathy in 40% (n=11). Patients with SCA1 and
SCA2 mostly displayed features of a neuronopathy, while both neuronopathies and
axonopathies were encountered in SCA3 and SCA7. No significant peripheral nerve
involvement was demonstrated in SCA6. The presence or type of peripheral nerve
involvement was not influenced by age, disease duration, or ataxia severity. 
Thus, pathology in ADCAs is not purely confined to central nervous system tissues. 
Peripheral nerve involvement in ADCA occurs frequently and manifests not only as a distal 
axonal neuropathy, but also as a primary neuronopathy of dorsal root ganglia or anterior horn 
cells. The peripheral nerve pathology seems to be often mild and even subclinical and the 
distinction between axonopathy and neuronopathy can hardly be made on symptoms and 
signs only.  
The mechanisms leading to these two types of peripheral neuropathy are unresolved. 
Theoretically, the occurrence of neuronopathy was expected because the polyQ stretches, 
through nuclear protein aggregation and disruption of transcriptional processes (see chapter 
5), result in nuclear dysfunction, which directly affects the soma (within the dorsal or anterior 
horn). On the other hand, some studies of polyQ models indicate that neuronal cell death is 
preceded by neuronal dysfunction that involves dendrites and axons, which makes the 
occurrence of typical axonopathies understandable. It is likely that both mechanisms are 
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evolving simultaneously and the predominance of either one depends on the SCA subtype 
as well as on genetic and environmental disease modifiers. The practical consequence of 
this study is first that neurophysiologic evaluations of the peripheral nervous system in ADCA 
patients should also be aimed at detecting neuronopathies. Second, neurophysiologic 
parameters might be used as possible surrogate disease progression markers in future drug 
trials and these protocols should also include upper extremity nerve conduction studies and 
electromyography of both distal and proximal muscles. 
 
 
Falls and balance disturbances 
In our clinical experience, ataxia patients often report falls that sometimes might even lead to 
injuries. However, in contrast with other movement disorders, data on the incidence of falls 
and fall characteristics in ataxia patients were not available.  
 
Summary chapter 4.2: 
We retrospectively and prospectively assessed the frequency and characteristics of falls in
42 and 26 patients, respectively, with degenerative cerebellar ataxias. Falls were very
common in these patients: 93% recalled one or more falls in the last 12 months. About
85% of ataxia patients reported injuries, which were mostly soft tissue injuries, but 31% of
fallers suffered a fracture or joint dislocation. In the 3-month prospective follow-up period, 
50% of the ataxia patients experienced one or more falls. Falls were found to occur as
early as 2 years after disease onset.  
This study basically demonstrated that falls in patients with degenerative cerebellar ataxias 
are frequent and often injurious. This means that falls are a very important, although 
unrecognized consequence of the cerebellar balance disturbances in these patients with a 
tremendous impact in every day live. Falls also have a number of secondary effects, such as 
immobility (leading to reduced physical fitness), social isolation, and fear (of future falls), and 
some of these effects paradoxically increase the risk of future falls.31 Clinicians must be 
aware of this problem in ataxia patients and should try to prevent falls. Although we did not 
study the effectiveness of preventive measures, some of these would seem to be logical 
options.32,33 Assessing and reducing domestic hazards to prevent injurious consequences of 
a fall, providing external support indoors (e.g. hand grips), hip protectors, and stimulating the 
use of appropriate walking aids comprise the initial obligatory measures. A physiotherapist 
may help to prevent falls by using gait training, fear reduction, learning to minimize the 
consequences of falls, and by practicing daily routines. 
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Studies on the physiologic aspects of the disturbances in posture and balance control in 
ADCA are rare. There are some static posturography studies in patients with cerebellar 
ataxia that suggested a cerebellar topography in the body sway abnormalities, because the 
direction and frequency of postural tremor in ataxia patients depended on the cerebellar 
regions affected.34 However, these studies involved patients with a relatively localized 
cerebellar lesion, e.g. anterior lobe atrophy in chronic alcoholics. In ADCAs, the cerebellar 
pathology is more diffuse and also involves cerebellar afferent and efferent pathways. 
In order to learn more about the physiology of the balance disturbances in ADCA patients, 
we initiated two types of studies in this patient group. The results of one of these studies 
(trunk sway) are included in thesis, the results of the other (dynamic posturography) are 
currently being analyzed. 
 
Summary chapter 4.3:  
Eleven genotyped ADCA patients and 11 age-matched controls were examined with the 
SwayStar™ system. Control of posture and balance was quantified by measuring trunk
angle and angular velocity in the roll (lateral) and pitch (anterior-posterior) directions 
during a standardized protocol of stance and gait tasks. In stance, trunk angle
displacement and angular velocity in both the pitch and roll planes were significantly larger
in the ADCA group. Among the ADCA patients, instability was more increased in the pitch
than in the roll direction for stance tasks, with pronounced oscillations in the pitch plane at
1.4 and 2.5 Hz. A similar dominance of pitch over roll instability was also observed in most
gait tasks, especially for tandem gait and while walking with simultaneous head rotations. 
This study demonstrated that trunk sway measurements with the SwayStar™ system 
effectively detected and quantified the gait and balance abnormalities in ADCA patients. This 
novel method might be used for follow-up studies of ADCA patients in a clinical or drug trial 
setting, or it might be used to analyze physiotherapy interventions. Other potential 
applications include the identification of early-symptomatic individuals and of patients with an 
increased risk of (injurious) falls.  
Although the postural instability in ADCA patients was found to be multi-directional, there 
was generally more pitch than roll instability. This probably reflects the predominant 
involvement of the spinocerebellum (and corresponding connections) in ADCA. Indeed, this 
part of the cerebellum is the earliest and most severely affected region in imaging and 
autopsy studies. The finding of more pitch than roll instability in the tandem gait task was 
rather unexpected. From a clinical point of view, the tandem gait disturbance seems to be 
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characterized by more roll than pitch instability. Thus, quantitative analyses such as these 
can reveal physiologic changes that are difficult to observe clinically. 
 
We would like to explore another potential tool that might be used as an objective marker for 
early detection as well as disease progression in ADCA: repetitive transcranial magnetic 
stimulation (rTMS). Applying low-frequency rTMS over the cerebellum has been shown to 
induce mild and temporary cerebellar ataxia of the hands in healthy subjects. 
Presymptomatic or very early symptomatic patients with genetically defined ADCA might 
manifest enhanced susceptibility to this rTMS intervention. We hypothesize that in patients 
with clinically manifest disease, rTMS can also be used as an objective quantitative measure 
to monitor the progression of ataxia over time. Also, a second future study could be a 
placebo-controlled trial that examines whether higher frequency rTMS can be used to reduce 
the cerebellar signs in symptomatic patients with overt ataxia.  
 
Recent advances 
This thesis concludes with a review of the recent advances in both dominant and recessive 
spinocerebellar ataxias (chapter 5), a summary of which is not included in this chapter. At 
present, the challenge is not only to unravel to pathophysiologic mechanisms in the dominant 
ataxias, but also to expand the knowledge of the recessive subtypes. The autosomal 
recessive cerebellar ataxias constitute, however, a more complex group of diseases for such 
studies. First, it can be hard to recognize recessive ataxias clinically. The recessive ataxias 
are very heterogeneous, are often multi-system diseases with marked non-neurological 
features, might evolve after the age of 25 years, and, in case of no documented 
consanguinity or in the absence of other sibs, the family pedigree often does not suggest a 
recessive disease. In addition, the phenotype in some of the genetically homogeneous 
recessive subtypes might be broader than expected, as has for example been demonstrated 
in Friedreich’s ataxia. Second, the relatively low number of affected subjects in a family 
complicates gene-finding studies. Also, the aforementioned clinical heterogeneity makes the 
recognition of homogeneous subtypes that can be pooled rather difficult. Nevertheless, new 
genes and proteins have recently been identified in the recessive ataxias (e.g. sacsin, 
aprataxin, senataxin). These new gene mutations have focussed attention on new disease 
mechanisms, such as abnormal DNA-repair processes, disturbed chaperone function, and 
mitochondrial dysfunction. As the dominant and recessive ataxias might share (a part) of the 
disease mechanisms that eventually result in the degeneration of cerebellar structures, the 
new data derived from the recessive ataxias can be used to target molecular genetic 
research in the dominant counterparts. 
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Hoofdstuk 1 
Autosomaal dominante cerebellaire ataxieën (ADCA’s) vormen zowel klinisch als genetisch 
een heterogene groep van neurodegeneratieve aandoeningen van het cerebellum. De ziekte 
manifesteert zich veelal na het 20e levensjaar en wordt gekenmerkt door langzaam-
progressieve gang- en extremiteitsataxie, dysarthrie en stoornissen in de oogmotoriek. 
Daarnaast kunnen zich allerlei andere symptomen voordoen als uiting van betrokkenheid 
van andere delen van het centrale zenuwstelsel en van het perifere zenuwstelsel.  
Inmiddels zijn er 24 genetische loci en 11 genmutaties geïdentificeerd. De meest 
voorkomende genotypes zijn SCA1, SCA2, SCA3, SCA6, en SCA7. De mutatie in deze vijf 
genen bestaat uit een verlengde CAG-repeat in het coderende deel van het gen, wat in het 
gecodeerde eiwit leidt tot een geëxpandeerde polyglutamine-keten. Er bestaat een sterke 
correlatie tussen de lengte van de CAG-repeat en de beginleeftijd. Dit gegeven, samen met 
de aanwezigheid van polyglutamine-aggregaten in de neuronale nuclei bij neuropathologisch 
onderzoek, suggereren een belangrijke rol van de polyglutamine-ketens in de pathofysiologie 
van deze aandoeningen. Desondanks zijn op dit moment de exacte ziektemechanismen 
onopgehelderd en is ziektemodulerende therapie dientengevolge nog niet beschikbaar.  
 
Hoofdstuk 2 
De doelen van de studies die in dit proefschrift beschreven worden zijn: het vaststellen van 
de prevalentie van ADCA in Nederland; het bestuderen van de genotype-fenotype correlaties 
in deze groep van aandoeningen en in het bijzonder de relatie tussen de lengte van de 
geëxpandeerde CAG-repeat en de beginleeftijd in de meest voorkomende SCA-subtypen; 
het identificeren van nieuwe genen en genetische loci in Nederlandse ADCA- families; het 
verrichten van klinische en fysiologische studies in ADCA-patiënten, in het bijzonder gericht 
op perifere zenuwpathologie, vallen en balansregulatie.  
 
Hoofdstuk 3.1 
Op basis van de gegevens van de drie DNA-laboratoria die de SCA-mutatieanalyse in 
Nederland verrichten en de gegevens van de Klinisch Genetische Centra die ADCA-
patiënten counselen zijn 145 ADCA-families met 391 patiënten geïdentificeerd. Omdat in 
36% van de gevallen geen mutatie in de (op dat moment) bekende SCA-genen gevonden 
werd is een totaal aantal van 227 families en 473 patiënten geëxtrapoleerd, culminerend in 
een geschatte prevalentie van 3,0 per 100.000 (spreiding 2,8-3,8). SCA3 bleek het meest 
voorkomende genotype. 
Daarnaast werden de gegevens over de lengte van de normale en verlengde CAG-repeat, 
beginleeftijd en SCA-subtype van 211 patiënten geanalyseerd. Regressieanalyse wees uit 
dat de geëxpandeerde CAG-repeat 52% tot 76% van de variantie in beginleeftijd verklaarde. 
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De hellingshoek van de regressielijn (CAG-repeatlengte versus beginleeftijd) in SCA6 
verschilde significant van die in SCA1, SCA2, SCA3 en SCA7. Dat suggereert dat het door 
polyglutamine geïnduceerde ziektemechanisme in SCA6 anders is dan in de andere SCA-
subtypen. Op dat moment werd waarschijnlijk geacht dat bij het bestuderen van grotere 
aantallen patiënten er ook voor de andere SCA-subtypen verschillende relaties tussen de 
CAG-repeatlengte en beginleeftijd gevonden zouden worden. Immers, de functie en structuur 
van de door de SCA-genen gecodeerde eiwitten zijn verschillend. 
 
Hoofdstuk 3.2 
Om de overwegingen zoals beschreven in hoofdstuk 3.1 te onderzoeken, is de relatie tussen 
de CAG-repeatlengte en beginleeftijd bestudeerd in 802 Nederlandse en Franse ADCA-
patiënten. Bij deze analyse is tevens gekeken naar de bijdrage van factoren die 
onafhankelijk zijn van de CAG-repeat. Afhankelijk van het SCA-subtype, verklaarde de 
lengte van CAG repeatexpansie 44% tot 75% van de variantie in beginleeftijd. Echter, in 
SCA3 en SCA6 was dit minder dan 50%, wat betekent dat er met name in deze twee 
subtypen een significante invloed van andere factoren (onafhankelijk van de CAG-repeat) 
bestaat. De richtingscoëfficiënt van de regressielijn in dit cohort vertoonde overeenkomsten 
tussen SCA1, SCA3, SCA6 en SCA7 met afwijkende parameters voor SCA2. Derhalve lijkt 
de relatie tussen de repeatexpansie en de beginleeftijd anders in SCA2; meer concreet is het 
door SCA2 gecodeerde eiwit (ataxine-2) gevoeliger voor polyglutamine-expansies.  
Voor SCA1 en SCA6 was er tevens een kleine maar significante bijdrage van de 
repeatlengte op het normale allel. Het geslacht van de aangedane ouder alsook het geslacht 
van de patiënt had geen modificerende invloed op de beginleeftijd. In SCA2 en SCA3 werd 
echter wel een significante invloed gevonden van een - nog onbekende, maar waarschijnlijk 
polygenetische – familiaire factor, die respectievelijk 17% en 45% van de 
beginleeftijdvariantie verklaarde. 
 
Hoofdstuk 3.3 
Dit hoofdstuk bevat een beschrijving van een familie met SCA7 (ADCA II, het enige subtype 
met een coëxistente maculadegeneratie), waarin door extreme anticipatie twee kinderen met 
een ernstige multisysteem ziekte voor het eerste levensjaar overleden waren, nog voordat de 
aangedane vader cerebellaire verschijnselen ontwikkelde. De niet-neurologische 
manifestaties bestonden uit hypotonie, open ductus Botalli, ‘capillary leak’-syndroom en 
hepatomegalie. De CAG-repeatexpansie bij vader bedroeg 49 repeats (met een beginleeftijd 
van 35 jaar), bij de twee kinderen 325 en 460 repeats: de grootste repeatexpansies die ooit 
gevonden zijn. Deze casus illustreert de relatie tussen genotype en fenotype in deze groep 
van erfelijke cerebellaire ataxieën, alsook de theoretische counselingproblemen bij dergelijke 
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ziekten waarbij een dergelijke anticipatie voor kan komen. Bij een ernstige onbegrepen 
congenitale hypotonie moet SCA7 in de differentiaal diagnose opgenomen worden, alhoewel 
de incidentie hiervan laag zal zijn. 
 
Hoofdstuk 3.4 
Een grote ADCA-familie, bestaande uit zes generaties, werd samengesteld door 
genealogisch onderzoek bij drie families waarbij met koppelingsonderzoek een 
overeenkomstig haplotype op chromosoom 19q13.4-qter (dat overlapte met het SCA14-
locus) gevonden was. In totaal waren er 13 aangedane personen. Het fenotype bestond 
voornamelijk uit een langzaam-progressieve spinocerebellaire ataxie met een gemiddelde 
beginleeftijd van bijna 41 jaar. Bij twee individuen, bij wie de ziekte zich reeds voor het 25e 
jaar manifesteerde, was er tevens sprake van een focale dystonie (schrijverskramp); bij een 
ander familielid werd rigiditeit van de armen gevonden. Dit suggereert dat extrapyramidale 
symptomatologie aanwezig kan zijn bij het SCA14-subtype, wat reeds eerder, in de vorm van 
axiale myoclonieën, beschreven was. In deze fase van het onderzoek werd duidelijk dat in 
andere SCA14-families en -patiënten de verantwoordelijke genmutatie gevonden was: 
missense mutaties in exon 4 van het PRKCG-gen, dat codeert voor PKCγ (proteine kinase C, 
γ-isovorm). Daaropvolgend werden ook in de hier beschreven familie de exonen 4 en 5 van 
het PRKCG-gen onderzocht en daarbij werd een nieuwe mutatie in exon 4 gevonden: 
353G→A wat op eiwitniveau resulteert in een substitutie van glycine door aspartaat op residu 
118 (Gly118Asp). 
 
Hoofdstuk 3.5 
Om de frequentie c.q. bijdrage van de in het vorige hoofdstuk beschreven mutatie in het 
PRKCG/SCA14-gen (353G→A) in de Nederlandse ADCA-populatie vast te stellen, werden 
ca. 900 samples, waarin mutaties in SCA1, SCA2, SCA3, SCA6 en SCA7 waren uitgesloten, 
op deze mutatie gescreend. De eerdergenoemde mutatie kon aangetoond worden in acht 
patiënten uit vijf kleine families. Naast de langzaam-progressieve relatief pure 
spinocerebellaire ataxie, vertoonde 1 patiënt invaliderende actiemyoclonieën van de 
ledematen. Middels genealogisch onderzoek bleek dat de vijf nieuwe families verwant waren 
aan de in hoofdstuk 3.4 beschreven familie. Derhalve is er in de Nederlandse ADCA-
populatie sprake van een zogenaamde founder mutatie (353G→A) in het PRKCG/SCA14-
gen (Gly118Asp in PKCγ). Deze mutatie is verantwoordelijk voor ongeveer 4% van de 
Nederlandse ADCA-populatie. 
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Hoofdstuk 3.6 
In een andere grote Nederlandse ADCA-familie werd met een genome-scan koppeling 
gevonden op chromosoom 20p13-p12. Aan dit locus, 18.2cM groot, werd het SCA23-
symbool toegewezen. De vijf onderzochte aangedane familieleden vertoonden, na een 
gemiddeld begin op ongeveer 50 jaar, een langzaam-progressieve ongecompliceerde 
spinocerebellaire ataxie. Neuropathologisch onderzoek bij een overleden familielid uit de 
eerste generatie toonde het volgende: neuronaal verval in de Purkinjecellaag, nucleus 
dentatus en oliva inferior; degeneratie van de cerebellopontiene verbindingen; demyelinisatie 
van de achter- en zijstrengen; en intranucleaire ubiquitine-positieve inclusies in de neuronen 
van de substantia nigra (Marinesco lichaampjes). Mutatieanalyse van neuronal cell death 
inducible kinase (SKIP3), major prion protein precursor (PRNP) en prion gene complex 
downstream (PRND) sloot betrokkenheid van deze genen in SCA23 uit.  
 
Hoofdstuk 4.1 
Om de frequentie en aard van de mogelijke perifere neuropathie bij ADCA in kaart te 
brengen werd, naast een geprotocolleerd klinisch-neurologisch onderzoek gericht op het 
perifere zenuwstelsel, een gestandaardiseerd neurofysiologisch onderzoek verricht bij 27 
gegenotypeerde ADCA-patiënten. Bij 70% van de patiënten werden electrofysiologische 
kenmerken van betrokkenheid van het perifeer zenuwstelsel gevonden, waarbij het in 40% 
om een sensibele en/of motore neuronopathie ging en in 30% om een ‘klassieke’ lengte-
afhankelijke axonale polyneuropathie. Bij SCA6-patiënten waren er geen aanwijzingen voor 
een neuronopathie of axonopathie. Het voorkomen van of het type perifere zenuwaantasting 
correleerde niet met leeftijd, ernst van de cerebellaire ataxie of ziekteduur. 
 
Hoofdstuk 4.2 
Vanuit de kliniek is bekend dat patiënten met een cerebellaire ataxie, en dus ook ADCA-
patiënten, regelmatig vallen. Terwijl er voor andere bewegingsstoorissen, zoals de ziekte van 
Parkinson, wel gegevens waren over de valfrequentie ontbraken deze gegevens voor 
cerebellaire ataxie. 
Zowel retrospectief (vragenlijst) als prospectief (valdagboek) werden in respectievelijk 42 en 
26 patiënten met een degeneratieve cerebellaire ataxie (ADCA of ILOCA – idiopathic late 
onset cerebellar ataxia) de valfrequentie en valomstandigheden onderzocht. In het 
retrospectief onderzoek bleek 93% van de patiënten één of meerdere malen gevallen te zijn 
de afgelopen 12 maanden. In ongeveer 85% van de gevallen liepen de patiënten 
verwondingen op, waarbij het in 31% om een fractuur of gewrichtsluxatie ging. In het 
prospectieve onderzoek (drie maanden) werden één of meerdere vallen gerapporteerd door 
50% van de patiënten. Vallen kwam reeds voor na een ziekteduur van 2 jaar.  
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Neurologen dienen zich bewust te zijn van het gegeven dat vallen (en de ernstige gevolgen 
daarvan) frequent voorkomt bij patiënten met een cerebellaire ataxie. 
 
Hoofdstuk 4.3 
Eén van de manieren om meer inzicht te krijgen in de houdings- en balansstoornissen bij 
ADCA is het bestuderen van de zwaaibewegingen van de romp (trunk sway). Elf ADCA-
patiënten met een bekend genotype en elf gezonde individuen werden onderzocht. Met het 
SwayStar™ systeem werden hoekverplaatsing en hoekversnelling van rompbewegingen in 
de voor-achterwaartse en zijwaartse richtingen gemeten tijdens gestandaardiseerde staan- 
en looptesten. Tijdens staan waren de hoekverplaatsingen en –versnellingen van de romp in 
beide bewegingsrichtingen in de ADCA-groep groter dan in de controlegroep. Binnen de 
groep ADCA-patiënten was er meer rompinstabiliteit in de voor-achterwaartse dan in de 
zijwaartse richting; hierbij werden tevens voor-achterwaartse 1,4 en 2,5 Hz oscillaties van de 
romp gezien. Ook waren er tijdens de meeste looptesten significante verschillen tussen de 
ADCA-groep en de controlegroep, waarbij wederom de groep ADCA-patiënten met name 
rompinstabiliteit in de voor-achterwaartse richting vertoonde. Opvallend was vooral de voor-
achterwaartse instabiliteit tijdens het koorddansen, omdat vanuit een klinisch perspectief 
hiermee juist de zijwaartse c.q. laterale instabiliteit geprovoceerd wordt.  
Het SwayStar™ systeem is dus in staat de gestoorde rompbalans bij patiënten met een 
cerebellaire ataxie te detecteren en te kwantificeren. Het systeem is mogelijk ook geschikt 
voor kwantitatieve follow-up en vroegdetectie, maar dit moet nog worden onderzocht. Bij 
ADCA is er meer instabiliteit in de voor-achterwaartse dan zijwaartse richting, wat als 
pathologisch-anatomisch correlaat een meer uitgesproken betrokkenheid van het 
spinocerebellum suggereert. 
 
Hoofdstuk 5 
Dit hoofdstuk bevat een samenvatting c.q. overzicht van de meest recente ontwikkelingen op 
het gebied van de erfelijke, zowel dominante als recessieve, cerebellaire ataxieën.  
Net als voor de dominante ataxieën wordt ook de genetische achtergrond van de recessieve 
ataxieën steeds duidelijker. Enkele recent ontdekte recessieve genen (SACS, APTX, SETX) 
wijzen op nieuwe en zeer interessante mechanismen die in de pathofysiologie van deze 
cerebellaire degeneraties een rol spelen, zoals stoornissen in de DNA-repair en disfunctie 
van chaperonne-eiwitten. Omdat er zeer waarschijnlijk een overlap zal zijn in (een deel van) 
de pathobiologie van de dominante en recessieve ataxieën zijn de bovengenoemde 
ontwikkelingen ook relevant voor de dominante groep van ataxieën. Zo kunnen deze 
ontwikkelingen nieuwe aanknopingspunten bieden voor  het celbiologisch onderzoek en 
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moeten bovendien ook andere groepen van kandidaatgenen overwogen worden bij de 
dominante ataxieën.   
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